On this page
Quick Reference
Overview and Recommendations
Key Facts
- •Staphylococcus aureus is a Gram-positive, coagulase-positive coccus and the leading cause of death from bacteremia worldwide, with an estimated 300,000 deaths annually and a case fatality rate of 15-30% even with appropriate therapy, making it one of the most lethal bacterial pathogens.
- •The organism is classified by methicillin susceptibility into MSSA (methicillin-susceptible) and MRSA (methicillin-resistant), the latter mediated by the mecA gene on SCCmec elements; MRSA accounts for ~40% of invasive isolates globally and carries a higher recurrence risk (sHR 1.69).
- •Virulence is driven by a potent arsenal: Panton-Valentine leukocidin (PVL) causes necrotizing pneumonia and recurrent SSTIs; TSST-1 triggers toxic shock syndrome; α-hemolysin mediates lung tissue destruction; and biofilm-forming strains (especially CC8/spa t008) predict higher readmission rates in device-related infections.
- •The spectrum of disease spans from superficial furuncles and cellulitis to life-threatening bacteremia, infective endocarditis, vertebral osteomyelitis, and toxin-mediated syndromes, with metastatic seeding occurring in >30% of bloodstream infections.
- •In the United States, the age-adjusted incidence of S. aureus bacteremia is 33.9 per 100,000 person-years, with highest rates in older adults, males, Black individuals, and people who inject drugs; community-associated MRSA (USA300 clone) disproportionately affects prisoners, athletes, and men who have sex with men.
Clinical Importance
- •Suspect S. aureus infection in any patient with purulent skin abscesses, recurrent furuncles, or rapidly progressive cellulitis, especially in young, otherwise healthy individuals without healthcare exposure, this pattern is classic for CA-MRSA (USA300).
- •In patients with fever and risk factors such as indwelling catheters, injection drug use, hemodialysis, or recent hospitalization, obtain two sets of blood cultures before starting antibiotics; a single positive bottle represents true infection in 89.8% of cases.
- •Ask specifically about new back pain (suggests vertebral osteomyelitis or spinal epidural abscess), joint pain (septic arthritis), chest pain or hemoptysis (septic pulmonary emboli from right-sided endocarditis), and headache or focal neurologic deficits (CNS infection).
- •Examine for skin abscesses, heart murmurs (especially new or changing murmurs suggest endocarditis), joint effusions, spinal tenderness, and neurologic deficits, the presence of a prosthetic valve or cardiac device raises the likelihood of seeding.
- •Order blood cultures from two separate sites, and send an MRSA nares PCR swab, a negative result has a negative predictive value of 96.5% for ruling out MRSA pneumonia and bloodstream infection, enabling early de-escalation of anti-MRSA therapy.
- •Perform transthoracic echocardiography (TTE) in all patients with S. aureus bacteremia; proceed to transesophageal echocardiography (TEE) if there is persistent bacteremia ≥48 hours, persistent fever >72 hours, metastatic foci, or an implantable cardiac device, TEE increases endocarditis detection from 2-15% to 14-28%.
- •Measure time to blood culture positivity (TTP): a TTP <13 hours independently predicts infective endocarditis (OR 3.59) with a negative predictive value of 96% for ruling out endocarditis when longer.
- •For suspected S. aureus pneumonia, consider the diagnosis in patients with severe community-acquired pneumonia, especially if preceded by influenza, presenting with hemoptysis, rapid respiratory decline, and cavitary lesions on imaging.
- •When evaluating a patient with positive blood cultures, assess for persistent bacteremia: repeat cultures at 24-48 hours, persistent positivity ≥2 days confers a 90-day mortality of 39% and mandates aggressive source control and search for metastatic infection.
- •In cases of prosthetic joint infection (PJI), suspect S. aureus when a patient with a prior arthroplasty develops acute pain, swelling, and erythema of the joint within a median of 1 day after positive blood culture; PJI occurs in 19% of SAB patients with preexisting hardware.
- •For children, a limp or refusal to bear weight may be the only sign of acute hematogenous osteomyelitis; the metaphysis of long bones (femur, tibia, humerus) is most commonly involved.
- •Always consider differential diagnoses: necrotizing fasciitis (severe pain out of proportion), gout (crystal analysis), viral pneumonia (PCR panels), and nonbacterial thrombotic endocarditis (modified Duke criteria).
Diagnosis and Treatment
- •Initiate empiric anti-MRSA therapy when local MRSA prevalence exceeds 10-20%, the patient has severe sepsis or septic shock, or there are risk factors for MRSA (prior colonization, injection drug use, hemodialysis, recent hospitalization).
- •For suspected MRSA bacteremia or endocarditis, administer vancomycin 15-20 mg/kg IV every 8-12 hours with a target AUC/MIC ratio of 400-600 mg·h/L (trough 15-20 µg/mL if AUC monitoring unavailable); alternative: daptomycin 6 mg/kg IV once daily for bacteremia, 8-10 mg/kg for endocarditis.
- •For suspected MSSA bacteremia, start cefazolin 2 g IV every 8 hours (preferred over antistaphylococcal penicillins due to significantly lower risk of acute kidney injury, NNT=18); if penicillin-susceptible, benzylpenicillin 1.8 g IV every 4 hours is an option.
- •For uncomplicated skin abscess, perform incision and drainage and consider adjunctive oral antibiotics: trimethoprim-sulfamethoxazole (160/800 mg) one double-strength tablet orally twice daily or clindamycin 300-450 mg orally three times daily for 5-7 days.
- •For severe SSTI with systemic toxicity, use intravenous vancomycin or daptomycin; linezolid 600 mg IV/orally every 12 hours is an alternative with good tissue penetration and lower nephrotoxicity.
- •Achieve source control urgently: remove all infected intravascular catheters within 72 hours (failure to do so increases 90-day mortality), drain abscesses ≥5 cm, debride necrotic tissue, and for native valve endocarditis consider early valve surgery if heart failure, uncontrolled infection, or embolic complications develop.
- •De-escalate anti-MRSA therapy to a β-lactam (cefazolin or antistaphylococcal penicillin) when MRSA nares PCR returns negative (NPV >96%) and cultures confirm MSSA, this reduces nephrotoxicity and cost; de-escalate by day 4 of therapy when possible.
- •Use therapeutic drug monitoring for vancomycin: target an AUC0-24/MIC of 400-600 (assuming MIC 1 mg/L); Bayesian dosing is preferred; avoid relying solely on trough monitoring.
- •Duration of therapy: 14 days for uncomplicated bacteremia (negative follow-up cultures at 48-72 hours, no endocarditis, no metastatic foci, defervescence within 72 hours); 4-6 weeks for complicated bacteremia (endocarditis, deep-seated infection, persistent bacteremia ≥48 hours).
- •Consider early oral switch in clinically stable, low-risk patients with uncomplicated bacteremia who have cleared blood cultures and have a removable source: the SABATO trial showed noninferiority of oral step-down after 5-7 days of IV therapy (13% vs 12% composite outcome); use linezolid 600 mg orally twice daily for MRSA or cephalexin 500 mg orally four times daily for MSSA.
- •For left-sided endocarditis, the POET trial supports oral switch after at least 10 days of IV therapy with noninferior outcomes (9.0% vs 12.1%); oral options include a fluoroquinolone plus rifampin or linezolid.
- •Avoid routine addition of gentamicin, it increases nephrotoxicity without improving survival; avoid rifampin as adjunctive therapy for uncomplicated MRSA bacteremia (ARREST trial showed no benefit, HR 0.96).
- •Avoid dual β-lactam therapy (e.g., vancomycin plus anti-MRSA β-lactam) for MRSA bacteremia, CAMERA2 showed no improvement in 90-day mortality and increased acute kidney injury (23% vs 6%).
- •For persistent MRSA bacteremia ≥5 days despite optimized vancomycin, switch to daptomycin 8-10 mg/kg IV daily plus ceftaroline 600 mg IV every 8 hours, this combination showed reduced in-hospital mortality in a pilot trial (0% vs 26%).
- •Monitor renal function daily during treatment with vancomycin or antistaphylococcal penicillins; monitor creatine phosphokinase (CPK) weekly if on daptomycin; monitor complete blood count weekly if on linezolid for more than 2 weeks due to risk of thrombocytopenia.
- •Refer to infectious diseases specialist for all cases of S. aureus bacteremia and endocarditis, ID consultation reduces 10-year mortality (HR 0.42) and risk of new bacteremia (OR 0.45).
- •For prosthetic joint infection, manage with surgical debridement, retention of prosthesis (DAIR) combined with rifampin-containing regimen if debridement is adequate; success rates are 69% for hip and 54% for knee.
- •For osteomyelitis, treat with 4-6 weeks of parenteral or highly bioavailable oral therapy after adequate debridement; longer courses (>6 weeks) do not improve outcomes in fracture-related infection.
- •Do not base therapy solely on vancomycin MIC ≥2 µg/mL, consider alternative agents (daptomycin, ceftaroline, ceftobiprole) as failure rates are high.
- •In ICUs, implement universal decolonization with chlorhexidine bathing and intranasal mupirocin to reduce MRSA clinical isolates (HR 0.63) and all-pathogen bloodstream infection (NNT=54 to prevent one BSI).
Board Review — High Yield
- •Persistent bacteremia ≥2 days, 90-day mortality 39% vs 22% for 1 day.
- •MRSA nares PCR NPV >96%, enables safe de-escalation of empiric anti-MRSA therapy.
- •Cefazolin preferred over antistaph penicillins for MSSA, lower AKI risk (SNAP, CloCeBa).
- •Vancomycin AUC/MIC target 400-600, replaces trough monitoring alone.
- •POET trial, oral switch noninferior in left-sided endocarditis after ≥10 days IV.
- •CAMERA2, adding β-lactam to vancomycin for MRSA BSI increased AKI without mortality benefit.
- •ARREST, no benefit of adjunctive rifampin for S. aureus bacteremia.
- •SABATO trial, early oral switch (5-7 days IV) noninferior in low-risk SAB.
- •REDUCE MRSA, universal decolonization in ICU reduces all-cause BSI (NNT=54).
- •Mupirocin resistance, associated with usage >25 DDD/1000 patient-days.
Deep Dive — Evidence Details
Definition, Classification and Causative Organisms
- ▸Classify clinically important isolates as MSSA, MRSA, or strains with additional resistance or persistence phenotypes. [856][858][862][867][873]
- ▸Nasal or occupational carriage does not by itself establish invasive infection. [860][868]
- ▸Major disease manifestations include sepsis, bacteremia, pneumonia, wound infection, osteomyelitis, empyema, foodborne disease, and staphylococcus-associated glomerulonephritis. [856][857][858][859][860][861][865][866]
- ▸Small-colony variants and biotope-dependent stress tolerance are relevant to chronicity and treatment persistence. [870][873]
- ▸Toxin and superantigen production provides an additional virulence-based classification. [864]
Definition
Staphylococcus aureus is a human and livestock-associated bacterial pathogen and a leading Gram-positive cause of wound infection. [875]D It is also classified among the ESKAPE pathogens because of its capacity to evade antibacterial treatment. [875]D Clinical disease ranges from colonization and localized wound infection to invasive, life-threatening syndromes, including sepsis, bacteremia, pneumonia, osteomyelitis, empyema, urinary or renal infection, and infection-associated glomerulonephritis. [856][857]C[858][860]C[865][872]D[874]D The distinction between colonization and infection is clinically important: nasal carriage may precede or predict subsequent disease, while colonization may occur without clinical infection. [860]C[864][868]C
S. aureus infection should generally be defined using the combination of compatible clinical disease and recovery or detection of the organism from an appropriate clinical specimen. This principle is illustrated by studies requiring microbiologically confirmed and clinically adjudicated infection, [863]C clinically and/or histopathologically confirmed osteomyelitis, [857]C or deep intraoperative tissue cultures for osteomyelitis. [861] Positive screening from the nose, skin, or another colonization site alone does not establish invasive infection. [860]C[868]C
Classification
The most clinically consequential classification is by susceptibility to β-lactam antibiotics:
- Methicillin-susceptible S. aureus (MSSA): isolates susceptible to methicillin-class agents; MSSA caused bacteremia, pyogenic sacroiliitis, iliopsoas abscesses, and subsequent staphylococcus-associated glomerulonephritis in a reported case. [858]
- Methicillin-resistant S. aureus (MRSA): isolates resistant to methicillin-class agents. MRSA is a major antimicrobial-resistant threat, particularly in neonatal intensive-care settings, and is associated with substantial morbidity when it causes bacteremia. [869]D[872]D In a nationwide Korean sepsis cohort, the clinical objective was to identify predictors of MRSA infection so that empiric MRSA therapy could be targeted to patients with increased risk rather than used indiscriminately. [856]
- Other resistance phenotypes: resistance may be specific to additional agents or drug classes. A neonatal intensive-care-unit outbreak involved tobramycin-resistant S. aureus of spa type t084, [862] while clinical isolates may exhibit constitutive or inducible clindamycin resistance mediated by erm genes. [867] Inducible clindamycin resistance can be missed by routine susceptibility testing and may result in treatment failure. [867]
Phenotypic classification is also relevant to persistence. Small-colony variants are persistence-adapted forms associated with chronic and recurrent mastitis and intracellular survival in mammary epithelial cells. [873]D S. aureus behavior is biotope-dependent: growth in milk versus serum alters the bacterial envelope, membrane fatty acids, rigidity, pigment production, proteome, reactive-oxygen-species resistance, and antimicrobial tolerance. [870]D A renal inner-medullary reservoir has additionally been demonstrated in a mouse model of intravenous USA300 MRSA infection, where hyperosmolar conditions supported persistence and later spread toward the renal cortex. [872]D
Causative organisms and clinical syndromes
The causative organism in this section is S. aureus, occurring as MSSA, MRSA, or a strain with additional resistance or persistence phenotypes. [856][858][862][867][873]D It is implicated across multiple anatomic and clinical categories:
- Bloodstream and systemic infection: S. aureus causes sepsis and bacteremia, including severe infection in adults presenting to emergency departments and neonates in intensive care. [856][862][869]D
- Skin and soft-tissue or wound infection: S. aureus is a leading Gram-positive wound pathogen; experimental endolysin therapy reduced S. aureus burden in infected murine wounds. [875]D
- Respiratory infection: it is a major cause of ventilator-associated pneumonia, including in mechanically ventilated adults with acute brain injury. [860]C In that setting, patients were screened within 24 hours of intensive-care admission and required invasive ventilation for at least 48 hours to meet the study population definition. [860]C
- Bone and joint infection: S. aureus is among the organisms recovered from hand, foot, and non-foot osteomyelitis, including disease requiring surgery or associated with chronic infection. [857]C[861][866]C
- Pleural infection: it is among the bacterial causes considered when selecting empirical treatment for childhood thoracic empyema. [865]
- Renal and immune-mediated disease: invasive S. aureus infection may be complicated by staphylococcus-associated glomerulonephritis, including an IgA-dominant form. [858]
- Foodborne disease: surveillance data from Yogyakarta identified S. aureus as one of the dominant organisms associated with foodborne outbreaks, alongside Bacillus cereus. [859]
Virulence-associated classifications include toxin-producing strains. TSST-1-producing strains and staphylococcal enterotoxin or enterotoxin-like proteins can act as superantigens; TSST-1 engages the T-cell-receptor Vβ2 chain, and exposure was examined in S. aureus-colonized patients with bullous pemphigoid. [864] Staphylococcal surface lectins, including SSL3 and related proteins, may also interact with host sialic-acid pathways and influence viral infectivity in experimental systems. [871]D
Host and environmental reservoirs include the nose, skin, healthcare environments, livestock, food, and infected tissues. [859][860]C[862][868]C[870]D Veterinary workers may carry antimicrobial-resistant organisms after occupational exposure, although carriage and microbiome findings require epidemiological interpretation rather than being equated with clinical infection. [868]C Gut microbiota and fecal metabolomic alterations have also been reported in hospitalized patients with confirmed S. aureus infection, but the exploratory study was small and most patients had received antibiotics before sampling. [863]C
| Classification | Defining feature or relevance |
|---|---|
| MSSA | Methicillin-susceptible isolate; reported in invasive bacteremia with deep-seated infection and glomerulonephritis. [858] |
| MRSA | Methicillin-resistant isolate; important cause of bacteremia and healthcare-associated antimicrobial resistance. [856][869]D[872]D |
| Additional resistance phenotype | Includes tobramycin resistance and inducible or constitutive clindamycin resistance. [862][867] |
| Small-colony variant | Persistence-adapted phenotype associated with chronic or recurrent infection. [873]D |
| Toxin-producing strain | May produce TSST-1, enterotoxins, or enterotoxin-like superantigens. [864] |
Microbiology and Pathogenesis
- ▸S. aureus pathogenicity integrates adhesion, invasion, biofilm formation, intracellular survival, metabolic adaptation, toxin production, regulatory networks and antimicrobial resistance.[885][884]
- ▸Host biotopes alter bacterial envelope properties, oxidative-stress resistance, antimicrobial tolerance and virulence.[870]
- ▸ArcR links arginine-deiminase-associated regulation with haemolysis, γ-haemolysin expression and Agr/RNAIII-mediated virulence in USA300 LAC.[882]
- ▸SCVs are persistence-adapted organisms associated with chronic and recurrent bovine mastitis and altered epithelial immune responses.[873]
- ▸Inducible *erm*-mediated clindamycin resistance may be missed by routine susceptibility testing and is clinically important.[867]
Overview
Staphylococcus aureus is presented in the available evidence as a versatile human and veterinary opportunistic pathogen whose disease spectrum is shaped by toxin production, adhesion and invasion, biofilm formation, metabolic adaptation, regulatory circuitry, intracellular survival, antimicrobial resistance and strain-specific traits.[885]D These mechanisms are not independent: host–pathogen protein–protein interactions connect colonisation with attachment, tissue invasion and immune evasion, supporting the transition from carriage to invasive disease.[885]D
Colonisation, adhesion and invasion
S. aureus uses surface adhesins with distinct binding architectures, including Dock–Lock–Latch, collagen-hug and tandem β-zipper mechanisms, to achieve force-resilient attachment under physiological conditions.[885]D This adhesive repertoire facilitates persistence on host tissues and prosthetic or other foreign materials, where biofilm-associated growth may contribute to chronic infection and treatment difficulty.[821][885]D Chronic prosthetic-joint infection is sufficiently complex that selected patients may undergo partial prosthetic exchange, reflecting the clinical importance of infection involving well-integrated implants; however, the supplied abstract does not provide organism-specific outcome estimates.[821]
S. aureus is also recognized as an intracellular pathogen. Intracellular residence can promote immune evasion and reduced antibiotic effectiveness.[884]D Bacterial uptake occurs through multiple host-cell entry routes. A recently described pathway depends on lysosomal calcium, lysosomal exocytosis and rapid internalization within minutes, and it operates concurrently with other established entry mechanisms in the same host-cell population.[884]D The entry route may influence the subsequent intracellular fate of the bacteria.[884]D
Metabolic adaptation, persistence and small-colony variants
The organism’s phenotype is strongly shaped by its infection biotope. Growth in milk versus serum produces major differences in cell-envelope physical properties, membrane fatty-acid composition and rigidity, pigment production and proteomic profiles.[870]D Compared with serum-grown organisms, milk-grown S. aureus showed extreme resistance to reactive-oxygen-species damage, marked antimicrobial tolerance and accelerated killing in a larval infection model.[870]D These findings indicate that host fluids can alter oxidative-stress resistance, drug tolerance and virulence rather than merely serving as passive nutrient environments.[870]D
Small-colony variants (SCVs) represent a persistence-adapted phenotype associated with chronic and recurrent bovine mastitis.[873]D In bovine mammary epithelial cells, experimental infection with an S. aureus SCV and its isogenic parental strain generated distinct host transcriptional responses, demonstrating that bacterial phenotype influences epithelial immune signalling.[873]D Loss of the interleukin-10 receptor α in these cells further rewired responses to intracellular SCV infection, supporting a role for anti-inflammatory host signalling in determining the cellular response to persistent staphylococcal infection.[873]D
Toxins and virulence regulation
S. aureus pathogenicity is controlled by regulatory networks that link metabolism with virulence.[882]D In the USA300 LAC strain, deletion of the transcriptional regulator ArcR increased haemolytic activity, upregulated hla, hld and psmα, downregulated psmβ, and increased transcription of components of the Agr quorum-sensing system and its effector RNAIII.[882]D ArcR directly repressed hlgC, indicating that it can restrain γ-haemolysin expression and broader toxin-associated activity.[882]D
Superantigens provide another route to immune dysregulation. TSST-1 engages T-cell receptors bearing the Vβ2 chain.[864] Among patients with bullous pemphigoid colonised by S. aureus, particularly TSST-1-producing strains, investigators identified selective expansion of TCR Vβ2-positive regulatory T cells and impaired peripheral lymphocyte responsiveness to TSST-1; responses to staphylococcal enterotoxin G and enterotoxin-like-I were also assessed.[864] These findings link colonising S. aureus superantigens with measurable alterations in the peripheral T-cell repertoire and toxin responsiveness.[864]
Strain diversity and antimicrobial resistance
S. aureus populations include epidemiologically distinct lineages. A hospital surveillance study in northeastern Iran detected livestock-associated MRSA ST398/t011 and hospital-associated MRSA ST239/t037, with molecular characterization including SCCmec, spa and multilocus sequence typing and PCR assessment of PVL and TSST-1 genes.[829]C In the Gambia, invasive-pathogen surveillance included whole-genome sequencing of S. aureus isolates to assess phylogeny and mecA genotype, illustrating the value of genomic epidemiology for tracking resistant lineages.[879]
Resistance also includes inducible phenotypes that may be missed by routine testing. Clindamycin resistance can result from erythromycin ribosomal methylases encoded by erm genes; inducible resistance may remain undetected without appropriate testing and can lead to treatment failure.[867] MRSA remains a major resistant Gram-positive threat in neonatal intensive-care units, where immunological immaturity and invasive procedures increase vulnerability to resistant infection.[869]D
Clinical microbiology context
S. aureus remains a major pathogen in diabetic-foot infection, although one five-year outpatient-centre study observed a decline in its proportion of cultures from 55.0% to 38.9%, while Enterobacterales increased from 36.1% to 47.7% of isolates; the overall polymicrobial index was 1.62.[753] In a decade-long study of postcaesarean surgical-site infections, wound-culture pathogens and susceptibilities were examined over the period preceding widespread adjunctive azithromycin prophylaxis and standardized prevention bundles, providing temporal context for changing SSI microbiology.[880] Pediatric pelvic acute hematogenous osteomyelitis remains uncommon and diagnostically nonspecific; a 10-year series included 37 children, but the supplied abstract does not provide the S. aureus-specific microbiological distribution.[878]C Pediatric infective-endocarditis surveillance likewise evaluated microbiology, valve type and outcomes in native- and prosthetic-valve disease, although organism-specific findings are not included in the supplied abstract.[825]
The cited systematic review of microorganisms in multiple sclerosis addresses infectious contributors to MS pathogenesis, particularly EBV, but the supplied evidence does not establish a specific role for S. aureus.[876] Similarly, the urinary-tract-infection review emphasizes dysbiosis and UPEC mechanisms rather than defining a central S. aureus pathway.[874]D
| Determinant | Mechanistic or clinical significance | Evidence |
|---|---|---|
| Surface adhesins | Force-resilient attachment through Dock–Lock–Latch, collagen-hug and tandem β-zipper architectures | [885]D |
| Intracellular entry | Lysosomal calcium- and exocytosis-dependent uptake can occur alongside other entry pathways | [884]D |
| Biotope adaptation | Milk growth increases ROS resistance and antimicrobial tolerance compared with serum growth | [870]D |
| ArcR regulation | Represses hlgC and modulates haemolytic and Agr-associated virulence programs | [882]D |
| Superantigens | TSST-1 engages TCR Vβ2 and is associated with altered T-cell responses in colonised bullous pemphigoid patients | [864] |
| Resistance | erm-mediated inducible clindamycin resistance may evade routine testing | [867] |
| Lineages | LA-MRSA ST398/t011 and HA-MRSA ST239/t037 were detected in Iranian hospital surveillance | [829]C |
Epidemiology, Transmission and Risk Factors
- ▸S. aureus remains a leading pathogen in diabetic foot infections, but its proportion declined from 55.0% to 38.9% of cultures between 2021 and 2025 in one Polish outpatient centre, amid increasing Enterobacterales and polymicrobial infection. [753]
- ▸Global genomic evidence based on more than 110,000 genomes from 2000–2025 supports a One-Health view spanning human, animal and environmental reservoirs; aminoglycoside resistance is primarily associated with aminoglycoside-modifying enzymes, often plasmid encoded. [733]
- ▸MRSA colonization documented within three months before lower-extremity orthopedic trauma surgery was associated with higher postoperative wound and systemic complications. [778]
- ▸ICU MDRO colonization was present in 25.52% of patients in one Chinese cohort and was evaluated as a predictor of infection within 28 days. [777]
- ▸Surgery, implanted or indwelling devices, haemodialysis, ICU care, pediatric sepsis, injection drug use and chronic wounds are important epidemiologic contexts for S. aureus or resistant-organism infection. [754][759][760][772][780][783][784]
Overview
Staphylococcus aureus causes infections across community, outpatient, hospital and device-associated settings, with epidemiology shaped by host factors, healthcare exposure, invasive procedures, antimicrobial selection and circulation of resistance determinants. The available evidence is predominantly retrospective and geographically heterogeneous; therefore, local surveillance remains essential when estimating prevalence, transmission and resistance risk. [753][754][775]C[776]C
Epidemiology across clinical settings
S. aureus remains a major pathogen in diabetic foot infections, although its relative contribution changed over 2021–2025 at a large Polish outpatient centre: it was the most common pathogen but declined from 55.0% to 38.9% of cultures, while Enterobacterales increased from 36.1% to 47.7% of all isolates. The cultures yielded 443 isolates from 274 cultures, with a polymicrobial index of 1.62, demonstrating that diabetic foot infections frequently involve more than one organism. [753]
S. aureus is also encountered in hospital-acquired pneumonia, including ventilator-associated and non-ventilator-associated disease. A 61-hospital surveillance study in Suzhou, China, compared pathogen distributions in these two pneumonia categories over 2020–2024, supporting differentiation of pathogen epidemiology by ventilation status and healthcare setting. [774] Pediatric community-acquired pneumonia surveillance in Chengdu enrolled 838 children tested by targeted next-generation sequencing between February 2023 and May 2025, reflecting the increasing use of molecular methods to characterize respiratory pathogens in children. [773]
Invasive disease is represented in pediatric bloodstream-infection-associated sepsis, for which a 10-year southwest China cohort reported 311 patients, 305 isolated pathogens and a predominance of Gram-positive organisms comprising 53.8% of isolates. The cohort had a 20.3% 28-day mortality, 51.8% septic shock and 26.0% acute kidney injury, indicating the severity of bloodstream infection in children. [780] S. aureus sepsis has also been investigated using human and murine data, in which lower complement receptor 2 expression was associated with fatal disease; the association was dose-dependent in the experimental model. [781]
S. aureus is an important cause of infection involving implanted or indwelling medical devices. A national U.S. analysis evaluated cardiovascular implantable electronic device infections requiring extraction during 2016–2022 and assessed incidence, predictors, microbiology, mortality and costs. [759] In haemodialysis patients, a 2009–2023 Irish cohort examined bloodstream infections alongside changes in infection-prevention bundles and described declining infection rates over time in temporal association with those interventions. [760] A neonatal intensive-care cohort included 66 infants and 161 external ventricular-drain insertions from 2011–2025; culture-positive drain-associated infections were described in relation to annual unit MRSA acquisition rates. [784]
Transmission and reservoirs
The global distribution of aminoglycoside-resistance determinants illustrates the One-Health nature of S. aureus epidemiology. An in-silico analysis of more than 110,000 S. aureus genomes collected from 2000–2025 mapped resistance determinants across human, animal and environmental reservoirs and assessed host-specific and temporal trends. Aminoglycoside resistance was primarily linked to aminoglycoside-modifying enzymes, which are frequently plasmid encoded, providing a genetic basis for dissemination across bacterial populations and ecological settings. [733]
Potential community and environmental interfaces have also been examined in children with yaws-like ulcers in Cameroon. The investigation sampled affected children, asymptomatic contacts, domestic animals, rivers and flies, explicitly evaluating whether non-Treponema pallidum bacteria and environmental matrices participate in these lesions. [782] The supplied evidence does not establish the relative contribution of S. aureus from these sources, so environmental sampling should be interpreted as assessment of possible reservoirs rather than proof of transmission.
People who inject drugs represent another population with potential exposure to inoculation-related and bloodstream infections. A six-month observational study in Fiji included 128 hospitalized people who inject drugs; 76% were male, 95% identified as iTaukei, and most were aged 18–25 years. The study collected injecting-practice, substance-use, demographic and clinical information to characterize infection epidemiology in this emerging risk population. [772]
Host and healthcare-associated risk factors
Colonization with MRSA before lower-extremity orthopedic trauma surgery was associated with postoperative wound and systemic complications in a matched adult cohort drawn from the TriNetX Research Network. Patients with a documented MRSA diagnosis within three months before surgery were compared with matched MRSA-negative controls, emphasizing preoperative colonization as a clinically relevant risk marker. [778]
Surgical exposure itself is an important context for S. aureus infection. A 10-year cohort of posterior cervical decompression and fusion assessed cervical surgical-site-infection risk factors, causative organisms and antibiotic use at a quaternary academic centre. [754] Postoperative wounds after perianal-abscess surgery were examined in 246 adults, with cultures categorized according to detection of multidrug-resistant organisms; 78 patients were MDR-culture positive and 168 were non-MDR-culture positive. Because the endpoint was MDR detection in wound secretion rather than clinical infection based solely on culture, these findings should not be equated directly with invasive S. aureus infection. [783]
ICU admission and prior colonization are important markers of subsequent MDRO infection risk. In a 2023–2025 Chinese ICU cohort of 388 patients, 99 (25.52%) were colonized by MDROs and 47 developed an MDRO infection within 28 days of admission; multivariable analyses evaluated factors associated with infection. [777] Hospital exposure and antimicrobial pressure may influence resistance: a multicentre U.S. Veterans Affairs study analyzed hospital-onset S. aureus isolates collected on or after the third hospital day from 138 medical centres between 2007 and 2021 and assessed relationships between antimicrobial prescribing and resistance. [775]C
Other single-centre surveillance studies reinforce the importance of local context. A South China tertiary-hospital analysis tracked bacterial distribution and resistance from 2021–2025, while a six-year Thai study evaluated MDRO changes before and during the COVID-19 pandemic. [776]C[779] A multicentre Iraqi surveillance analysis compared inpatient and outpatient resistance patterns across four governorates, highlighting the need for integrated surveillance and stewardship in settings where laboratory data may be fragmented. [758] Among patients with moderate chronic kidney disease receiving vancomycin for MRSA infection, a multicentre Chinese cohort from 2009–2024 specifically evaluated vancomycin-associated acute kidney injury and its risk factors; this is a treatment-toxicity consideration rather than a transmission determinant. [771]
Key implications
S. aureus epidemiology is dynamic, setting-specific and increasingly connected across human, animal and environmental reservoirs. [733] Risk assessment should consider colonization, recent hospitalization or antimicrobial exposure, ICU care, invasive devices, surgery, dialysis, injection drug use, chronic wounds and major comorbidity, while recognizing that the strength and direction of associations vary by population and study design. [753][754][759][760][772][775]C[777][778][783]
Sources and interpretation
Most cited studies were retrospective, single-centre or regional investigations, limiting direct comparison of incidence and prevalence between countries. [753][754][754][773][774][776]C[777][779][780][783][784] Findings from surveillance cohorts should therefore inform, but not replace, facility-specific microbiology, colonization monitoring, infection-prevention data and antimicrobial-stewardship assessment. [733][758][775]C[779]
| Setting or population | Evidence relevant to S. aureus epidemiology | Reference |
|---|---|---|
| Diabetic foot infection | S. aureus remained the most common pathogen but declined from 55.0% to 38.9% of cultures during 2021–2025; polymicrobial infection was common. | [753] |
| Hospital-acquired pneumonia | Pathogen profiles were compared between VAP and NV-HAP across 61 hospitals during 2020–2024. | [774] |
| Pediatric bloodstream sepsis | 311 patients; 53.8% of isolates were Gram-positive; mortality was 20.3%. | [780] |
| Medical devices and dialysis | Device infection requiring extraction and haemodialysis bloodstream infection were evaluated in national or longitudinal cohorts. | [759][760] |
| Preoperative MRSA colonization | Colonization within three months before orthopedic trauma surgery marked increased postoperative complication risk. | [778] |
| One-Health reservoirs | More than 110,000 genomes from 2000–2025 were analyzed across human, animal and environmental sources. | [733] |
Clinical Presentation
- ▸S. aureus may cause localized, bloodstream, pulmonary, osteoarticular, endovascular, ocular, hand, and prosthetic-device infections. [861][825][826][887]
- ▸S. aureus bacteremia can be complicated by acute kidney injury, metastatic infection, embolic stroke, recurrence, sepsis, septic shock, and death. [738][826][893]
- ▸Influenza-associated S. aureus pneumonia may rapidly progress to necrotizing pneumonia, ARDS, refractory hypoxemia, and septic shock; methicillin-susceptible strains can be similarly severe. [828]
- ▸IE-related emboli may persist despite clinical stabilization; follow-up imaging before antibiotic discontinuation changed antibiotics or prompted intervention in 54% of the reported cohort. [886]
- ▸Pediatric pelvic hematogenous osteomyelitis may be nonspecific and delayed in diagnosis; 43.2% of children in one series had concomitant septic arthritis. [878]
Overview
Staphylococcus aureus can present as localized skin and soft-tissue infection, invasive bloodstream infection, pneumonia, osteoarticular infection, endocarditis with embolic disease, endogenous endophthalmitis, and infection involving prosthetic material. The supplied evidence is predominantly retrospective and disease-specific; therefore, frequencies and clinical patterns should not be generalized to all S. aureus infections. [861][825][826][887]
Bloodstream infection and systemic disease
S. aureus bacteremia (SAB) may be complicated by acute kidney injury, metastatic infection, embolic stroke, recurrent infection, or death. In a multicentre cohort of adults with SAB, AKI was sufficiently frequent and clinically important to be evaluated by incidence, timing, severity, recovery, and antibiotic exposure. [826] Among patients receiving anti-IL-6-receptor antibodies, bloodstream infection was assessed as complicated when it caused infection-related mortality, a remote or localized suppurative complication, embolic stroke, or recurrence within 90 days. [738] Critically ill adults with MRSA bacteremia were described as having substantial morbidity and mortality risk, particularly when effective treatment was delayed and sepsis or septic shock developed. [893]
Infective endocarditis and embolic presentation
Pediatric infective endocarditis (IE) occurs particularly in patients with congenital heart disease and may involve prosthetic material; clinical evaluation includes valve type, underlying cardiac defect, microbiology, complications, and outcomes. [825] In IE complicated by extracardiac embolic events, emboli may persist or remain clinically occult after initial treatment. A prospective multicentre study therefore evaluated follow-up imaging in asymptomatic or clinically stable patients before antibiotic discontinuation; the study population included definite or possible IE with embolic events, while patients imaged for new clinical indications were excluded. [886] The supplied abstract reports a therapeutic impact of follow-up imaging in 54% of patients, defined as antibiotic modification and/or intervention, supporting the possibility that residual embolic foci can influence the apparent clinical course even when symptoms have stabilized. [886]
Neurologic embolic disease may include intracranial mycotic aneurysm and hemorrhage. In a reported case of disseminated S. aureus bacteremia originating from lower-limb cellulitis, IE was accompanied by septic emboli to the brain, spleen, and kidney; on hospital day 17, rupture of a cerebral mycotic aneurysm caused a large intraparenchymal hemorrhage with obtundation, global aphasia, and right-sided hemiplegia. [794]
Pneumonia and toxin-mediated disease
Influenza-associated community-acquired S. aureus pneumonia can progress rapidly to necrotizing pneumonia, septic shock, severe hypoxemia, and acute respiratory distress syndrome (ARDS). A pediatric case involving influenza A (H3N2) and community-acquired methicillin-susceptible S. aureus required immediate intubation and veno-venous extracorporeal membrane oxygenation on the first hospital day because of refractory respiratory failure; metagenomic sequencing identified S. aureus as the dominant pathogen in bronchoalveolar lavage fluid. [828]C The report emphasizes that methicillin-susceptible strains can produce disease as severe as that commonly associated with community-acquired MRSA. [828]C
Staphylococcal scalded skin syndrome (SSSS) is another acute presentation considered in hospitalized children. A retrospective pediatric cohort compared empiric regimens with and without MRSA coverage, using hospital length of stay and return visits within 2 weeks as outcomes; the supplied abstract does not provide the comparative results or clinical predictors. [822]C
Osteoarticular and prosthetic infection
The clinical phenotype of S. aureus osteomyelitis varies with anatomic site and mechanism. Foot osteomyelitis is commonly associated with diabetic foot infection and contiguous spread, whereas non-foot osteomyelitis more often reflects post-traumatic, hematogenous, or postoperative infection. [861] In a separate cohort of 704 osteomyelitis cases, pathogen epidemiology and clinical characteristics were evaluated in both culture-positive and probable culture-negative disease, with confirmed cases requiring pathogen isolation correlated with radiologic findings; the supplied abstract does not report the S. aureus-specific findings. [824]
Acute pelvic hematogenous osteomyelitis in children is uncommon and often presents with nonspecific symptoms, creating potential diagnostic delay. In a 10-year pediatric series, pelvic disease represented 16% of all acute hematogenous osteomyelitis cases; median age was 8.9 years, 70% of patients were male, the ilium was most frequently involved, and 43.2% had concomitant septic arthritis. [878]C The supplied abstract does not state the organism-specific proportion attributable to S. aureus. [878]C
Recurrent S. aureus prosthetic joint infection is defined in one longitudinal study by at least two S. aureus isolates from distinct clinical samples separated by more than 90 days. The investigation focused on in-host phenotypic and genomic evolution during recurrent knee, hip, or shoulder infection, including antimicrobial susceptibility, growth, biofilm production, metabolic characteristics, and virulence. [888]C
Eye, hand, and postoperative presentations
Endogenous endophthalmitis is an ocular manifestation of hematogenous infection without a recent exogenous ocular risk factor. A multicentre cohort included clinically diagnosed cases requiring anterior-chamber paracentesis, intravitreal aspiration, or vitrectomy with intravitreal antimicrobials and compared presentation, treatment, culture, and visual outcomes by pathogen; the supplied abstract does not provide the S. aureus-specific findings. [887]
Pyogenic flexor tenosynovitis is an acute hand infection and surgical emergency. Diagnosis in a 341-patient adult cohort was based on Kanavel signs, and severity was graded using the Michon classification; outcomes included final function, DASH score, and grip strength. The abstract does not provide the organism-specific clinical features or the proportion caused by S. aureus. [889] Early deep infection after lumbar spine surgery may require repeated surgery, negative-pressure wound therapy, prolonged antimicrobials, and complex implant decisions, although the supplied study does not identify S. aureus-specific manifestations. [891]C
Diagnostic context and limitations of the evidence
Targeted next-generation sequencing was evaluated in 838 children with community-acquired pneumonia, but the supplied abstract does not report S. aureus-specific detection rates or presentation patterns. [773] Similarly, the provided report of severe ventilator-associated lower respiratory infection concerned Streptomyces in polymicrobial COVID-19 ARDS rather than S. aureus, and the bacterial-meningitis PCR study evaluated pathogens broadly without supplying S. aureus-specific findings. [892]C[894] These studies should not be used to infer organism-specific clinical features for S. aureus.
| Syndrome | Clinical presentation or defining feature | Evidence |
|---|---|---|
| Bacteremia | AKI, metastatic or suppurative complications, embolic stroke, recurrence, sepsis, septic shock | [738][826][893] |
| Endocarditis | Congenital heart disease, prosthetic material, extracardiac emboli, intracranial mycotic aneurysm | [794][825][886] |
| Pneumonia | Influenza-associated necrotizing pneumonia, ARDS, refractory hypoxemia, septic shock | [828]C |
| Osteomyelitis | Contiguous diabetic-foot disease, hematogenous pelvic disease, postoperative or post-traumatic disease | [861][878]C |
| Prosthetic joint infection | Recurrent infection with isolates separated by more than 90 days | [888]C |
| Endophthalmitis | Endogenous ocular infection requiring intraocular sampling and intravitreal therapy | [887] |
| Hand infection | Pyogenic flexor tenosynovitis diagnosed using Kanavel signs | [889] |
Diagnosis and Workup
- ▸Use a clinically appropriate specimen and distinguish colonization or contamination from infection, particularly for nonsterile sites and blood cultures. [867][896][903][908]
- ▸Prefer intraoperative deep tissue specimens over superficial sampling when evaluating osteomyelitis; diabetic foot disease may be polymicrobial. [861][902][907]
- ▸For bloodstream infection, document the number of culture sets, collection timing, and any collection restrictions; a single-set strategy can alter observed bloodstream-infection epidemiology. [896][901]
- ▸Always classify bloodstream isolates as MRSA or MSSA and perform susceptibility testing; investigate possible inducible clindamycin resistance when indicated. [867][898]
- ▸Use WGS with epidemiologic data for surveillance and transmission investigation, while retaining culture-based identification and phenotypic susceptibility testing for clinical diagnosis. [895]
- ▸Consider tissue histopathology and metagenomic testing in chronic, atypical, refractory, or apparently polymicrobial lesions. [905]
Diagnostic approach
Diagnosis of Staphylococcus aureus infection requires integration of the clinical syndrome, an appropriately collected specimen, organism identification, and antimicrobial susceptibility testing. The diagnostic strategy should distinguish colonization or contamination from invasive disease, particularly when S. aureus is recovered from nonsterile sites or from blood. Recent studies have used conventional microbiological identification followed by susceptibility testing for skin, wound, respiratory, urinary, and device-associated specimens. [867][902][903][906][907]
Specimen selection should reflect the suspected focus. For osteomyelitis, intraoperative deep tissue specimens are preferable to superficial material; a comparative study specifically analyzed only surgically obtained deep tissue samples to characterize the microbiology of foot and non-foot disease. [861] In diabetic Charcot neuroarthropathy with associated foot ulcers, cultures were obtained from deep tissue or the ulcer base, with 74.4% of patients having a positive culture; monomicrobial growth occurred in 47.6%, demonstrating the importance of considering polymicrobial infection. [902] Similar caution applies to diabetic foot ulcers, where superficial or deep wound cultures were used to identify multidrug-resistant organisms and evaluate associated risk factors. [907]
For impetigo, lesion swabs can be cultured and isolates identified by conventional methods, with susceptibility testing performed according to Clinical and Laboratory Standards Institute procedures. [906] In chronic or diagnostically unresolved ulcers, histopathology and culture may need to be combined with molecular testing: in a chronic forearm ulcer, tissue histopathology showed an infectious granuloma, bacterial culture identified methicillin-resistant S. aureus together with other organisms, and probe-capture metagenomic next-generation sequencing detected Cryptococcus neoformans with 99% confidence, illustrating how molecular testing can reveal coinfection or an alternative pathogen. [905]C
Bloodstream infection workup
When S. aureus is recovered from blood, the result should prompt an invasive-infection workup rather than automatic dismissal as contamination. Blood-culture interpretation depends on the number and timing of sets, sampling quality, clinical context, and the possibility of concurrent infection. In a pediatric study of paired aerobic and anaerobic bottles, the cohort included 24,485 multi-set episodes from 8,658 patients; 999 (4.1%) episodes were positive and 387 (1.6%) were classified as potential contaminants. Anaerobic bottles provided additional diagnostic information in 208 (20.8%) positive episodes, including additional organism recovery in 159 (15.9%). [896]
Blood-culture collection practices directly affect diagnostic yield and epidemiologic interpretation. During a 2024 bottle shortage, two hospitals restricted collection to one blood-culture set per patient every 24 hours; an interrupted-time-series analysis evaluated organism-specific bloodstream-infection rates before, during, and after the restriction. [901]D Accordingly, the number of available sets and any collection restriction should be documented when interpreting a negative culture or assessing the significance of a positive result. [901]D
In patients hospitalized with COVID-19, culture positivity and pathogen distribution varied with case mix, disease severity, sampling timing, inflammatory findings, and antimicrobial exposure; therefore, a positive blood culture should be interpreted in its clinical context rather than attributed automatically to viral illness or presumed contamination. [897] Population-based surveillance of adult S. aureus bacteremia has separately tracked methicillin-resistant and methicillin-susceptible infections and linked clinical records with vital-statistics data, supporting explicit classification of MRSA versus MSSA at the time of diagnosis. [898]D
Identification and resistance testing
Laboratories should report species identification and a complete susceptibility profile, including methicillin resistance and agents being considered for treatment. Clindamycin results require particular attention: inducible resistance mediated by erm genes may be missed by routine susceptibility testing and can lead to treatment failure. Phenotypic evaluation of clinical isolates therefore remains important when erythromycin and clindamycin results suggest possible inducible resistance. [867]
For surveillance, outbreak investigation, and transmission analysis, whole-genome sequencing can be integrated with epidemiologic information. A systematic review of routine national or subnational surveillance systems evaluated systems combining epidemiologic data with WGS for antibiotic-resistant bacteria, including methicillin-resistant S. aureus among the targeted organisms. [895] WGS is best regarded as a complementary epidemiologic tool rather than a replacement for culture-based diagnosis and phenotypic susceptibility testing. [895][867]
Site-specific and special-population considerations
Endogenous endophthalmitis requires ophthalmologic sampling when clinically indicated: a multicenter cohort included patients who underwent anterior-chamber paracentesis, intravitreal aspiration, or vitrectomy with intravitreal antimicrobial administration, and analyzed culture-positive disease by pathogen. [887] Suspected bacterial keratitis in immunodeficiency may follow viral disease and can be caused by MRSA; the reported DOCK8-deficiency case illustrates the need for early suspicion and microbiologic confirmation in prolonged or atypical keratitis. [904]C Tracheostomy patients may require assessment of stoma specimens, but microbiologic findings should be correlated with clinical infection because the prospective study evaluated organisms recovered from tracheostomy-stoma cultures alongside clinical characteristics and outcomes. [903]
Urinary isolation of S. aureus should be interpreted in the context of urinary symptoms, instrumentation, and possible systemic infection; contemporary UTI literature emphasizes that microbial findings must be integrated with clinical classification rather than treated as an isolated laboratory result. [874]D Environmental or device-associated recovery, such as S. aureus from contaminated mobile phones, demonstrates exposure or colonization potential but does not establish infection without compatible clinical findings. [908] Experimental wound studies and investigations of novel anti-staphylococcal agents do not substitute for diagnostic culture, susceptibility testing, or source evaluation in clinical disease. [875]D[899]D[900]D
| Clinical setting | Recommended diagnostic emphasis | Evidence |
|---|---|---|
| Suspected osteomyelitis | Intraoperative deep tissue sampling; avoid relying solely on superficial material | [861] |
| Diabetic foot or Charcot neuroarthropathy | Deep tissue or ulcer-base culture; assess for polymicrobial infection and resistance | [902][907] |
| Impetigo | Lesion swab, organism identification, and standardized susceptibility testing | [906] |
| Suspected S. aureus bacteremia | Obtain and interpret multiple culture sets in clinical context; classify MRSA versus MSSA | [896][898]D[901]D |
| Chronic or atypical ulcer | Combine culture with histopathology and, when needed, metagenomic testing | [905]C |
| Endogenous endophthalmitis or atypical keratitis | Ophthalmic sampling when indicated; maintain suspicion for MRSA in high-risk hosts | [887][904]C |
Severity Assessment and Risk Stratification
- ▸Use syndrome-specific assessment; SAB, IE, septic shock, spinal epidural abscess, and graft infection require urgent evaluation for organ dysfunction and metastatic disease. [349][811][886][815]
- ▸In AD, S. aureus colonization is common and associated with disease-severity research, but colonization alone is not a sufficient severity threshold. [369][372]
- ▸High-risk SAB features include methicillin resistance, respiratory failure, mechanical ventilation, renal dysfunction, hypoalbuminemia, abnormal platelet trajectories, and an uncontrolled or deep source. [349][811][812]
- ▸Renal replacement therapy is a major adverse prognostic marker in IE; embolic disease requires reassessment because persistent extracardiac foci may change management. [819][886]
- ▸Severe baseline neurologic deficit in S. aureus spinal epidural abscess does not alone determine outcome. [815]
Scope and general principles
Severity assessment in Staphylococcus aureus infection should be syndrome-specific. The most clinically important high-risk presentations in the available evidence are S. aureus bloodstream infection (SAB), infective endocarditis (IE), septic shock, spinal epidural abscess, vascular graft infection, and severe skin disease. Prognostic variables should be interpreted with the infection source, metastatic complications, organ dysfunction, antimicrobial susceptibility, and trajectory over time rather than with colonization or a single laboratory value alone. [349]B3b[811][819]
Atopic dermatitis and colonization-associated severity
In atopic dermatitis (AD), S. aureus overgrowth and reduced microbial diversity are reported in approximately 70%-90% of patients. [372]A1b A systematic review and meta-analysis of 7 randomized controlled trials involving 929 participants evaluated the correlation between S. aureus colonization and AD severity using converted correlation coefficients and a random-effects model; the available abstract confirms that the association was specifically assessed, but does not provide the pooled estimate or confidence interval. [369]A1a Therefore, colonization may support assessment of inflammatory burden and disease phenotype, but it should not be used as a stand-alone severity threshold without clinical scoring and barrier assessment. [369]A1a[372]A1b
Microbiome-directed treatment results also caution against equating colonization with short-term clinical severity. In moderate-to-severe AD, 12 weeks of abrocitinib at 100 or 200 mg once daily was evaluated with serial microbiome sampling at baseline and weeks 2, 4, and 12 alongside clinical, inflammatory, and barrier outcomes. [909] In mild-to-moderate AD, topical XZ.700 was studied in lesions involving 1%-10% or 1%-15% body surface area, and short-term treatment did not produce the reported clinical or colonization improvement in the available study summary. [910] Similarly, a vehicle-controlled trial of topical SA.100 in 53 patients with mild-to-moderate AD found no reduction in S. aureus, no microbiome change after 2 weeks, and no statistically significant clinical improvement; treatment was safe and well tolerated. [372]A1b These findings indicate that persistent colonization after a brief intervention does not necessarily identify acute clinical deterioration, and that severity assessment should remain clinically anchored. [372]A1b[910]
SAB: immediate risk assessment
SAB should be treated as a potentially life-threatening infection requiring early assessment of hemodynamic status, respiratory function, renal function, platelet count, mental status, source, and evidence of metastatic infection. [349]B3b[811][812] In a 321-patient retrospective SAB study, the principal sources were pulmonary (26.8%), catheter-related (24.3%), and skin/soft-tissue infections (23.4%); hemodialysis was the predominant comorbidity (21.2%). [811] Methicillin resistance, biomarker abnormalities, and treatment effectiveness were identified as components of the study’s risk-stratification framework, although the abstract does not provide all threshold values. [811]
Organ dysfunction markers may refine risk estimation. A single-center model of 160 patients with SAB developed a six-variable nomogram incorporating the PaO2/FiO2 ratio, urea, albumin, red-cell distribution width, mechanical ventilation, and platelet count; it was internally validated by bootstrap resampling and compared with SOFA. [349]B3b In a separate cohort of 1,609 SAB episodes—1,242 MSSA and 367 MRSA—mortality was inversely associated with platelet count, with the day-3 platelet analysis showing an adjusted odds ratio of 3.11 for the reported higher-risk platelet category; the full confidence interval and category definition should be checked in the primary publication before applying a numeric cutoff. [812]
Endocarditis and metastatic complications
S. aureus is a major pathogen in IE and should prompt evaluation for embolic, cardiac, neurologic, renal, and other extracardiac complications. [68]C4[886][814]C[819] In a contemporary systematic review of isolated pulmonary-valve IE, S. aureus caused 39% of reported adult cases; congenital heart disease and injection drug use were present in 30.4% and 27.8%, respectively, while 41.8% had neither risk factor. [68]C4 Embolic events are associated with poor prognosis in IE, and a prospective multicenter REASSESS-IE study evaluated follow-up imaging before antibiotic discontinuation in clinically stable or asymptomatic patients with embolic events because persistent extracardiac foci may alter treatment. [886]
In left-sided IE, embolism present at admission and embolism developing during hospitalization have different prognostic significance, supporting repeated clinical and echocardiographic assessment rather than a one-time evaluation. [814]C In a Colombian multicenter IE cohort, in-hospital mortality was 32.7% overall, with renal replacement therapy independently associated with death at an adjusted odds ratio of 9.19; mortality varied substantially between centers (9.6%-45.9%). [819] Methicillin-resistant staphylococcal left-sided IE also warrants explicit renal-risk assessment when selecting therapy: a prospective multicenter cohort compared daptomycin with vancomycin, while a multicenter study specifically examined vancomycin-associated acute kidney injury in patients with moderate chronic kidney disease. [810][771]
Other severe focal infections
Vascular graft and endograft infection carries substantial morbidity and mortality. In a 129-patient cohort, most patients were older adults, and smoking, hypertension, and diabetes were frequent comorbidities. [264]B2b In a separate 171-patient cohort, S. aureus was the most frequent pathogen, 41.1% of microbiologically characterized infections were polymicrobial, and 78.4% involved extracavitary grafts. [373]B3b These features support risk stratification by graft location, polymicrobial infection, surgical feasibility, and host comorbidity. [264]B2b[373]B3b
S. aureus spinal epidural abscess is a neurologic emergency. A two-center series of 65 patients evaluated primary versus spondylodiscitis-associated abscesses and medical versus surgical management; severe initial neurologic deficits alone did not predict worse outcomes compared with associated cases, so prognosis should incorporate anatomical extent, source control, bacteremia, and clinical evolution rather than baseline deficit alone. [815] In critically ill adults with bloodstream infection, S. aureus BSI was also specifically evaluated for its association with incident delirium during the first 7 days, emphasizing mental-status surveillance as part of severity assessment. [813]
Interpretation of risk scores
The Pitt bacteremia score, qSOFA, and Charlson Comorbidity Index were compared for mortality prediction in adults with nonbacteremic multidrug-resistant infections, but this evidence does not establish a validated S. aureus-specific cutoff for nonbacteremic disease. [911] Pediatric septic-shock risk factors and pathogen patterns were examined in a 10-year retrospective cohort, but pediatric estimates should not be extrapolated directly to adults. [238]B2b Overall, validated tools can complement—not replace—serial assessment of organ failure, bacteremia persistence, source control, embolic disease, and treatment response. [349]B3b[811][911]
| Domain | High-risk considerations | Evidence |
|---|---|---|
| AD | Extensive clinical disease; colonization interpreted with clinical scores and barrier dysfunction; colonization commonly reported in 70%-90% | [369]A1a[372]A1b |
| SAB | Respiratory failure, mechanical ventilation, low PaO2/FiO2, renal or biochemical abnormalities, thrombocytopenia, MRSA, persistent or deep-source infection | [349]B3b[811][812] |
| IE | Embolic events, renal replacement therapy, extracardiac foci, left-sided disease, MR staphylococcal infection | [810][814]C[819][886] |
| Focal infection | Neurologic compromise in epidural abscess; graft location, polymicrobial infection, and comorbidity in graft infection | [264]B2b[373]B3b[815] |
Empiric Management, Acute Care and Source Control
- ▸Drain purulent skin and soft-tissue infection promptly; treatment is typically **7 days after drainage** if clinical response is adequate. [838]
- ▸Base empiric MSSA/MRSA coverage on local resistance data, patient risk factors, infection severity, and healthcare or livestock exposure. [823] [829]
- ▸Use structured SAB management, monitor renal function for AKI, and reassess antibiotic dosing and duration. [826] [827]
- ▸Fulminant influenza-associated MSSA pneumonia may require early intubation, extracorporeal support, and critical-care management. [828]
- ▸Chronic prosthetic infection requires multidisciplinary source-control planning; partial component exchange is reserved for selected cases. [821]
- ▸Photodynamic therapy, engineered hydrogels, essential oils, nanocrystals, and postbiotic dressings remain investigational or preclinical. [831] [833] [834] [836] [839] [840]
Immediate assessment and empiric therapy
Management should begin with rapid assessment of airway, breathing, circulation, organ dysfunction, infection severity, likely anatomical focus, recent healthcare exposure, and local S. aureus susceptibility patterns. Empiric antibiotic selection should reflect locally circulating MSSA and MRSA strains, because resistance epidemiology varies by setting and region. [838]D Long-term surveillance from a secondary hospital in China demonstrated changing pathogen distribution and antimicrobial-resistance patterns over 2014–2025, supporting institution-specific rather than universally fixed empiric regimens. [823] Surveillance in northeastern Iran also identified persistent livestock-associated MRSA ST398/t011 and hospital-associated MRSA ST239/t037, illustrating that clone distribution and exposure-associated risk may influence empiric coverage. [829]C
For purulent skin and soft-tissue infection, incision and drainage is the central intervention; adjunctive antibiotics further increase cure rates, and treatment is typically continued for 7 days after drainage when the clinical response is adequate. [838]D Antibiotics should cover locally prevalent S. aureus strains, with subsequent narrowing based on culture and susceptibility results. [838]D Staphylococcal scalded skin syndrome (SSSS) requires hospitalization-level supportive care and antistaphylococcal treatment. A pediatric retrospective noninferiority study specifically evaluated empiric regimens with versus without MRSA coverage, but the available abstract does not establish a universal regimen; therefore, MRSA coverage should be individualized to local epidemiology, severity, and patient risk factors. [822]C A multicenter pediatric intensive-care study likewise addressed reduction of empiric vancomycin use where MRSA prevalence was low, supporting stewardship-guided avoidance of routine vancomycin exposure when clinical and epidemiologic risk is limited. [830]D
Acute care for invasive disease
S. aureus bacteremia (SAB) warrants urgent microbiologic evaluation, assessment for metastatic infection, serial clinical reassessment, and coordinated infectious-disease and antimicrobial-stewardship management. A pharmacist-coordinated treatment bundle for MRSA bacteremia included diagnostic, dosing, and treatment-duration optimization; the study evaluated bundle adherence using a threshold of at least 9 of 12 items (≥75%) and assessed 28-day and 90-day outcomes, supporting structured care processes even though the abstract does not provide a universally applicable treatment protocol. [827]C
Renal function must be monitored closely during treatment. In a multicenter cohort of adults with SAB treated with cefazolin or flucloxacillin, acute kidney injury (AKI) was examined for incidence, severity, timing, recovery, and associations with antibiotic treatment and dosing. [826] These findings support dose adjustment and active surveillance for AKI during antistaphylococcal therapy, particularly when using flucloxacillin or other potentially nephrotoxic combinations. [826]
Severe pneumonia or septic shock requires immediate critical-care support in addition to antimicrobial therapy and evaluation for pulmonary source control. Influenza-associated community-acquired MSSA can cause rapidly progressive necrotizing pneumonia, septic shock, and acute respiratory distress syndrome; a reported child required intubation and veno-venous extracorporeal membrane oxygenation on day 1 for refractory hypoxemia. [828]C Thus, influenza coinfection does not exclude MSSA as the cause of fulminant disease, and early escalation of respiratory and circulatory support may be required. [828]C
Pediatric infective endocarditis should be considered in bacteremia with compatible cardiac risk, persistent infection, embolic phenomena, or prosthetic material. A 2013–2024 pediatric cohort evaluated native- and prosthetic-valve endocarditis in children, emphasizing diagnostic and outcome differences associated with congenital heart disease and prosthetic material. [825] Such patients require specialist cardiac and infectious-disease assessment and evaluation for surgical management when infection involves prosthetic material or causes complications. [825]
Source control and difficult foci
Source control includes drainage of purulent collections, debridement of devitalized tissue, removal or exchange of infected foreign material when indicated, and evaluation for bone, joint, cardiac, or pulmonary complications. For osteomyelitis, a cohort of 704 patients used microbiologic isolation with radiologic correlation to define confirmed disease and identified clinical factors associated with prolonged hospitalization and disease course. [824] These data support early microbiologic sampling, imaging correlation, and individualized planning for prolonged antimicrobial therapy and surgical management when necrotic bone, abscess, hardware, or failure of medical therapy is present. [824]
Chronic prosthetic hip infection commonly requires prolonged antibiotics plus complete prosthesis exchange, performed as either one-stage or two-stage revision. [821] A systematic review evaluated partial exchange—removal of one component while retaining a well-integrated component—as an alternative for selected chronic infections, particularly when removal of a well-osseointegrated component carries substantial surgical risk. [821] Partial exchange should therefore be regarded as a selected, multidisciplinary strategy rather than routine source control. [821]
Biofilm and intracellular persistence can complicate eradication. S. aureus is a facultative intracellular pathogen capable of persistence in professional and nonprofessional phagocytes, adoption of slow-replicating states, and evasion of conventional antibiotic therapy. [832]D These mechanisms provide a biologic rationale for combining adequate source control with prolonged, susceptibility-directed therapy in relapsing or device-associated infection. [832]D
Adjunctive and investigational approaches
Novel non-antibiotic or local-delivery approaches remain investigational. Antimicrobial photodynamic therapy is being developed against ESKAPE pathogens, including S. aureus, but limitations in efficacy, delivery, and clinical translation remain. [839]D Experimental wound systems include a sprayable NIR/pH-responsive hydrogel containing molybdenum dioxide, ciprofloxacin, and FGF-2, which showed in-vitro antibacterial and regenerative effects. [834]D A gelatin-hydrogel cefazolin delivery system improved antimicrobial activity in a rat MSSA spondylodiscitis model, but this is preclinical evidence and cannot replace established systemic therapy or surgical source control. [836]D Zanthoxylum beecheyanum essential oil potentiated vancomycin activity and inhibited biofilm formation in laboratory studies, while catalytic nanocrystals and postbiotic dressings also showed in-vitro antibacterial activity; none should be considered standard clinical treatment. [833]D [831]D [840]D
Stewardship and reassessment
Empiric therapy should be reassessed promptly after cultures, susceptibility results, clinical trajectory, organ-function data, and source-control findings become available. [823] [826] [827]C Reducing unnecessary vancomycin exposure is particularly relevant where MRSA prevalence is low, while maintaining coverage in patients with severe disease or credible MRSA risk. [830]D Neonatal practice requires additional caution: a Vietnam-focused review reported substantial MRSA burden, regional variation, frequent antibiotic overuse, and limited neonatal evidence, underscoring the need for local surveillance, dosing expertise, and infection-prevention measures. [835]D
| Clinical situation | Immediate priority | Evidence-supported qualification |
|---|---|---|
| Purulent skin/soft-tissue infection | Incision and drainage plus empiric antibiotics when indicated | Cover locally circulating strains; commonly 7 days after drainage with adequate response. [838]D |
| SAB or MRSA bacteremia | Structured diagnostic, dosing, duration, and complication assessment | Bundle adherence of ≥75% was used in a pharmacist-coordinated program. [827]C |
| Severe pneumonia or shock | Critical-care resuscitation and respiratory support | Influenza-associated MSSA may cause necrotizing pneumonia, ARDS, and need for VV-ECMO. [828]C |
| Chronic prosthetic hip infection | Multidisciplinary revision or component-exchange planning | Partial exchange is an option only for selected infections with favorable retained-component circumstances. [821] |
| Osteomyelitis | Culture, imaging correlation, and assessment for debridement | Confirmed disease requires pathogen isolation with radiologic correlation in the cited cohort. [824] |
Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
- ▸Cefazolin and antistaphylococcal penicillins remain first-line definitive options for MSSA bacteremia; recent trials summarized in a 2026 review report cefazolin noninferior to ASPs with a more favorable safety profile. [913,919]
- ▸A cefazolin inoculum effect was present in 31.9% of blaZ-positive MSSA bloodstream isolates, but the supplied evidence does not establish that this finding alone should determine clinical therapy. [918]
- ▸DSTA4637S was studied weekly at 15, 45, or 100 mg/kg with standard-of-care antibiotics in a 25-patient phase 1b study; it remains investigational. [912]
- ▸Rifampicin may have a role in biofilm-associated osteoarticular infection, but it requires combination therapy and careful interaction assessment. [921]
- ▸No universal duration schedule can be derived from the supplied references; duration should reflect culture clearance, source control, site, prosthetic material, metastatic infection, and response. [912,919,921]
- ▸Inducible clindamycin resistance can be missed by routine testing; dedicated phenotypic testing is required before relying on clindamycin for serious infection. [867]
Core principles
Definitive treatment of Staphylococcus aureus infection should be individualized according to methicillin susceptibility, infection site, source-control status, metastatic foci, prosthetic material, renal/hepatic function, and susceptibility results. The supplied evidence supports cefazolin or an antistaphylococcal penicillin (ASP) as first-line definitive agents for MSSA bacteremia; however, the references provided do not supply a complete organism-specific dosing table or a universal duration algorithm. [913] For MRSA bacteremia, the supplied studies describe the clinical burden and investigational strategies but do not provide sufficient comparative evidence to establish a new standard definitive regimen. [893]
MSSA: cefazolin, ASPs, and de-escalation
Cefazolin and ASPs are established first-line definitive options for MSSA bacteremia. [913] A 2026 narrative review reports that the CloCeBa trial and the MSSA domain of the SNAP adaptive-platform trial found cefazolin noninferior to ASPs for MSSA bacteremia, with a generally more favorable safety profile. [919]D These findings support de-escalation from empiric broad-spectrum therapy to cefazolin or an ASP once MSSA is confirmed and clinically appropriate source control has been achieved. [919]D
The evidence does not justify routine avoidance of cefazolin solely because of historical concern regarding the cefazolin inoculum effect (CzIE). In a genomic study of 488 MSSA bloodstream isolates, 76.5% (373/488) carried blaZ, and 31.9% (119/373) of blaZ-positive isolates exhibited CzIE. [918]D The study characterized the prevalence and genetic determinants of CzIE but, from the supplied abstract, does not establish that CzIE should independently determine clinical drug selection or treatment duration. [918]D
Hypoalbuminemia is relevant to interpretation of exposure because cefazolin and ASPs are substantially protein-bound. [913] A retrospective cohort study specifically evaluated whether hypoalbuminemia was associated with delayed blood-culture clearance in MSSA bacteremia treated with cefazolin or an ASP, but the supplied evidence does not report the study’s outcome estimates or support a specific dose-adjustment threshold. [913] Accordingly, albumin concentration should be incorporated into clinical assessment rather than used alone to mandate escalation, therapeutic-drug monitoring, or prolonged therapy. [913]
MRSA and investigational antibody–antibiotic therapy
DSTA4637S is an antibody–antibiotic conjugate combining an anti-S. aureus antibody with a rifamycin-class antibiotic and was investigated as an adjunct to standard-of-care antibiotics in hospitalized patients with complicated S. aureus bacteremia. [912] In the phase 1b randomized, double-blind, placebo-controlled multiple-ascending-dose study, 25 patients with complicated bacteremia received weekly intravenous DSTA4637S at 15, 45, or 100 mg/kg alongside at least 4 weeks of standard-of-care antibiotics; 68% had MSSA and 32% had MRSA. [912] This was an early-phase safety, tolerability, and pharmacokinetic study, so these doses should not be interpreted as an established definitive regimen or as a basis for routine de-escalation. [912]
The rationale for DSTA4637S is eradication of intracellular bacterial reservoirs that may contribute to treatment failure; the supplied evidence does not establish comparative efficacy, optimal duration, or a validated PK/PD target. [912] Use therefore remains investigational and should be restricted to an appropriate clinical-trial or specialist context. [912]
Rifampicin, biofilm infection, and drug interactions
For osteoarticular infection, including prosthetic-joint infection, fracture-related infection, and osteomyelitis, definitive management requires source control combined with prolonged antimicrobial therapy. [919]D Rifampicin is described in a 2026 review as a potentially important component of treatment for Gram-positive osteoarticular infection because of bactericidal activity against quiescent, biofilm-embedded bacteria and excellent oral bioavailability. [921]D The supplied evidence does not specify a universal rifampicin dose, duration, or requirement for combination partners; therefore, rifampicin should not be used as monotherapy, and regimen selection must account for susceptibility, implant status, source control, and drug interactions. [921]D
Rifampicin can cause clinically important pharmacokinetic interactions. In a pharmacokinetic case report, rifampicin 600 mg twice daily for 7 days was given with levofloxacin for MRSA eradication therapy in a patient receiving long-acting cabotegravir/rilpivirine; temporary oral bridging with tenofovir disoproxil fumarate/emtricitabine and dolutegravir was used because rifampicin is contraindicated with long-acting cabotegravir/rilpivirine. [914]C This case demonstrates the need for medication reconciliation and interaction planning before rifampicin initiation, but it does not define a general S. aureus treatment regimen. [914]C
Duration and monitoring
The supplied references do not provide a complete evidence-based duration schedule for uncomplicated versus complicated bacteremia, endocarditis, osteomyelitis, prosthetic-joint infection, or metastatic disease. [912][919]D[921]D Duration should therefore be determined by documented blood-culture clearance, infection site, adequacy of source control, presence of prosthetic material, metastatic infection, and clinical response rather than by a fixed duration applied to every patient. [912][919]D[921]D Persistent bacteremia, inadequate source control, biofilm-associated infection, or suspected intracellular persistence should prompt renewed diagnostic evaluation and specialist review rather than automatic antimicrobial broadening. [912][921]D
Clindamycin should not be selected for serious definitive therapy without attention to inducible resistance. erm-mediated inducible clindamycin resistance can be missed by routine susceptibility testing and has been associated with treatment-failure concern; phenotypic testing is therefore essential when clindamycin is being considered. [867]
| Clinical context | Evidence-supported approach | Dosing/PK-PD limits |
|---|---|---|
| MSSA bacteremia | Cefazolin or an ASP; cefazolin is supported as noninferior to ASPs in trials summarized by a 2026 review. [913][919]D | Supplied references do not provide a complete dosing table or target exposure. [913][919]D |
| MSSA with hypoalbuminemia | Interpret exposure and clearance cautiously because cefazolin and ASPs are substantially protein-bound. [913] | No albumin-based dose-adjustment threshold is reported in the supplied abstract. [913] |
| Complicated MSSA/MRSA bacteremia | DSTA4637S was investigationally administered weekly with standard-of-care antibiotics. [912] | Phase 1b data do not establish routine efficacy, duration, or a validated PK/PD target. [912] |
| Biofilm-associated osteoarticular infection | Consider rifampicin only within an appropriate combination regimen after source-control assessment. [921]D | Exact dose and duration are not established by the supplied review; interactions may be major. [914]C[921]D |
History and Evolution of Treatment
- ▸Treatment evolved from largely supportive and surgical care in the pre-antibiotic era to microbiology-guided antimicrobial therapy, source control, and resistance-directed management. [852, 853]
- ▸mecA-mediated production of penicillin-binding protein 2a is the central mechanism of methicillin resistance, while additional resistance mechanisms complicate treatment selection. [853]
- ▸Admission MRSA carriage, especially in rehabilitation facilities, is now incorporated into prevention and treatment planning because it may promote transmission and complications. [846]
- ▸Diabetic-foot, ocular, neonatal, injection-associated, bone, endocardial, and unusual hematogenous infections require site- and population-specific treatment strategies. [753, 772, 789, 796, 847, 854, 855]
- ▸Modern endocarditis research is testing response-tailored therapy after at least 2–4 weeks of initial treatment rather than relying exclusively on fixed courses of up to 6 weeks. [842]
- ▸Phage engineering and bacterial DNA-repair pathways represent emerging nontraditional approaches for difficult MRSA infections. [849, 850, 851]
From pre-antibiotic disease to targeted antimicrobial therapy
Before antibiotics, osteomyelitis was frequently fatal; historical analysis of German osteomyelitis specimens from the nineteenth and twentieth centuries is now being used to identify pathogens, virulence traits, and antimicrobial-resistance features that may connect pre-antibiotic organisms with contemporary hospital strains. Staphylococcus aureus remains the leading cause of osteomyelitis, alongside other healthcare-associated pathogens. [852]D The modern treatment era therefore evolved from predominantly supportive and surgical management toward pathogen-directed antimicrobial therapy, source control, and resistance-guided treatment. This historical transition remains clinically relevant because MRSA now causes infections ranging from skin disease to bacteremia, pneumonia, endocarditis, osteomyelitis, and sepsis. [853]D
The MRSA era and escalation of resistance-directed treatment
The acquisition of mecA, which encodes penicillin-binding protein 2a, is the principal mechanism of methicillin resistance and eliminates the reliability of traditional β-lactam therapy against MRSA. [853]D MRSA has subsequently accumulated additional resistance through target-site mutations, efflux mechanisms, horizontal gene transfer, biofilm formation, and adaptive phenotypic changes, producing increasingly complex therapeutic decisions. [853]D Contemporary management consequently depends on microbiological confirmation, susceptibility testing, assessment of infection severity, and selection of agents active against multidrug-resistant organisms rather than use of conventional empiric therapy alone. [734]
Treatment has also become more explicitly linked to epidemiology and prevention. MRSA carriage at admission to rehabilitation facilities is important because it may facilitate onward transmission, infectious complications, and poorer rehabilitation outcomes; a systematic review and meta-analysis specifically evaluated admission-screening studies and associated risk factors through 4 February 2025. [846] In neonatal intensive-care settings, MRSA was already recognized among important resistant pathogens during 2000–2005, and resistance remains a major challenge in the 2020–2025 period, supporting the continuing importance of surveillance, infection prevention, and antimicrobial stewardship. [855]D
Site-specific and population-specific treatment evolution
Therapeutic strategy increasingly reflects the infection site and local microbiology. In diabetic-foot infection, S. aureus remained the most common pathogen in a 2021–2025 outpatient series, but its proportion fell from 55.0% to 38.9% of cultures while Enterobacterales increased from 36.1% to 47.7% of isolates; the polymicrobial index was 1.62, emphasizing the need for culture-directed and often broader initial assessment rather than assuming monomicrobial MRSA disease. [753] A separate 2013–2024 study of toe amputations for diabetic-foot infection evaluated resistance across three periods and included substantial comorbidity, including dialysis in 30% of patients, illustrating why antimicrobial selection must account for both longitudinal resistance and host factors. [847]
In ocular disease, longitudinal surveillance from 2013–2022 used molecular typing, including multilocus sequence typing and staphylococcal cassette chromosome mec characterization, together with susceptibility testing to follow changing MRSA clones and fluoroquinolone resistance. [854]D In people who inject drugs, a six-month Fijian hospital study documented a substantial burden of acute infections in a predominantly young male population, reinforcing the need to adapt treatment and prevention strategies to injection-associated risk and local epidemiology. [772] Rare or diagnostically difficult infections also require individualized management: pubic-symphysis osteomyelitis may be delayed or mistaken for inflammatory disease in rheumatoid arthritis, while hematogenous S. aureus infection can rarely cause ovarian abscess and septic shock in a sexually inactive patient with atopic dermatitis. [789][796]C
Duration, severe infection, and response-guided therapy
For severe infections caused by multidrug-resistant organisms, including MRSA, a 2026 German clinical-practice guideline provides evidence-based antibiotic recommendations developed through systematic literature retrieval and GRADE evaluation. [734] Infective endocarditis illustrates the movement from fixed-duration treatment toward response-adapted care. Traditionally, left-sided endocarditis has been treated for up to 6 weeks, largely on the basis of expert consensus; a randomized international trial evaluated response-tailored therapy after patients had received at least 2–4 weeks of treatment and achieved clinical stabilization, including cases caused by S. aureus. [842]D Contemporary reviews of aortic-valve endocarditis likewise reassess diagnosis, antimicrobial management, and cardiac surgery in light of evidence emerging since the 2015 European guidance. [748]D
Beyond conventional antibiotics
Because resistance, persistence, and biofilm-associated disease limit antibiotic options, treatment development is expanding beyond standard drugs. Base-excision DNA repair is being investigated as a potential target because it supports S. aureus survival under oxidative and nitrosative immune stress and antibiotic-induced damage. [849]D Phage therapy is another emerging approach: experimental evolution of phage K generated phage KJ25 with enhanced activity against USA300 MRSA in lung-infection models, while directed evolution of the Kayvirus SAVM02 against diabetic-foot isolates produced a trained pool active against approximately 77% of tested S. aureus isolates. [850]D[851]D Reviews of emerging MRSA therapies therefore frame future treatment as a combination of optimized antimicrobial stewardship, resistance surveillance, source control, precision microbiology, novel antibacterial targets, and individualized or adjunctive approaches. [853]D
| Treatment stage | Defining development | Evidence |
|---|---|---|
| Pre-antibiotic era | Osteomyelitis was frequently fatal; historical pathogen and genome analysis informs modern comparisons. | [852]D |
| β-lactam era | Methicillin resistance emerged through mecA-encoded PBP2a. | [853]D |
| Resistance-directed era | Severe MDRO infections require guideline-based, susceptibility-informed therapy. | [734] |
| Surveillance-informed era | Carriage screening, molecular typing, and longitudinal resistance monitoring guide prevention and drug selection. | [846][847][854]D[855]D |
| Precision and adjunctive era | Response-tailored duration, engineered phages, and novel bacterial targets are being evaluated. | [842]D[849]D[850]D[851]D |
Antimicrobial Resistance and Stewardship
- ▸MRSA incidence has declined in North America and Europe since peaking around 2005-2008, while Gram-negative resistance continues to rise [237, 579].
- ▸Mupirocin resistance in MRSA correlates with usage volume; consumption exceeding 25 DDD/1000 patient-days is linked to increasing resistance [537].
- ▸Negative MRSA nasal PCR is a powerful stewardship tool (NPV 96.5%) to de-escalate empiric anti-MRSA therapy for pneumonia [11].
The evolution of treatment has been paralleled by a dynamic landscape of antimicrobial resistance, requiring clinicians to understand both the mechanisms that undermine therapy and the stewardship strategies that preserve it.
Mechanisms of Resistance
Staphylococcus aureus has acquired resistance to every antibiotic class introduced. The principal determinant of methicillin resistance is the mecA gene on elements (13 types), encoding PBP2a with low β-lactam affinity [42]D5. Homologues mecC and plasmid-borne mecB also exist [581]C4. resistance occurs via the vanA operon (acquired from enterococci, producing VRSA) or stepwise mutations yielding vancomycin-intermediate S. aureus (VISA) and heteroresistance (hVISA) [55]C4[558]D5[565]D5. resistance arises from 23S rRNA mutations (G2576T) or the cfr methyltransferase [233]C4[416]C4. resistance involves mutations in mprF and cls, sometimes cross-selected by vancomycin [60]D5[558]D5. High-level mupirocin resistance is mediated by mupA; low-level resistance by ileS mutations [306]D5[576]C4. Additional mechanisms include PBP4 alterations [573]D5, bacitracin resistance via bcrABD operons [571]D5, and biofilm-mediated tolerance [46]D5[585]D5.
of Multidrug-Resistant Variants
MRSA remains the dominant multidrug-resistant variant. In the SENTRY program (1997-2016), MRSA accounted for 40.3% of 191,460 isolates globally, peaking at 44.2% in 2005-2008 then declining to 39.0% by 2013-2016 [579]B2c. In US hospitals, MRSA infection incidence fell from 114 to 94 per 10,000 hospitalizations between 2012 and 2017 [237]B2b. VRSA remains rare (9 US cases by 2009) [565]D5, but methicillin-susceptible VRSA has emerged in Brazil [100]C4. Linezolid-resistant S. aureus prevalence is 0.05%, though outbreaks occur in high-use settings [233]C4[416]C4. Mupirocin resistance reaches 34.4% in some MRSA populations, tightly linked to usage volume [576]C4. Regional variation is notable: MRSA exceeds 60% in parts of the Arab League and Brazil [562]D5[563]D5. Refugees and asylum seekers have higher odds of AMR carriage [557]B2a.
Stewardship Principles for Preserving Antibiotic Efficacy
programs (ASPs) reduce MRSA infections by 37% (IR 0.63, 95%) [196]A1a. MRSA nasal PCR screening provides a negative predictive value of 96.5% for MRSA pneumonia, enabling safe de-escalation [11]B2a. Selective digestive decontamination in ICUs does not significantly increase MRSA resistance [449]A1a. Mupirocin use above 25 defined daily doses per 1000 patient-days correlates with rising resistance [537]B2b. Universal glove and gown use in ICUs reduced MRSA acquisition by 2.98 per 1000 patient-days [509]A1b. Enhanced terminal room disinfection with UV light reduced target organism acquisition [25]A1b. In Latin American hospitals, higher ASP scores were associated with 8.59 fewer defined daily doses of anti-MRSA agents [95]C4.
Controversies and Guideline Disagreement
Universal decolonization with chlorhexidine bathing in non-ICU wards did not reduce MRSA/VRE clinical cultures in the ABATE Infection trial [210]A1b, whereas ICU-based decolonization with mupirocin-CHG outperformed iodophor-CHG [30]A1b. Selective decontamination, though not associated with increased resistance in meta-analyses [449]A1a, has limited adoption outside Europe due to unresolved long-term ecological concerns.
Pearl: A negative MRSA nares PCR has a negative predictive value of 96.5% for ruling out MRSA pneumonia, making it a high-yield antimicrobial stewardship tool to avoid unnecessary empiric anti-MRSA therapy [11]B2a.
| Intervention | Effect Metric | Outcome | Reference |
|---|---|---|---|
| Antibiotic stewardship programs | Incidence ratio (IR) | 37% reduction (IR 0.63) | [196]A1a |
| MRSA nares screen (pneumonia NPV) | NPV | 96.5% | [11]B2a |
| SDD/SOD in ICU | OR for MRSA resistance | 1.46 (not significant) | [449]A1a |
| Mupirocin-CHG decolonization threshold | DDD/1000 patient-days | >25 associated with resistance rise | [537]B2b |
| Universal glove & gown (ICU) | MRSA acquisition difference | -2.98 per 1000 patient-days | [509]A1b |
| UV room disinfection | RR for target organisms | 0.70 | [25]A1b |
| Hospital ASP score (Latin America) | DDD change (anti-MRSA) | -8.59 (SE 4.12) | [95]C4 |
Supportive Care and Complications
- ▸Acute kidney injury is the most common therapy-related complication; cefazolin is associated with significantly less nephrotoxicity than antistaphylococcal penicillins (OR 0.225, 95% CI 0.127-0.513) [591].
- ▸Routine addition of rifampin to standard therapy does not improve outcomes and increases adverse events (17% vs 10%); avoid unless required for specific device-related infection [24].
- ▸Delayed appropriate antimicrobial therapy is a key risk factor for metastatic complications (RR 7.16 for metastatic infection without endocarditis) [387].
Resistance-guided antibiotic selection, detailed in the preceding section, must be paired with a systematic approach to supportive care that anticipates the major drivers of morbidity in S. aureus infections. Complications arise both from the infection itself (metastatic seeding, toxin-mediated shock, septic emboli) and from therapy (nephrotoxicity, drug interactions, adverse events). Proactive monitoring and prevention are as critical as antibiotic choice.
Hospital-Acquired and Therapy-Related Complications
| Complication | Frequency | Prevention | |
|---|---|---|---|
| Acute kidney injury ( , antistaph penicillins) | 18.2% vancomycin [7]A1b; 12% cloxacillin [22]A1b | Prefer cefazolin when MSSA [591]A1a; maintain adequate hydration; monitor creatinine | Dose-adjust or switch to alternative ( 6 mg/kg IV daily [16]A1b) |
| Adverse events requiring antibiotic modification ( combination) | 17% vs 10% placebo [24]A1b | Avoid combination therapy unless clear benefit; do not add rifampin routinely [24]A1b[405]B3b | Discontinue rifampin; continue backbone therapy |
| Metastatic infection (endocarditis, osteomyelitis, epidural abscess) | Osteomyelitis recurrence ~40% [46]D5; most often due to S. aureus [52]D5 | Early source control; adequate antibiotic duration; rapid clearance of bacteremia [387]B3b | Prolonged ; surgical debridement/valve replacement as indicated [602]B2b |
| Toxic shock syndrome | Mortality ~8% [113]C4 | Identify superantigen-producing strains; use toxin-suppressing antibiotics (clindamycin, ) [32]D5 | ICU support; IVIG may neutralize superantigen [32]D5 |
| Septic pulmonary emboli / Lemierre-like syndrome | Rare; high morbidity [79]C4 | Prompt treatment of primary infection; consider anticoagulation for jugular thrombosis | Source control; anticoagulation (case-dependent) [79]C4 |
| Coinfection-associated mortality (respiratory virus + S. aureus) | 30-day mortality 31.6% vs 18.0% [612]B2b; odds of death >4× with influenza [616]B2b | Annual influenza vaccination; early antiviral therapy | Broad-spectrum antibiotics covering MRSA; ICU support |
Respiratory Monitoring
Patients with S. aureus pneumonia or sepsis require close respiratory monitoring. Forced vital capacity (FVC) <20 mL/kg or rapid decline suggests impending respiratory failure. Use the table below to guide intubation decisions. Continuous and arterial blood gases are essential.
| Parameter | Threshold for Concern | Action |
|---|---|---|
| FVC | <20 mL/kg | Assess for noninvasive ventilation; prepare for intubation |
| PaO₂/FiO₂ | <200 | Initiate lung-protective ventilation |
| Work of breathing | Accessory muscle use, tachypnea >30/min | Low threshold for intubation |
| Mental status | Worsening confusion, agitation | Secure airway |
Autonomic Complications
Toxin-mediated superantigen activity can cause autonomic instability: arrhythmias, refractory hypotension, paralytic ileus, and urinary retention [32]D5[113]C4. Manage with aggressive fluid resuscitation, vasopressors (norepinephrine first-line), and cardiac monitoring. and urinary catheters are supportive until resolution.
DVT/PE Prophylaxis
Immobilized patients with S. aureus bacteremia or endocarditis are at high risk for venous thromboembolism. Initiate pharmacologic prophylaxis with low-molecular-weight (e.g., 40 mg subcutaneously daily) or unfractionated heparin 5000 units subcutaneously every 8-12 hours, provided no active bleeding or high bleeding risk. Mechanical prophylaxis (sequential compression devices) should be added when anticoagulation is contraindicated.
Pain Management
Pain in S. aureus infections is typically nociceptive (from abscess, osteomyelitis, surgical wounds) and neuropathic (if nerve involvement, e.g., spinal epidural abscess [52]D5). Acetaminophen 650 mg every 6 hours is safe for mild pain. For moderate-severe pain, opioids ( 5-10 mg IV every 4 hours as needed) may be necessary, but avoid NSAIDs in patients with renal impairment or risk of bleeding. Neuropathic pain (persistent radicular symptoms) may respond to gabapentinoids.
Rehabilitation
Early mobilization after source control improves functional outcomes. Physical therapy should begin once the patient is hemodynamically stable and infection is controlled. For patients with osteomyelitis or prosthetic joint infections, weight-bearing restrictions may apply; consult orthopedics. Prolonged hospitalization requires attention to preventing pressure injuries and deconditioning.
Pearl: The single most modifiable complication of S. aureus therapy is acute kidney injury, choosing cefazolin over antistaphylococcal penicillins for MSSA infections significantly reduces nephrotoxicity without sacrificing efficacy [22]A1b[591]A1a.
Prognosis and Natural History
- ▸The case fatality rate of S. aureus bacteremia is 15-30%, driven by host factors, source, and timeliness of source control.
- ▸Persistent bacteremia ≥48 hours is the strongest modifiable predictor of death (90-day mortality 39%).
- ▸Infectious disease consultation and appropriate empirical therapy reduce mortality; the absolute benefit of empirical anti-MRSA coverage is small for common syndromes.
Complications of S. aureus infection, whether metastatic seeding, endocarditis, or septic shock, shape the prognosis more than the index infection itself. Untreated S. aureus bacteremia (SAB) is nearly uniformly fatal. With appropriate therapy, the case fatality rate stands at 15% to 30%, accounting for an estimated 300 000 deaths annually worldwide [58]D5. Understanding the natural history across infection syndromes and the factors that modify outcome is essential for prognostication and treatment intensity.
Treated Outcomes by Syndrome
The outcomes of SAB vary substantially by source, host, and treatment fidelity. The table below summarizes key outcome data from recent trials and cohort studies.
| Syndrome | Key Outcome | Reference |
|---|---|---|
| MSSA bacteremia (cefazolin vs antistaphylococcal penicillin) | 90-day mortality: 15.0% vs 17.0% (adjusted OR 0.81; probability of noninferiority 99.2%) | [15]A1b |
| MRSA bacteremia ( / ± β-lactam) | 90-day mortality: 21% vs 16% (difference not significant) | [29]A1b |
| MRSA nosocomial pneumonia | 60-day mortality: 15.7% vs 17.0% ( vs vancomycin) | [7]A1b |
| Complicated SAB (ceftobiprole vs daptomycin) | 70-day mortality: 9.0% vs 9.1% | [14]A1b |
| Persistent SAB (≥2 days bacteremia) | 90-day mortality: 39% (vs 22% with 1 day) | [28]B2b |
| Infective endocarditis (S. aureus, overall) | 1-year survival: 84.3% with suppressive therapy | [596]C4 |
| (S. aureus, DAIR) | Success rate: hip 69%, knee 54% | [407]A1a |
| Skin abscess (drainage + TMP-SMX) | Cure: 80.5% | [452]A1b |
| Skin abscess (drainage + placebo) | Cure: 68.9% | [499]A1b |
Persistent bacteremia is the single strongest modifiable prognostic marker. Patients with ≥2 days of positive blood cultures despite active therapy have a 90-day mortality of 39% compared with 22% in those clearing within 24 hours; the second day of bacteremia carries the highest adjusted hazard [28]B2b. Short time to blood culture positivity (<13 hours) independently predicts endocarditis (OR 3.59), with a negative predictive value of 96% [199]B2b.
Methicillin resistance influences crude but not adjusted mortality. In a large Australian cohort, MRSA bacteremia had shorter crude survival (14 vs 54 months), but after adjustment for age, comorbidities, and severity, the association disappeared [129]B3b. Similarly, a meta-analysis found no significant mortality difference between high-vancomycin MIC (≥1.5 mg/L) and low-MIC isolates [212]A1a. The adverse prognosis often attributed to MRSA likely reflects the sicker patients it afflicts.
Predictors of Mortality
Multiple factors independently predict death in SAB [262]D5:
- Host: older age, diabetes, chronic kidney disease, cirrhosis, immunosuppression
- Disease-specific: septic shock at presentation, community acquisition (higher endocarditis risk), persistent bacteremia, metastatic foci (e.g., endocarditis, )
- Treatment-related: inappropriate empirical , delayed source control, absence of infectious disease consultation
Inappropriate empirical therapy in MRSA bacteremia is associated with a nearly 2-fold increased odds of death (adjusted OR 1.98) [453]B3b. However, the absolute benefit of anti-MRSA coverage varies by syndrome: for pneumonia it is estimated at 0%, for non-critically ill skin infections 0.1%, and for patients with septic shock 0.6% [621]A1a. This underscores the need to narrow therapy once susceptibilities are known.
Special Populations
- Cystic fibrosis: MRSA respiratory colonization is associated with worse survival (adjusted HR 1.27) and contributes to accelerated lung function decline [82]B2b.
- Children: Treatment failure occurs in 16% of pediatric SAB; rural residence increases the odds 2.3-fold, likely reflecting delayed access to specialized care [296]B3b.
- Older adults: Age >75 years is an independent predictor of infection-related mortality in vascular graft infections (43% 1-year mortality) and post-sternotomy mediastinitis [264]B2b.
Prognostic Tools
The duration of bacteremia and the presence of metastatic infection are the most clinically actionable predictors. An algorithm-based approach to testing and treatment duration has been shown safe and reduces antibiotic days by a mean of 1.8 days [397]A1b. Infectious disease consultation is consistently associated with lower mortality and higher adherence to standards [623]B2a [640]B2b.
Pearl: Persistent bacteremia ≥48 hours is the most powerful modifiable predictor of death; repeat blood cultures at 24-48 hours are mandatory for risk stratification, a single negative follow-up culture at 48 hours reduces 90-day mortality from 39% to 22% [28]B2b.
Prevention and Infection Control
- ▸Universal decolonisation (chlorhexidine + mupirocin) in ICUs reduces all-pathogen bloodstream infection; post-discharge decolonisation in MRSA carriers prevents infection (NNT 30).
- ▸The evidence for active surveillance and contact precautions is mixed; horizontal strategies (hand hygiene, environmental cleaning, and universal decolonisation) may have greater impact.
- ▸No licensed S. aureus vaccine exists; current prevention relies on decolonisation, evidence-based surgical prophylaxis, and antimicrobial stewardship.
Given that S. aureus infections frequently arise from endogenous carriage or nosocomial transmission, prevention strategies must target both the individual carrier and the healthcare environment. The evidence supports a multimodal approach: hand hygiene, environmental cleaning, targeted or universal decolonization in high-risk settings, and evidence-based surgical prophylaxis.
Hand and Environmental Hygiene
Improved hand hygiene compliance reduces healthcare-associated S. aureus bacteraemia (HA-SAB). In the Australian National Hand Hygiene Initiative, a 10% increase in compliance was associated with a 15% decrease in HA-SAB (incidence rate ratio 0.85, 95% CI 0.79-0.93) [665]B2b. The REACH randomised trial demonstrated that a cleaning bundle (optimising technique, product, auditing) increased thoroughness of cleaning (from 64% to 86% for bedrooms) and reduced -resistant enterococci, but did not significantly reduce S. aureus bacteraemia (0.97 to 0.80 per 10 000 occupied bed-days; relative risk 0.82, 95%) [495]A1b. Adding ultraviolet-C (UV-C) to standard terminal disinfection lowered acquisition of target organisms including MRSA (RR 0.70, 95% CI 0.50-0.98) in the BETR Disinfection study [25]A1b.
Decolonisation Strategies
Decolonisation with intranasal mupirocin and chlorhexidine bathing is effective in specific populations. In the REDUCE MRSA cluster-randomised trial, universal decolonisation in ICUs (no screening, all patients bathed with chlorhexidine and received mupirocin) reduced MRSA clinical isolates (hazard ratio 0.63) and all-pathogen bloodstream infection (HR 0.56) compared with screening-and-isolation alone; one bloodstream infection was prevented per 54 patients treated [18]A1b. The ABATE Infection trial extended this to non-critical-care units: universal chlorhexidine bathing plus targeted mupirocin for known MRSA carriers did not significantly reduce MRSA/VRE clinical cultures compared with routine care (p=0.17) [210]A1b. For post-discharge MRSA carriers, the Project CLEAR trial showed that a 6-month regimen of monthly 5-day cycles of chlorhexidine and mupirocin reduced MRSA infection (HR 0.70; NNT 30) and infection-related hospitalisation (HR 0.76) [201]A1b. The HONEYPOT trial found that honey applied to peritoneal dialysis exit sites was not superior to standard care and increased peritonitis risk in patients with diabetes [497]A1b.
Screening and Contact Precautions
The optimal role of active surveillance and contact precautions remains debated. The VA MRSA Prevention Initiative, universal nasal surveillance, contact precautions, hand hygiene, and culture change, was associated with a 62% decline in ICU MRSA infections (from 1.64 to 0.62 per 1000 patient-days) [314]B2c. However, the STAR*ICU cluster-randomised trial found that surveillance plus expanded barrier precautions did not reduce MRSA/VRE transmission compared with existing practice [203]A1b. In a subsequent VA analysis, suspending active surveillance and contact precautions during the pandemic was associated with higher MRSA HAI rates (ICU: 0.65 vs 0.20 per 1000 patient-days; p<0.001) [657]B2b. The SHEA/IDSA/APIC 2023 update lists contact precautions as an “essential practice”, but others argue that evidence from hospitals that discontinued them shows no increase in MRSA acquisition, and that harms (reduced patient contact, environmental waste) may outweigh benefits [655]D5.
Surgical Prophylaxis and Bundles
A bundle of preoperative S. aureus screening, decolonisation (mupirocin + chlorhexidine), and targeted prophylaxis (vancomycin + cefazolin for MRSA carriers) was associated with a 42% reduction in complex S. aureus SSI (rate ratio 0.58, 95% CI 0.37-0.92) across 20 US hospitals [40]B2b. However, a large trial of adding vancomycin to cefazolin in arthroplasty patients without known MRSA colonisation found no benefit (RR 1.28, 95% CI 0.94-1.73) and increased hypersensitivity reactions (1.2% vs 0.5%; RR 2.20) [202]A1b. A 2026 meta-analysis of 1 041 058 arthroplasty patients reported that dual prophylaxis (vancomycin + cefazolin) reduced periprosthetic joint infection (OR 0.64) but increased surgical site infection (OR 1.39) and did not reduce overall SSIs [669]A1a. Routine addition of vancomycin is not recommended; selection should be guided by patient- and pathogen-specific risk [648]D5.
Vaccine Development
Despite decades of research, there is no licensed S. aureus vaccine. The V710 vaccine (targeting iron surface determinant B) failed in a phase 2b/3 trial of cardiothoracic surgery patients and was associated with increased multiorgan failure (HR not calculable from reported data; 31 vs 17 events per 100 person-years;) [508]A1b. A four-antigen vaccine (SA4Ag) showed persistent functional immune responses through 36 months but has not yet demonstrated clinical efficacy [690]C4. Multiple approaches, including targeting protein A and T-helper 17 pathways, are under investigation [647]D5.
and Emerging Tools
post-exposure prophylaxis (doxy PEP) for bacterial STI prevention has been associated with increased tetracycline-resistant S. aureus colonization (18% vs 8% in users vs non-users;) [654]B2b. administered for prophylaxis during the wet season in a haemodialysis unit was associated with a 56% lower rate of S. aureus bloodstream infection [689]C4. Bacteriophage therapy, though investigational, has been used on a compassionate basis for recalcitrant S. aureus infections with safety and feasibility demonstrated in a small case series [692]C4.
Patient Education
Patients colonised with MRSA should receive clear written and verbal instruction on decolonisation technique: chlorhexidine bathing (avoiding eyes, ears, and mucous membranes) and intranasal mupirocin applied to each nostril twice daily for 5 days [201]A1b. Hand hygiene with soap and water or alcohol-based hand rub after touching wounds or dressings is essential. Household contacts of patients with recurrent SSTI may benefit from environmental decontamination (surface disinfection, separate towels, and laundry hygiene), although the evidence for reducing SSTI is strongest in those with a prior year history of infection [642]A1b.
Pearl: Universal decolonisation with chlorhexidine and mupirocin in ICU patients reduces all-cause bloodstream infection (NNT 54) and is more effective than screening-based targeted decolonisation [18]A1b; in non-ICU settings, post-discharge decolonisation for MRSA carriers prevents one infection per 30 patients treated and reduces hospitalisations [201]A1b.
| Strategy | Evidence Summary | Recommendation |
|---|---|---|
| Hand hygiene | 10% increase → 15% reduction in HA-SAB [665]B2b | Essential, monitor compliance |
| Environmental cleaning bundle | Improved thoroughness; reduced VRE but not SAB in one trial [495]A1b | Implement multimodal cleaning |
| UV-C terminal disinfection | Reduced MRSA/VRE acquisition (RR 0.70) [25]A1b | Consider in high-risk settings |
| Universal ICU decolonisation (chlorhexidine + mupirocin) | Reduced MRSA isolates (HR 0.63) and all-BSI (HR 0.56); NNT 54 [18]A1b | Use in ICUs with high endemicity |
| Post-discharge decolonisation (MRSA carriers) | Reduced MRSA infection (HR 0.70; NNT 30) and hospitalisation (HR 0.76) [201]A1b | Offer 6-month cyclic regimen |
| Preoperative screening + decolonisation + targeted prophylaxis | 42% reduction in complex S. aureus SSI [40]B2b | Implement for cardiac and arthroplasty patients |
| Adding vancomycin to cefazolin arthroplasty (no known MRSA) | No benefit; increased hypersensitivity (RR 2.20) [202]A1b[669]A1a | Not recommended routinely |
Special Hosts and Populations
- ▸HIV infection confers a 6-fold higher incidence of CA-MRSA SSTI; nasal screening alone misses at least one third of carriers, so add groin, perirectal, and throat cultures [492, 702].
- ▸In children with S. aureus bacteremia, empiric vancomycin does not improve survival and increases nephrotoxicity (OR 3.1); ID consultation is strongly protective (aOR 0.07) [700].
- ▸In pregnancy, S. aureus bacteremia is frequently associated with injection drug use and infective endocarditis (56%), with poor fetal outcomes (16% death) [726].
These prevention strategies must be tailored to the special hosts whose altered immune defences, physiology, or microbial ecology fundamentally shift the risk-to-benefit balance of every diagnostic and therapeutic decision. The clinician cannot extrapolate from general-population data: host status dictates which S. aureus syndromes occur, which antimicrobials are safe, and what outcomes to expect.
HIV Infection
People living with HIV (PLWH) carry a markedly elevated burden of MRSA. The pooled prevalence of MRSA colonization in HIV-infected individuals is 6.9% (95% CI, 4.8%-9.3%), rising to 8.8% in North American studies [492]B2a. Prior hospitalization (RR 3.11) and incarceration (RR 1.77) are strong predictors [492]B2a. Nasal screening alone underestimates true carriage by at least one third; adding groin, perirectal, and throat cultures increases detection by 19-20% each [492]B2a.
The incidence of CA-MRSA SSTIs is 6-fold higher in HIV-infected patients (996 vs 157 per 100,000; P<0.001) [702]B3b. The predominant strain is USA300, which accounted for 86% of isolates in one cohort [702]B3b. Risk factors include residence in shelters, incarceration, younger age, and being seen in the later epidemic period (2004-2007) [702]B3b. Interestingly, in a cohort with well-controlled HIV (96% had CD4 >200), colonization with Staphylococcus epidermidis was protective, reducing the odds of S. aureus carriage by 80% (aOR 0.20; 95% CI, 0.09-0.45) [727]C4. Behavioural factors, illicit drug use (HR 4.26), public gym use (HR 1.66), predict colonization, while antibacterial soap use is protective (HR 0.50) [728]B2b. CD4 count, HIV RNA level, and antiretroviral use were not independently associated with colonization or SSTI [728]B2b. S. aureus is a leading cause of community-acquired bloodstream infection in PLWH, with mortality rates ranging from 7% to 46% [695]B2a.
Children and Neonates
Paediatric S. aureus bacteremia carries an incidence of 4.4/100,000/year in Australia and New Zealand; Indigenous children, those from lower socioeconomic areas, and neonates are overrepresented [700]B2b. Mortality is infrequent (3%) but one in three children experiences a composite adverse outcome (prolonged stay, ICU admission, relapse, or death) [700]B2b. Predictors of mortality include prematurity (aOR 16.8), multifocal infection (aOR 22.6), necrotizing pneumonia (aOR 38.9), and multiorgan dysfunction (aOR 26.5) [700]B2b. Infectious diseases consultation was strongly protective (aOR 0.07) [700]B2b. Empiric did not improve survival but was associated with nephrotoxicity (OR 3.1) [700]B2b.
Among paediatric acute haematogenous osteomyelitis (AHO), the cefazolin inoculum effect (CzIE; MIC ≥16 μg/mL at high inoculum) is present in 14.4% of MSSA isolates and is independently associated with progression to chronic osteomyelitis (aOR not calculable from reported data) [470]B3b. Meanwhile, penicillin-susceptible MSSA (PSSA) is re-emerging, rising from 0% to 20.4% of paediatric AHO isolates by 2019 [279]B2c, though clinical outcomes resemble those of penicillin-resistant MSSA. Oral step-down therapy with cephalexin or the twice-daily alternative cefadroxil achieves pharmacokinetic/pharmacodynamic targets for MSSA [468]C4[613]B2b. In S. aureus septic arthritis, infection with S. aureus is an independent risk factor for concurrent osteomyelitis (aOR 3.17) [711]B2b.
In paediatric bloodstream infections, S. aureus bacteremia is an independent predictor of definite or possible infective endocarditis [712]B2b. Despite this, an oral switch strategy is used in 58.6% of paediatric S. aureus bacteremia cases at one tertiary centre, with comparable 30-day failure rates (2.4% vs 3.4%) and a significantly shorter hospital stay (13 vs 48 days) [713]B2b. Decolonisation with mupirocin and chlorhexidine in children <6 years showed no significant benefit over a wait-and-see approach (HR 0.92 for <2 years; HR 0.54 for 2-5 years) [722]B2b. Mupirocin resistance in children with recurrent SSTI is non-trivial (14.7% in one series) [715]C4, and qacA/B or smr genes conferring chlorhexidine tolerance are found in 44.9% of nosocomial paediatric isolates [681]C4.
Pregnancy and Postpartum
Pregnancy alters the and consequences of S. aureus infection. In one cohort of 27 pregnant patients with S. aureus bacteremia, 56% had infective endocarditis, 82% had MRSA, and 85% reported active injection drug use [726]C4. Fetal outcomes were poor: 16% of infants/fetuses died during hospitalisation, and 27% of mothers were readmitted within 6 months for infectious complications [726]C4. S. aureus is also a common cause of urinary tract infection in pregnancy, accounting for 22.6% of isolates in one Palestinian cohort, with multidrug resistance in 55.7% of all UTI isolates [77]B2b.
Elderly
The incidence of S. aureus bacteremia in Denmark increased by 48% from 2008 to 2015, driven disproportionately by older adults. Persons >80 years experienced a 90% increase, and those >90 years had an annual increase of 13.0% (p<0.001) [252]B2c. The 30-day case-fatality rate remained stable at 24%, meaning crude population death rates rose by 53% [252]B2c. Age >64 years is also an independent predictor of acute kidney injury during antistaphylococcal therapy (aOR 1.76) [718]B2b.
Cystic Fibrosis
Detection of MRSA in the respiratory tract of patients with cystic fibrosis is associated with worse survival (adjusted HR 1.27; 95% CI, 1.11-1.45) [82]B2b. S. aureus colonisation influences transplant outcomes: in children with CF awaiting lung transplantation, S. aureus infection increased waiting-list survival but decreased post-transplantation survival, contributing to net harm for the majority of listed patients [708]B2b. Co-colonisation with Pseudomonas aeruginosa selects for upregulation of the NorA efflux pump in S. aureus, a partial adaptation to persistent co-colonisation [637]D5.
Other High-Risk Populations
Persons who inject drugs (PWID) are at extreme risk for MRSA SSTI and bacteraemia, particularly in pregnancy [726]C4. Incarceration doubles the risk of MRSA colonisation in HIV-infected individuals (RR 1.77) and amplifies the community spread of USA300 [492]B2a[730]B2c. Indigenous populations in Australia, New Zealand, and Canada bear a disproportionate burden: Māori and Pacific Peoples in New Zealand have the highest rates of S. aureus SSTI and invasive disease, correlated with socioeconomic deprivation [104]B2c. Livestock-associated MRSA (LA-MRSA) can acquire phage-encoded immune evasion cluster genes, increasing household transmission and spillover into the general population [185]B2b.
Pearl: For the elderly and for children with S. aureus bacteremia, an infectious diseases consultation is independently associated with reduced mortality (aOR 0.07 in children) [700]B2b; in febrile neutropenia, combination beta-lactam therapy for MSSA bacteremia is associated with worse outcomes and should be avoided, choose either a narrow- or broad-spectrum beta-lactam, not both [704]B2b.
References
- [1]
Liu C, Bayer A, Cosgrove SE et al.. “Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21208910 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations - [2]
Stevens DL, Bisno AL, Chambers HF et al.. “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24973422 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [3]
Stevens DL, Bisno AL, Chambers HF et al.. “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24947530 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [4]
Liu C, Bayer A, Cosgrove SE et al.. “Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21217178 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations - [5]
Rybak MJ, Le J, Lodise TP et al.. “Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32658968 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations - [6]
Mourad A, Nwafo N, Skalla L et al.. “Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39290168 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [7]
Wunderink RG, Niederman MS, Kollef MH et al.. “Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22247123 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [8]
. “Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.” The Lancet. Infectious diseases (2024). PMID: 38636536 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations - [9]
Reddy EA, Shaw AV, Crump JA. “Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2010). PMID: 20510282 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Prognosis and Natural History, Special Hosts and Populations - [10]
de Kretser D, Mora J, Bloomfield M et al.. “Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37921609 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [11]
Parente DM, Cunha CB, Mylonakis E et al.. “The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29340593 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [12]
McDanel JS, Roghmann MC, Perencevich EN et al.. “Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28379314 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Complications - [13]
Iversen K, Ihlemann N, Gill SU et al.. “Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.” The New England journal of medicine (2018). PMID: 30152252 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [14]
Holland TL, Cosgrove SE, Doernberg SB et al.. “Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.” The New England journal of medicine (2023). PMID: 37754204 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [15]
Lee TC, Barina LA, Walls G et al.. “Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.” The New England journal of medicine (2026). PMID: 42308484 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History, Special Hosts and Populations - [16]
Fowler VG, Boucher HW, Corey GR et al.. “Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.” The New England journal of medicine (2006). PMID: 16914701 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [17]
O'Riordan W, Green S, Overcash JS et al.. “Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.” The New England journal of medicine (2019). PMID: 30726689 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [18]
Huang SS, Septimus E, Kleinman K et al.. “Targeted versus universal decolonization to prevent ICU infection.” The New England journal of medicine (2013). PMID: 23718152 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications, Prevention and Infection Control - [19]
Corey GR, Kabler H, Mehra P et al.. “Single-dose oritavancin in the treatment of acute bacterial skin infections.” The New England journal of medicine (2014). PMID: 24897083 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Complications - [20]
Bode LG, Kluytmans JA, Wertheim HF et al.. “Preventing surgical-site infections in nasal carriers of Staphylococcus aureus.” The New England journal of medicine (2010). PMID: 20054045 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [21]
. “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.” Lancet (London, England) (2022). PMID: 35065702 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [22]
Burdet C, Saïdani N, Dupieux C et al.. “Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.” Lancet (London, England) (2025). PMID: 41115439 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [23]
. “Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.” Lancet (London, England) (2026). PMID: 42309115 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [24]
Thwaites GE, Scarborough M, Szubert A et al.. “Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2017). PMID: 29249276 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [25]
Anderson DJ, Chen LF, Weber DJ et al.. “Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study.” Lancet (London, England) (2017). PMID: 28104287 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [26]
Schumm MA, Hadaya JE, Mody N et al.. “Filtering Facepiece Respirator (N95 Respirator) Reprocessing: A Systematic Review.” JAMA (2021). PMID: 33656543 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Prevention and Infection Control - [27]
Mellett M, Lawandi A, Caya C et al.. “Antibiotic synergy against Staphylococcus aureus: a systematic review and meta-analysis.” Antimicrobial agents and chemotherapy (2025). PMID: 40526084 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [28]
Kuehl R, Morata L, Boeing C et al.. “Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.” The Lancet. Infectious diseases (2020). PMID: 32763194 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [29]
Tong SYC, Lye DC, Yahav D et al.. “Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.” JAMA (2020). PMID: 32044943 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [30]
Huang SS, Septimus EJ, Kleinman K et al.. “Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial.” JAMA (2023). PMID: 37815567 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [31]
Geriak M, Haddad F, Rizvi K et al.. “Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2019). PMID: 30858203 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [32]
Lappin E, Ferguson AJ. “Gram-positive toxic shock syndromes.” The Lancet. Infectious diseases (2009). PMID: 19393958 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [33]
Davis MF, Iverson SA, Baron P et al.. “Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci.” The Lancet. Infectious diseases (2012). PMID: 22917102 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship - [34]
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al.. “Clinical management of Staphylococcus aureus bacteraemia.” The Lancet. Infectious diseases (2011). PMID: 21371655 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [35]
Nickerson EK, West TE, Day NP et al.. “Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east Asia.” The Lancet. Infectious diseases (2009). PMID: 19179228 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [36]
Moise PA, North D, Steenbergen JN et al.. “Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.” The Lancet. Infectious diseases (2009). PMID: 19778764 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [37]
Aiello AE, Lowy FD, Wright LN et al.. “Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies.” The Lancet. Infectious diseases (2006). PMID: 16728319 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [38]
Clements A, Halton K, Graves N et al.. “Overcrowding and understaffing in modern health-care systems: key determinants in meticillin-resistant Staphylococcus aureus transmission.” The Lancet. Infectious diseases (2008). PMID: 18582835 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications - [39]
Harbarth S, Fankhauser C, Schrenzel J et al.. “Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients.” JAMA (2008). PMID: 18334690 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [40]
Schweizer ML, Chiang HY, Septimus E et al.. “Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery.” JAMA (2015). PMID: 26034956 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Prevention and Infection Control - [41]
Aiken AM, Mturi N, Njuguna P et al.. “Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study.” Lancet (London, England) (2011). PMID: 22133536 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations - [42]
Lakhundi S, Zhang K. “Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology.” Clinical microbiology reviews (2018). PMID: 30209034 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [43]
Tong SY, Davis JS, Eichenberger E et al.. “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.” Clinical microbiology reviews (2015). PMID: 26016486 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [44]
De Oliveira DMP, Forde BM, Kidd TJ et al.. “Antimicrobial Resistance in ESKAPE Pathogens.” Clinical microbiology reviews (2020). PMID: 32404435 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [45]
Becker K, Heilmann C, Peters G. “Coagulase-negative staphylococci.” Clinical microbiology reviews (2014). PMID: 25278577 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [46]
Kavanagh N, Ryan EJ, Widaa A et al.. “Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions.” Clinical microbiology reviews (2018). PMID: 29444953 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications - [47]
David MZ, Daum RS. “Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.” Clinical microbiology reviews (2010). PMID: 20610826 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [48]
Gadsby NJ, Musher DM. “The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures.” Clinical microbiology reviews (2022). PMID: 36165783 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [49]
Boggio CMT, Veronese F, Armari M et al.. “Skin microbiota in atopic dermatitis: victim or executioner?” Clinical microbiology reviews (2025). PMID: 40459300 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [50]
Saiman L, Waters V, LiPuma JJ et al.. “Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.” Clinical microbiology reviews (2024). PMID: 39158301 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications - [51]
Schlievert PM, Davis CC. “Device-Associated Menstrual Toxic Shock Syndrome.” Clinical microbiology reviews (2020). PMID: 32461307 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment - [52]
Tande AJ, Currier BL, Osmon DR. “Spinal Epidural Abscess.” The New England journal of medicine (2026). PMID: 42019020 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications - [53]
de Benedictis FM, Kerem E, Chang AB et al.. “Complicated pneumonia in children.” Lancet (London, England) (2020). PMID: 32919518 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History, Special Hosts and Populations - [54]
DeLeo FR, Otto M, Kreiswirth BN et al.. “Community-associated meticillin-resistant Staphylococcus aureus.” Lancet (London, England) (2010). PMID: 20206987 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [55]
Rossi F, Diaz L, Wollam A et al.. “Transferable vancomycin resistance in a community-associated MRSA lineage.” The New England journal of medicine (2014). PMID: 24738669 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [56]
Renz N, Trampuz A, Perka C et al.. “Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study.” Open forum infectious diseases (2022). PMID: 35355896 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History - [57]
Bruun T, Oppegaard O, Kittang BR et al.. “Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.” Open forum infectious diseases (2015). PMID: 26734653 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms - [58]
Tong SYC, Fowler VG, Skalla L et al.. “Management of Staphylococcus aureus Bacteremia: A Review.” JAMA (2025). PMID: 40193249 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [59]
Raff AB, Kroshinsky D. “Cellulitis: A Review.” JAMA (2016). PMID: 27434444 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations - [60]
Heidary M, Khosravi AD, Khoshnood S et al.. “Daptomycin.” The Journal of antimicrobial chemotherapy (2018). PMID: 29059358 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [61]
Livermore DM. “Future directions with daptomycin.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829725 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [62]
Moellering RC. “MRSA: the first half century.” The Journal of antimicrobial chemotherapy (2011). PMID: 22010206 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [63]
Tenover FC, Goering RV. “Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology.” The Journal of antimicrobial chemotherapy (2009). PMID: 19608582 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [64]
Dryden MS. “Complicated skin and soft tissue infection.” The Journal of antimicrobial chemotherapy (2010). PMID: 20876627 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control, Special Hosts and Populations - [65]
Troeman DPR, Van Hout D, Kluytmans JAJW. “Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.” The Journal of antimicrobial chemotherapy (2019). PMID: 30376041 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Prevention and Infection Control - [66]
Morgan M. “Methicillin-resistant Staphylococcus aureus and animals: zoonosis or humanosis?” The Journal of antimicrobial chemotherapy (2008). PMID: 18819971 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [67]
Barrett L, Atkins B. “The clinical presentation of prosthetic joint infection.” The Journal of antimicrobial chemotherapy (2014). PMID: 25135085 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [68]
Cuervo G, Chesdachai S, Hindy JR et al.. “Clinical Features of Adult Patients with Isolated Pulmonary Valve Endocarditis: A Systematic Review.” Microorganisms (2026). PMID: 42354833 ↗
L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Prognosis and Natural History - [69]
Lowenthal A, Weisblum-Neuman H, Birk E et al.. “Clinical Features and Comparison of Kingella and Non-Kingella Endocarditis in Children, Israel.” Emerging infectious diseases (2021). PMID: 33622463 ↗
L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, History and Evolution of Treatment, Special Hosts and Populations - [70]
Lee YW, Huh JW, Hong SB et al.. “Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014-2019.” Emerging infectious diseases (2022). PMID: 36287034 ↗
L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [71]
Moellering RC. “A 39-year-old man with a skin infection.” JAMA (2007). PMID: 18056894 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [72]
Sakoulas G, Olson J, Yim J et al.. “Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 27572414 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [73]
Totten KMC, Patel R. “Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.” Antimicrobial agents and chemotherapy (2021). PMID: 34662191 ↗
L5CASE_REPORTCited in: Definition, Classification and Causative Organisms - [74]
. “Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.” Lancet (London, England) (2024). PMID: 39299261 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control, Special Hosts and Populations - [75]
Tissari P, Zumla A, Tarkka E et al.. “Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study.” Lancet (London, England) (2009). PMID: 20004964 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [76]
Sánchez-Villamil JP, Morales-Peña VA, Flórez-Joya JF. “Prevalence of methicillin-resistant Staphylococcus aureus carriers in dental care staff: A systematic review and meta-analysis.” Biomedica : revista del Instituto Nacional de Salud (2026). PMID: 42413096 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [77]
Khatatba LZ, Daraghmeh DN. “Bacterial profiles, antibiotic resistance, and recurrence of UTIs during pregnancy: a prospective cohort study from Palestine.” BMC infectious diseases (2026). PMID: 42426664 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [78]
Cusumano JA, Dupper AC, Malik Y et al.. “Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series.” Open forum infectious diseases (2020). PMID: 33269299 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [79]
Newman N, Bantikassegn A, West TG et al.. “An Unusual Etiology of Lemierre-Like Syndrome: Preseptal Cellulitis due to Methicillin-Resistant Staphylococcus aureus.” Open forum infectious diseases (2022). PMID: 35531375 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Complications - [80]
Bethe A, Schink AK, Brombach J et al.. “Panton-Valentine Leukocidin-Positive Staphylococcus aureus in Family and Pet Cat.” Emerging infectious diseases (2024). PMID: 39043433 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [81]
Shoji K, Yoshida K, Takenouchi M et al.. “Skin Infections Caused by Panton-Valentine Leukocidin and Methicillin-Susceptible Staphylococcus aureus in Child, Japan.” Emerging infectious diseases (2025). PMID: 40439546 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [82]
Dasenbrook EC, Checkley W, Merlo CA et al.. “Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.” JAMA (2010). PMID: 20551409 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Prognosis and Natural History, Special Hosts and Populations - [83]
Klevens RM, Morrison MA, Nadle J et al.. “Invasive methicillin-resistant Staphylococcus aureus infections in the United States.” JAMA (2007). PMID: 17940231 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [84]
Hogan S, O'Gara JP, O'Neill E. “Novel Treatment of Staphylococcus aureus Device-Related Infections Using Fibrinolytic Agents.” Antimicrobial agents and chemotherapy (2018). PMID: 29203484 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [85]
Hull RC, Wright RCT, Sayers JR et al.. “Antibiotics Limit Adaptation of Drug-Resistant Staphylococcus aureus to Hypoxia.” Antimicrobial agents and chemotherapy (2022). PMID: 36409116 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Prognosis and Natural History - [86]
Gehrke AE, Mendoza-Bertelli A, Ledo C et al.. “Neutralization of Staphylococcus aureus Protein A Prevents Exacerbated Osteoclast Activity and Bone Loss during Osteomyelitis.” Antimicrobial agents and chemotherapy (2022). PMID: 36533935 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [87]
Valour F, Trouillet-Assant S, Riffard N et al.. “Antimicrobial activity against intraosteoblastic Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2015). PMID: 25605365 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [88]
Ai Q, Wang S, Chen Z et al.. “Synergistic antibacterial activity and prevention of drug resistance of daptomycin combined with fosfomycin against methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40530996 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [89]
Truong-Bolduc QC, Wang Y, Lawton BG et al.. “NorA and Tet38 efflux pumps enable Staphylococcus aureus survival in the cystic fibrosis airway environment, resistance to antibiotics, and coinfection with Pseudomonas aeruginosa.” Antimicrobial agents and chemotherapy (2025). PMID: 40631986 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History - [90]
Shah S, Clarke LG, Ludwig J et al.. “Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2024). PMID: 38946294 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [91]
Kihlberg P, Bech Johannesen T, Stegger M et al.. “Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492523 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [92]
Goodman AL, Easom N, Bielopolski D et al.. “A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.” The Journal of antimicrobial chemotherapy (2026). PMID: 42396858 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [93]
Huang GJ, Chen ZQ, Long CQ et al.. “Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis.” Frontiers in immunology (2026). PMID: 42382746 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [94]
Berg DM, Binkley A, Foster SD et al.. “Clinical Microbiology in Xylazine-Associated Wound Infections.” Open forum infectious diseases (2025). PMID: 40799792 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [95]
Fabre V, Cosgrove SE, Hsu YJ et al.. “Multicenter Evaluation of Antibiotic Use and Antibiotic Stewardship Programs in Latin American Hospitals.” Open forum infectious diseases (2025). PMID: 40689250 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [96]
Alonso-Menchén D, Bouza E, Valerio M et al.. “Non-nosocomial Healthcare-Associated Infective Endocarditis: A Distinct Entity? Data From the GAMES Series (2008-2021).” Open forum infectious diseases (2023). PMID: 37564744 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms - [97]
Flurin L, Fisher CR, Wolf MJ et al.. “Comparison of Blood-Based Shotgun and Targeted Metagenomic Sequencing for Microbiological Diagnosis of Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 38075017 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [98]
Kim DY, Kim UJ, Yu Y et al.. “Microbial Etiology of Pyogenic Vertebral Osteomyelitis According to Patient Characteristics.” Open forum infectious diseases (2020). PMID: 32523973 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [99]
McCormick DW, Kaplan J, Whigham C et al.. “The Changing Epidemiology and Microbiology of Patients With Prostate Abscess: Increase in Staphylococcal Infection.” Open forum infectious diseases (2021). PMID: 34805434 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation - [100]
Panesso D, Planet PJ, Diaz L et al.. “Methicillin-Susceptible, Vancomycin-Resistant Staphylococcus aureus, Brazil.” Emerging infectious diseases (2015). PMID: 26402569 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [101]
Boudebouch N, Sarih M, Chakib A et al.. “Blood Culture-Negative Endocarditis, Morocco.” Emerging infectious diseases (2017). PMID: 29048299 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup - [102]
Baum M, Anuka E, Davidovich-Cohen M et al.. “ST913-IVa-t991 Methicillin-Resistant Staphylococcus aureus among Pediatric Patients, Israel.” Emerging infectious diseases (2024). PMID: 39043440 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [103]
Xu Q, Almudervar A, Casey JR et al.. “Nasopharyngeal bacterial interactions in children.” Emerging infectious diseases (2012). PMID: 23092680 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [104]
Williamson DA, Zhang J, Ritchie SR et al.. “Staphylococcus aureus infections in New Zealand, 2000-2011.” Emerging infectious diseases (2014). PMID: 24960446 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [105]
LeBlanc L, Pépin J, Toulouse K et al.. “Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada.” Emerging infectious diseases (2006). PMID: 17073089 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [106]
Silva MJDR, Stephen AH, Dias E et al.. “Aortic Infections-A Narrative Review.” Surgical infections (2026). PMID: 42421298 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [107]
Busti A, Annoni G, Napoleone CP. “Endocarditis in Adults with Congenital Heart Disease.” Methodist DeBakey cardiovascular journal (2026). PMID: 42403547 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications - [108]
Deng L, Ling X, Li L et al.. “Advances in Scalp Microbiome Research: Molecular Insights into the Metabolism-Inflammation-Barrier Axis and Dandruff Pathogenesis.” Molecules (Basel, Switzerland) (2026). PMID: 42357491 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [109]
Ramadani A, Marco G, Vazquez O et al.. “Osteoarticular Infections in Immunocompetent Children Due to Atypical, Fastidious or Unusual Bacterial Pathogens: A Review.” Pathogens (Basel, Switzerland) (2026). PMID: 42347261 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [110]
Karthikeyan A, Javaid A, Charway GNA et al.. “Prophages in Skin Pathogens: From Virulence to Therapy.” Pathogens (Basel, Switzerland) (2026). PMID: 42347211 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [111]
Shallcross LJ, Fragaszy E, Johnson AM et al.. “The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2012). PMID: 23103172 ↗
L1SR_OBSCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Prognosis and Natural History - [112]
Deen J, von Seidlein L, Andersen F et al.. “Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review.” The Lancet. Infectious diseases (2012). PMID: 22632186 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [113]
Berger S, Kunerl A, Wasmuth S et al.. “Menstrual toxic shock syndrome: case report and systematic review of the literature.” The Lancet. Infectious diseases (2019). PMID: 31151811 ↗
L4SR_OBSCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Complications - [114]
Anpalagan K, Dotel R, MacFadden DR et al.. “Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38801783 ↗
L5TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis - [115]
Bart SM, Farley JJ, Bala S et al.. “Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32161946 ↗
L2TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis - [116]
François B, Jafri HS, Chastre J et al.. “Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.” The Lancet. Infectious diseases (2021). PMID: 33894131 ↗
L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications - [117]
Contou D, Colin G, Travert B et al.. “Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 33906228 ↗
L3COHORTCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Special Hosts and Populations - [118]
Critchley IA, Eckburg PB, Jandourek A et al.. “Review of ceftaroline fosamil microbiology: integrated FOCUS studies.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482569 ↗
L5RCTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [119]
Karlowsky JA, Steenbergen J, Zhanel GG. “Microbiology and Preclinical Review of Omadacycline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367743 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [120]
Gordon RJ, Lowy FD. “Pathogenesis of methicillin-resistant Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462090 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [121]
Appelbaum PC. “Microbiology of antibiotic resistance in Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17712742 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [122]
Cameron DR, Howden BP, Peleg AY. “The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21865195 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [123]
Miller LG, Diep BA. “Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18220477 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [124]
Jones RN. “Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20597676 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [125]
Cho SY, Chung DR. “Infection Prevention Strategy in Hospitals in the Era of Community-Associated Methicillin-Resistant Staphylococcus aureus in the Asia-Pacific Region: A Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28475795 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prevention and Infection Control - [126]
Campbell AJ, Dotel R, Blyth CC et al.. “Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal.” The Journal of antimicrobial chemotherapy (2019). PMID: 30307507 ↗
L5SR_OBSCited in: Microbiology and Pathogenesis - [127]
Pham TM, Zhang Y, Nevers M et al.. “Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22).” The Lancet. Infectious diseases (2024). PMID: 39151443 ↗
L3COHORTCited in: Microbiology and Pathogenesis - [128]
Hidron AI, Low CE, Honig EG et al.. “Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia.” The Lancet. Infectious diseases (2009). PMID: 19467478 ↗
L5CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation - [129]
Yaw LK, Robinson JO, Ho KM. “A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study.” The Lancet. Infectious diseases (2014). PMID: 25185461 ↗
L3COHORTCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History - [130]
Sievert DM, Rudrik JT, Patel JB et al.. “Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18257700 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Prevention and Infection Control - [131]
Jiang J-H, Cameron DR, Nethercott C et al.. “Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages.” Clinical microbiology reviews (2023). PMID: 37982596 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [132]
Grousd JA, Rich HE, Alcorn JF. “Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.” Clinical microbiology reviews (2019). PMID: 31142498 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [133]
Hodille E, Rose W, Diep BA et al.. “The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.” Clinical microbiology reviews (2017). PMID: 28724662 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [134]
Speziale P, Foster TJ, Arciola CR. “The endothelium at the interface between tissues and Staphylococcus aureus in the bloodstream.” Clinical microbiology reviews (2025). PMID: 39807893 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [135]
Spaulding AR, Salgado-Pabón W, Kohler PL et al.. “Staphylococcal and streptococcal superantigen exotoxins.” Clinical microbiology reviews (2013). PMID: 23824366 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Complications - [136]
Frank KL, Del Pozo JL, Patel R. “From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis.” Clinical microbiology reviews (2008). PMID: 18202439 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [137]
Heilbronner S, Foster TJ. “Staphylococcus lugdunensis: a Skin Commensal with Invasive Pathogenic Potential.” Clinical microbiology reviews (2020). PMID: 33361142 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prognosis and Natural History - [138]
Kahl BC, Becker K, Löffler B. “Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.” Clinical microbiology reviews (2016). PMID: 26960941 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup - [139]
Trastoy R, Manso T, Fernández-García L et al.. “Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.” Clinical microbiology reviews (2018). PMID: 30068737 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [140]
Baker MA, Sands KE, Huang SS et al.. “The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34370014 ↗
L3OTHERCited in: Microbiology and Pathogenesis - [141]
Diep BA, Gill SR, Chang RF et al.. “Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus.” Lancet (London, England) (2006). PMID: 16517273 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [142]
Suh GA, Lodise TP, Tamma PD et al.. “Considerations for the Use of Phage Therapy in Clinical Practice.” Antimicrobial agents and chemotherapy (2022). PMID: 35041506 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship - [143]
Garcia LG, Lemaire S, Kahl BC et al.. “Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data.” The Journal of antimicrobial chemotherapy (2013). PMID: 23485724 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [144]
Moran GJ, Krishnadasan A, Gorwitz RJ et al.. “Methicillin-resistant S. aureus infections among patients in the emergency department.” The New England journal of medicine (2006). PMID: 16914702 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [145]
Köser CU, Holden MT, Ellington MJ et al.. “Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak.” The New England journal of medicine (2012). PMID: 22693998 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [146]
Schuler F, Barth PJ, Niemann S et al.. “A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.” Open forum infectious diseases (2021). PMID: 34189162 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [147]
Corsini Campioli C, Go JR, Abu Saleh O et al.. “Antistaphylococcal Penicillin vs Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Spinal Epidural Abscesses.” Open forum infectious diseases (2021). PMID: 33738321 ↗
L3REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control - [148]
Chertow DS, Memoli MJ. “Bacterial coinfection in influenza: a grand rounds review.” JAMA (2013). PMID: 23321766 ↗
L5CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [149]
Shah A, Romagnoli R, Dhingra N et al.. “Mediastinitis after cardiac surgery, from microbes to management: a systematic review.” Mediastinum (Hong Kong, China) (2026). PMID: 42427474 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Prevention and Infection Control - [150]
Orhan Z, Doğan S, Mohamud SM et al.. “Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.” BMC infectious diseases (2026). PMID: 42410515 ↗
L4COHORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [151]
Joris G, Jozef D, Petra H et al.. “How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42398659 ↗
L4COHORTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [152]
Palmer A, Carter M, Yeo J et al.. “Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.” The Medical journal of Australia (2026). PMID: 42289398 ↗
L4COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [153]
Diekema DJ, Hsueh PR, Mendes RE et al.. “The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.” Antimicrobial agents and chemotherapy (2019). PMID: 31010862 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [154]
Boyd JM, Price EE, Roman Rodriguez F et al.. “Treatment of Staphylococcus aureus with environmentally relevant concentrations of triclosan activates SaeRS-dependent virulence factor expression.” Antimicrobial agents and chemotherapy (2025). PMID: 40531055 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [155]
Kwiecinski JM, Jelani DA, Fuentes EJ et al.. “Therapeutic Inhibition of Staphylococcus aureus ArlRS Two-Component Regulatory System Blocks Virulence.” Antimicrobial agents and chemotherapy (2022). PMID: 35736133 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [156]
Mahé A, Verneuil N, Coupri D et al.. “D-alanylation of lipoteichoic acids inhibitor provides anti-virulence and anti-resistance effects against methicillin-resistant Staphylococcus epidermidis.” Antimicrobial agents and chemotherapy (2025). PMID: 40116514 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [157]
McConville TH, Austin ED, Geng W et al.. “In Vitro Cytotoxicity and Clinical Correlates of MRSA Bacteremia.” Antimicrobial agents and chemotherapy (2021). PMID: 34748383 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [158]
Kong X, Wang B, Chen X et al.. “Hinokiflavone Attenuates the Virulence of Methicillin-Resistant Staphylococcus aureus by Targeting Caseinolytic Protease P.” Antimicrobial agents and chemotherapy (2022). PMID: 35862746 ↗
L5OTHERCited in: Microbiology and Pathogenesis, History and Evolution of Treatment - [159]
Daly SM, Elmore BO, Kavanaugh JS et al.. “ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation.” Antimicrobial agents and chemotherapy (2015). PMID: 25645827 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [160]
Gomi S, Price E, Burgoyne H et al.. “Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.” Antimicrobial agents and chemotherapy (2025). PMID: 40757816 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History - [161]
Luther MK, Parente DM, Caffrey AR et al.. “Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2018). PMID: 29530854 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [162]
Khodaverdian V, Pesho M, Truitt B et al.. “Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2013). PMID: 23689713 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prevention and Infection Control - [163]
Guillamet MCV, Vazquez R, Deaton B et al.. “Host-Pathogen-Treatment Triad: Host Factors Matter Most in Methicillin-Resistant Staphylococcus aureus Bacteremia Outcomes.” Antimicrobial agents and chemotherapy (2018). PMID: 29203479 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [164]
Xu W, Yan P, Li Y et al.. “The toxin-antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening.” The Journal of antimicrobial chemotherapy (2025). PMID: 40985144 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [165]
Koszczol C, Bernardo K, Krönke M et al.. “Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2006). PMID: 16895938 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [166]
Deplano A, Hallin M, Bustos Sierra N et al.. “Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.” The Journal of antimicrobial chemotherapy (2023). PMID: 37358399 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [167]
Gomez-Villegas SI, Rincon S, Carvajal LP et al.. “Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.” The Journal of antimicrobial chemotherapy (2025). PMID: 40126549 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [168]
Guo Y, Han R, Zhang G et al.. “Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.” The Journal of antimicrobial chemotherapy (2023). PMID: 36849586 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [169]
Deplano A, Dodémont M, Denis O et al.. “European external quality assessments for identification, molecular typing and characterization of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2018). PMID: 30099486 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [170]
Pant N, Wallis SC, Roberts JA et al.. “In vitro effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation.” The Journal of antimicrobial chemotherapy (2022). PMID: 35045178 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [171]
Kaneko H, Yanagi Y, Otake S et al.. “The emerging threat of methicillin-resistant Staphylococcus aureus (MRSA) clone ST22-PT, carrying both Panton-Valentine leucocidin and toxic shock syndrome toxin 1 genes.” The Journal of antimicrobial chemotherapy (2023). PMID: 36814074 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [172]
Hanawa T, Tanaka M, Nagano DS et al.. “Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.” Frontiers in immunology (2026). PMID: 42367797 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [173]
Fairholm JD, Paul GT, Birket S et al.. “Microbial and host innate immune factors affecting the persistence of Staphylococcus aureus in cystic fibrosis airways.” Frontiers in cellular and infection microbiology (2026). PMID: 42318016 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History - [174]
Ge Y, Wang Y, He X et al.. “Comprehensive management of hemodialysis catheter-related bloodstream infections: a narrative review.” Frontiers in cellular and infection microbiology (2026). PMID: 42312032 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [175]
de Waha S, Noack T, Kister T et al.. “Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection.” Annals of cardiothoracic surgery (2026). PMID: 42292592 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation - [176]
Calvão J, Iselin C, Wasmayr J et al.. “Pathogenesis of cutaneous T-cell lymphoma: Malignant inflammation, immune reprogramming, and microenvironmental drivers.” The Journal of investigative dermatology (2026). PMID: 42274451 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [177]
Musgrove MA, Kenney RM, Kendall RE et al.. “Microbiology Comment Nudge Improves Pneumonia Prescribing.” Open forum infectious diseases (2018). PMID: 30057928 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [178]
Hindy JR, Quintero-Martinez JA, Lahr BD et al.. “Incidence of Monomicrobial Staphylococcus aureus Bacteremia: A Population-Based Study in Olmsted County, Minnesota-2006 to 2020.” Open forum infectious diseases (2022). PMID: 35794939 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [179]
Go JR, Challener D, Corsini Campioli C et al.. “Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle.” Open forum infectious diseases (2021). PMID: 35071685 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification, Prognosis and Natural History - [180]
Kim JJ, Kang H, Stewart KO. “The Effect of Retained Hardware on Failure Among Prosthetic Joint Infections of the Knee in the Presence and Absence of Staphylococcus aureus.” Open forum infectious diseases (2024). PMID: 38919513 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [181]
Pralea A, Has P, Auld D et al.. “Microbes Causing Spinal Epidural Infection in Patients Who Use Drugs.” Open forum infectious diseases (2024). PMID: 39416991 ↗
L4OTHERCited in: Microbiology and Pathogenesis, History and Evolution of Treatment - [182]
Khamash DF, Mongodin EF, White JR et al.. “The Association Between the Developing Nasal Microbiota of Hospitalized Neonates and Staphylococcus aureus Colonization.” Open forum infectious diseases (2019). PMID: 30949531 ↗
L3OTHERCited in: Microbiology and Pathogenesis - [183]
Muñoz-Gallego I, Viedma E, Esteban J et al.. “Genotypic and Phenotypic Characteristics of Staphylococcus aureus Prosthetic Joint Infections: Insight on the Pathogenesis and Prognosis of a Multicenter Prospective Cohort.” Open forum infectious diseases (2020). PMID: 33005695 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Severity Assessment and Risk Stratification - [184]
Simmons SC, Budavari AI, Kusne S et al.. “Culture-Proven Thorn-Associated Infections in Arizona: 10-Year Experience at Mayo Clinic.” Open forum infectious diseases (2017). PMID: 28480288 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [185]
Sieber RN, Urth TR, Petersen A et al.. “Phage-Mediated Immune Evasion and Transmission of Livestock-Associated Methicillin-Resistant Staphylococcus aureus in Humans.” Emerging infectious diseases (2020). PMID: 33079052 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Special Hosts and Populations - [186]
Coombs GW, Pang S, Daley DA et al.. “Severe Disease Caused by Community-Associated MRSA ST398 Type V, Australia, 2017.” Emerging infectious diseases (2019). PMID: 30561308 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History - [187]
Coombs GW, Pearson JC, O'Brien FG et al.. “Methicillin-resistant Staphylococcus aureus clones, Western Australia.” Emerging infectious diseases (2006). PMID: 16494749 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [188]
Sharma H, Smith D, Turner CE et al.. “Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom.” Emerging infectious diseases (2018). PMID: 29350159 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [189]
Sun L, Chen Y, Wang D et al.. “Surgical Site Infections Caused by Highly Virulent Methicillin-Resistant Staphylococcus aureus Sequence Type 398, China.” Emerging infectious diseases (2019). PMID: 30561317 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [190]
Tristan A, Bes M, Meugnier H et al.. “Global distribution of Panton-Valentine leukocidin--positive methicillin-resistant Staphylococcus aureus, 2006.” Emerging infectious diseases (2007). PMID: 17553275 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [191]
Kajumbula H, Fujita AW, Mbabazi O et al.. “Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda.” Emerging infectious diseases (2018). PMID: 29260682 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [192]
Hageman JC, Uyeki TM, Francis JS et al.. “Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.” Emerging infectious diseases (2006). PMID: 16707043 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [193]
Ferdinands JM, Denison AM, Dowling NF et al.. “A pilot study of host genetic variants associated with influenza-associated deaths among children and young adults.” Emerging infectious diseases (2011). PMID: 22172537 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History - [194]
Hutchinson K, Banks J, Arnold A et al.. “Orthoplastic management of delayed sternal osteomyelitis and non-union: a retrospective case series applying fracture-related infection principles.” International orthopaedics (2026). PMID: 42329262 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [195]
Shi L, Ruan Y, Wang X et al.. “First fatal human bloodstream infection caused by Macrococcus caseolyticus subsp. caseolyticus in China: genomic insights into virulence and antimicrobial resistance.” Frontiers in cellular and infection microbiology (2026). PMID: 42306534 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis - [196]
Baur D, Gladstone BP, Burkert F et al.. “Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2017). PMID: 28629876 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [197]
Tacconelli E, De Angelis G, de Waure C et al.. “Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis.” The Lancet. Infectious diseases (2009). PMID: 19695491 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [198]
Nellums LB, Thompson H, Holmes A et al.. “Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2018). PMID: 29779917 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [199]
Strömdahl M, Hagman K, Hedman K et al.. “Time to Staphylococcus aureus Blood Culture Positivity as a Risk Marker of Infective Endocarditis: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39707905 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [200]
Shappell CN, Yu T, Klompas M et al.. “Frequency of Antibiotic Overtreatment and Associated Harms in Patients Presenting With Suspected Sepsis to the Emergency Department: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40231968 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [201]
Huang SS, Singh R, McKinnell JA et al.. “Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers.” The New England journal of medicine (2019). PMID: 30763195 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control - [202]
Peel TN, Astbury S, Cheng AC et al.. “Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty.” The New England journal of medicine (2023). PMID: 37851875 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control - [203]
Huskins WC, Huckabee CM, O'Grady NP et al.. “Intervention to reduce transmission of resistant bacteria in intensive care.” The New England journal of medicine (2011). PMID: 21488763 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [204]
. “A randomized trial of diagnostic techniques for ventilator-associated pneumonia.” The New England journal of medicine (2006). PMID: 17182987 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [205]
Allegranzi B, Bagheri Nejad S, Combescure C et al.. “Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis.” Lancet (London, England) (2010). PMID: 21146207 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [206]
Minter DJ, Appa A, Chambers HF et al.. “Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37950887 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [207]
Boucher HW, Corey GR. “Epidemiology of methicillin-resistant Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462089 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [208]
Saravolatz LD, Stein GE. “Oritavancin: A Long-Half-Life Lipoglycopeptide.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25900171 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Complications - [209]
Dinh A, Ropers J, Duran C et al.. “Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.” Lancet (London, England) (2021). PMID: 33773631 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations - [210]
Huang SS, Septimus E, Kleinman K et al.. “Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial.” Lancet (London, England) (2019). PMID: 30850112 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Prevention and Infection Control - [211]
Kalra L, Irshad S, Hodsoll J et al.. “Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial.” Lancet (London, England) (2015). PMID: 26343840 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control - [212]
Kalil AC, Van Schooneveld TC, Fey PD et al.. “Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis.” JAMA (2014). PMID: 25321910 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [213]
Cai Y, Wang R, Liang B et al.. “Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.” Antimicrobial agents and chemotherapy (2010). PMID: 21173186 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications - [214]
van Hal SJ, Paterson DL. “Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.” Antimicrobial agents and chemotherapy (2010). PMID: 21078939 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [215]
Hurley JC. “The perfidious effect of topical placebo: calibration of Staphylococcus aureus ventilator-associated pneumonia incidence within selective digestive decontamination studies versus the broader evidence base.” Antimicrobial agents and chemotherapy (2013). PMID: 23836178 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [216]
Heizmann WR, Dupont H, Montravers P et al.. “Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.” The Journal of antimicrobial chemotherapy (2013). PMID: 23772046 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [217]
Milstone AM, Voskertchian A, Koontz DW et al.. “Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial.” JAMA (2020). PMID: 31886828 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prevention and Infection Control - [218]
Ciapponi A, Bardach A, Sandoval MM et al.. “Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America.” Emerging infectious diseases (2023). PMID: 37877573 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [219]
Chuang YY, Huang YC. “Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia.” The Lancet. Infectious diseases (2013). PMID: 23827369 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [220]
Albrich WC, Harbarth S. “Health-care workers: source, vector, or victim of MRSA?” The Lancet. Infectious diseases (2008). PMID: 18471774 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [221]
Otter JA, French GL. “Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe.” The Lancet. Infectious diseases (2010). PMID: 20334846 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [222]
Bush K, Bradford PA. “Epidemiology of β-Lactamase-Producing Pathogens.” Clinical microbiology reviews (2020). PMID: 32102899 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [223]
Sauvat L, Verhoeven PO, Gagnaire J et al.. “Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.” Clinical microbiology reviews (2024). PMID: 39120140 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [224]
Galar A, Weil AA, Dudzinski DM et al.. “Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.” Clinical microbiology reviews (2019). PMID: 30760474 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [225]
Park S, Ronholm J. “Staphylococcus aureus in Agriculture: Lessons in Evolution from a Multispecies Pathogen.” Clinical microbiology reviews (2021). PMID: 33568553 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment - [226]
Swets MC, Bakk Z, Westgeest AC et al.. “Clinical Subphenotypes of Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38916975 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [227]
Kam KQ, Chen T, Kadri SS et al.. “Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39657050 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [228]
. “Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.” Lancet (London, England) (2019). PMID: 31257127 ↗
L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations - [229]
Bengtsen KH, Falkentoft AC, Le MV et al.. “Incidence of Staphylococcus aureus Bacteremia in Patients Following Implantation of Cardiac Implantable Electronic Devices: A Danish Nationwide Cohort Study.” Open forum infectious diseases (2024). PMID: 39329108 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [230]
Wang A, Gaca JG, Chu VH. “Management Considerations in Infective Endocarditis: A Review.” JAMA (2018). PMID: 29971402 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [231]
Hawkey PM, Jones AM. “The changing epidemiology of resistance.” The Journal of antimicrobial chemotherapy (2009). PMID: 19675017 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [232]
Gouliouris T, Aliyu SH, Brown NM. “Spondylodiscitis: update on diagnosis and management.” The Journal of antimicrobial chemotherapy (2010). PMID: 20876624 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control - [233]
Gu B, Kelesidis T, Tsiodras S et al.. “The emerging problem of linezolid-resistant Staphylococcus.” The Journal of antimicrobial chemotherapy (2012). PMID: 22949625 ↗
L4REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [234]
Ramirez JA, Anzueto AR. “Changing needs of community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482567 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Prognosis and Natural History - [235]
Garcia-Alvarez L, Dawson S, Cookson B et al.. “Working across the veterinary and human health sectors.” The Journal of antimicrobial chemotherapy (2012). PMID: 22855878 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [236]
Daneman N, Rishu A, Pinto R et al.. “Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.” The New England journal of medicine (2024). PMID: 39565030 ↗
L1OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [237]
Jernigan JA, Hatfield KM, Wolford H et al.. “Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.” The New England journal of medicine (2020). PMID: 32242356 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [238]
Wang Y, Chen G, Zhai N et al.. “Risk factors for 28-day mortality and pathogen characteristics of septic shock in children: a 10-year retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 42256218 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations - [239]
Landrum ML, Neumann C, Cook C et al.. “Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010.” JAMA (2012). PMID: 22760291 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [240]
Bae S, Kim ES, Kim HS et al.. “Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.” Antimicrobial agents and chemotherapy (2022). PMID: 35762799 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification - [241]
Rhodes NJ, Rohani R, Yarnold PR et al.. “Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2022). PMID: 36472425 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [242]
Svishchuk J, Ebbert K, Waddell B et al.. “Epidemiology and impact of methicillin-sensitive Staphylococcus aureus with β-lactam antibiotic inoculum effects in adults with cystic fibrosis.” Antimicrobial agents and chemotherapy (2023). PMID: 37966229 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [243]
Gross AE, Van Schooneveld TC, Olsen KM et al.. “Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.” Antimicrobial agents and chemotherapy (2014). PMID: 24957843 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [244]
Bae S, Kook MS, Chang E et al.. “Risk and Distribution of Metastatic Infections by Primary Infection Focus in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2025). PMID: 40568004 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [245]
Biggs HM, Li R, Jackson KA et al.. “Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005-2022.” Open forum infectious diseases (2025). PMID: 40453873 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [246]
Warren DK, Nickel KB, Wallace AE et al.. “Risk Factors for Surgical Site Infection After Cholecystectomy.” Open forum infectious diseases (2017). PMID: 28491887 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [247]
Kim T, Huh JW, Hong SB et al.. “Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults.” Open forum infectious diseases (2023). PMID: 37035491 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [248]
Blauw M, Foxman B, Wu J et al.. “Risk Factors and Outcomes Associated With Hospital-Onset Peripheral Intravenous Catheter-Associated Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 30949543 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [249]
Neofytos D, Stampf S, Hoessly LD et al.. “Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update.” Open forum infectious diseases (2023). PMID: 37323422 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prevention and Infection Control - [250]
Molina KC, Lunowa C, Lebin M et al.. “Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections.” Open forum infectious diseases (2022). PMID: 35899276 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control - [251]
Stenhem M, Ortqvist A, Ringberg H et al.. “Imported methicillin-resistant Staphylococcus aureus, Sweden.” Emerging infectious diseases (2010). PMID: 20113546 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [252]
Thorlacius-Ussing L, Sandholdt H, Larsen AR et al.. “Age-Dependent Increase in Incidence of Staphylococcus aureus Bacteremia, Denmark, 2008-2015.” Emerging infectious diseases (2019). PMID: 31002300 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Special Hosts and Populations - [253]
Torres Valenzuela LM, Garza-Leon M, Beltran F et al.. “Trends in pathogens causing microbial keratitis in studies conducted in Mexico: a 38-year literature review.” International ophthalmology (2026). PMID: 42319559 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [254]
Akasha R, Binsaleh NK, Abdalla RAH et al.. “Infectious disease outcomes in end-stage renal disease: the influence of dialysis type on patient vulnerability in Hail region.” Frontiers in medicine (2026). PMID: 42428264 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors - [255]
Berbari EF, Kanj SS, Kowalski TJ et al.. “2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26229122 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [256]
Kaasch AJ, López-Cortés LE, Rodríguez-Baño J et al.. “Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2024). PMID: 38244557 ↗
L1RCTCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [257]
Derde LPG, Cooper BS, Goossens H et al.. “Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial.” The Lancet. Infectious diseases (2013). PMID: 24161233 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prevention and Infection Control - [258]
Buehler SS, Madison B, Snyder SR et al.. “Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis.” Clinical microbiology reviews (2016). PMID: 26598385 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [259]
Rubinstein E, Kollef MH, Nathwani D. “Pneumonia caused by methicillin-resistant Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462093 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [260]
Aliberti S, Reyes LF, Faverio P et al.. “Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.” The Lancet. Infectious diseases (2016). PMID: 27593581 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis and Workup - [261]
Crum-Cianflone NF. “Bacterial, fungal, parasitic, and viral myositis.” Clinical microbiology reviews (2008). PMID: 18625683 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment - [262]
van Hal SJ, Jensen SO, Vaska VL et al.. “Predictors of mortality in Staphylococcus aureus Bacteremia.” Clinical microbiology reviews (2012). PMID: 22491776 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [263]
Mergenhagen KA, Starr KE, Wattengel BA et al.. “Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31573026 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [264]
Lamloumi M, Javerliat I, Duran C et al.. “Characteristics and Risk Factors for Mortality of Vascular Graft Infections: a Cohort Study.” Open forum infectious diseases (2026). PMID: 42415734 ↗
L2COHORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [265]
Dufour S, Piroth L, Chirouze C et al.. “Staphylococcus aureus Bloodstream Infection in Patients With Prosthetic Joints in the Prospective VIRSTA Cohort Study: Frequency and Time of Occurrence of Periprosthetic Joint Infection.” Open forum infectious diseases (2019). PMID: 31890721 ↗
L2COHORTCited in: Clinical Presentation - [266]
Shenoy ES, Macy E, Rowe T et al.. “Evaluation and Management of Penicillin Allergy: A Review.” JAMA (2019). PMID: 30644987 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications - [267]
Holland TL, Arnold C, Fowler VG. “Clinical management of Staphylococcus aureus bacteremia: a review.” JAMA (2014). PMID: 25268440 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [268]
Gould IM. “Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2011). PMID: 21521703 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [269]
Nissen JL, Skov R, Knudsen JD et al.. “Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis.” The Journal of antimicrobial chemotherapy (2013). PMID: 23599360 ↗
L2CASE_CONTROLCited in: Clinical Presentation - [270]
Duss FR, Garcia de la Mària C, Croxatto A et al.. “Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.” The Journal of antimicrobial chemotherapy (2019). PMID: 31298264 ↗
L4CASE_REPORTCited in: Clinical Presentation - [271]
Takayama A, Meguro K, Yokota M et al.. “Atypical X-linked agammaglobulinemia diagnosed in adulthood with arthritis caused by a hypomorphic BTK splice-site variant: a case report and literature review.” Frontiers in immunology (2026). PMID: 42253969 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment, Complications - [272]
Duployez C, Le Guern R, Tinez C et al.. “Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19.” Emerging infectious diseases (2020). PMID: 32298228 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [273]
Jewell P, Dixon L, Singanayagam A et al.. “Severe Disseminated Infection with Emerging Lineage of Methicillin-Sensitive Staphylococcus aureus.” Emerging infectious diseases (2019). PMID: 30561304 ↗
L4CASE_REPORTCited in: Clinical Presentation - [274]
Rigaill J, Grattard F, Grange S et al.. “Community-Acquired Staphylococcus argenteus Sequence Type 2250 Bone and Joint Infection, France, 2017.” Emerging infectious diseases (2018). PMID: 30226182 ↗
L4CASE_REPORTCited in: Clinical Presentation - [275]
Bergevin M, Marion A, Farber D et al.. “Severe MRSA Enterocolitis Caused by a Strain Harboring Enterotoxins D, G, and I.” Emerging infectious diseases (2017). PMID: 28418301 ↗
L4CASE_REPORTCited in: Clinical Presentation - [276]
Oh JT, Ambler JE, Cassino C et al.. “Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.” Antimicrobial agents and chemotherapy (2021). PMID: 33903102 ↗
L5OTHERCited in: Clinical Presentation - [277]
Casapao AM, Leonard SN, Davis SL et al.. “Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.” Antimicrobial agents and chemotherapy (2013). PMID: 23796929 ↗
L3OTHERCited in: Clinical Presentation - [278]
Herren SC, Huemer M, Acevedo CT et al.. “Assessing Antibiotic Tolerance of Staphylococcus aureus Derived Directly from Patients by the Replica Plating Tolerance Isolation System (REPTIS).” Antimicrobial agents and chemotherapy (2021). PMID: 34694884 ↗
L4OTHERCited in: Clinical Presentation - [279]
McNeil JC, Sommer LM, Vallejo JG et al.. “Going Back in Time: Increasing Penicillin Susceptibility among Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2023). PMID: 36598265 ↗
L2OTHERCited in: Clinical Presentation, Special Hosts and Populations - [280]
Claeys KC, Smith JR, Casapao AM et al.. “Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.” Antimicrobial agents and chemotherapy (2015). PMID: 25605354 ↗
L3OTHERCited in: Clinical Presentation - [281]
Bayer AS, Mishra NN, Chen L et al.. “Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides.” Antimicrobial agents and chemotherapy (2015). PMID: 26055370 ↗
L4OTHERCited in: Clinical Presentation - [282]
Dangerfield B, Chung A, Webb B et al.. “Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia.” Antimicrobial agents and chemotherapy (2013). PMID: 24277023 ↗
L3OTHERCited in: Clinical Presentation - [283]
Baxi SM, Clemenzi-Allen A, Gahbauer A et al.. “Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 27324762 ↗
L2OTHERCited in: Clinical Presentation - [284]
Casapao AM, Davis SL, Barr VO et al.. “Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.” Antimicrobial agents and chemotherapy (2014). PMID: 24550331 ↗
L4OTHERCited in: Clinical Presentation - [285]
San Juan R, Garcia-Reyne A, Caba P et al.. “Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.” Antimicrobial agents and chemotherapy (2010). PMID: 20855727 ↗
L4OTHERCited in: Clinical Presentation - [286]
Britt NS, Patel N, Shireman TI et al.. “Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2016). PMID: 27999028 ↗
L3OTHERCited in: Clinical Presentation - [287]
Vindel A, Trincado P, Cuevas O et al.. “Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Spain: 2004-12.” The Journal of antimicrobial chemotherapy (2014). PMID: 24990868 ↗
L2OTHERCited in: Clinical Presentation, Special Hosts and Populations - [288]
Joseph JP, Meddows TR, Webster DP et al.. “Prioritizing echocardiography in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2012). PMID: 23111851 ↗
L3OTHERCited in: Clinical Presentation - [289]
Van Besien RF, Vazquez Guillamet MC. “The Evolving Etiology of Hospital-Acquired and Ventilator-Associated Pneumonia.” Clinics in chest medicine (2026). PMID: 42203422 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [290]
Comune M, Furnari I, Silvestro E et al.. “Neonatal Osteomyelitis Caused by Staphylococcus aureus: Case Series and Review of the Literature.” Children (Basel, Switzerland) (2026). PMID: 42353950 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [291]
Webb G, Choi J, Younes A et al.. “Comparing clinical manifestations, treatment strategies and outcomes of Staphylococcus lugdunensis bacteraemia versus Staphylococcus aureus bacteraemia - a retrospective cohort study.” Internal medicine journal (2026). PMID: 42250238 ↗
L3COHORTCited in: Clinical Presentation - [292]
Soti Khiabani M, Talari SM, Khodabandeh M. “Ten-Year Epidemiology and Antimicrobial Susceptibility of Pediatric Staphylococcal Scalded Skin Syndrome: A Retrospective Study From a Tertiary Referral Center.” Pediatric dermatology (2026). PMID: 42219159 ↗
L4COHORTCited in: Clinical Presentation - [293]
Ali MN, Gahnug M, Jama AA et al.. “Septic pulmonary embolism in Somali children: a retrospective study from a tertiary hospital.” Frontiers in pediatrics (2026). PMID: 42212102 ↗
L4COHORTCited in: Clinical Presentation - [294]
Schulz SH, Dally FJ, Vogel J et al.. “Whole-Spine MRI Reveals High Prevalence of Multifocal Spondylodiscitis and Identifies a High-Risk Subgroup: A Retrospective Cohort Study of 274 Patients.” Medicina (Kaunas, Lithuania) (2026). PMID: 42195242 ↗
L3COHORTCited in: Clinical Presentation - [295]
Campbell S, MacGregor K, Smith EL et al.. “Clinical Presentation and Outcomes Following Infection With Vibrio spp, Aeromonas spp, Chromobacterium violaceum, and Shewanella spp Water-Associated Organisms in Tropical Australia, 2015-2022.” Open forum infectious diseases (2024). PMID: 38975250 ↗
L3OTHERCited in: Clinical Presentation - [296]
Whittington KJ, Malone SM, Hogan PG et al.. “Staphylococcus aureus Bacteremia in Pediatric Patients: Uncovering a Rural Health Challenge.” Open forum infectious diseases (2023). PMID: 37469617 ↗
L3OTHERCited in: Clinical Presentation, Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [297]
An TJ, Benvenuti MA, Mignemi ME et al.. “Similar Clinical Severity and Outcomes for Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Pediatric Musculoskeletal Infections.” Open forum infectious diseases (2017). PMID: 28480284 ↗
L3OTHERCited in: Clinical Presentation - [298]
Wilson Dib R, Chaftari AM, Hachem RY et al.. “Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy.” Open forum infectious diseases (2018). PMID: 30377625 ↗
L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment - [299]
Bodavula P, Liang SY, Wu J et al.. “Pressure Ulcer-Related Pelvic Osteomyelitis: A Neglected Disease?” Open forum infectious diseases (2015). PMID: 26322317 ↗
L3OTHERCited in: Clinical Presentation - [300]
Meier R, Wirth T, Hahn F et al.. “Pyogenic Arthritis of the Fingers and the Wrist: Can We Shorten Antimicrobial Treatment Duration?” Open forum infectious diseases (2017). PMID: 28491895 ↗
L4OTHERCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [301]
Sinnar SA, Schiff SJ. “The Problem of Microbial Dark Matter in Neonatal Sepsis.” Emerging infectious diseases (2020). PMID: 33080169 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [302]
Bordeau V, Cady A, Revest M et al.. “Staphylococcus aureus Regulatory RNAs as Potential Biomarkers for Bloodstream Infections.” Emerging infectious diseases (2016). PMID: 27224202 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup - [303]
Prinz JC, Stadler PC. “Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma - GASD syndrome by TNF antagonists.” Frontiers in immunology (2026). PMID: 42344923 ↗
L4CASE_REPORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [304]
Okomo U, Akpalu ENK, Le Doare K et al.. “Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines.” The Lancet. Infectious diseases (2019). PMID: 31522858 ↗
L1SR_OBSCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [305]
Mork RL, Hogan PG, Muenks CE et al.. “Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study.” The Lancet. Infectious diseases (2019). PMID: 31784369 ↗
L2COHORTCited in: Diagnosis and Workup - [306]
Patel JB, Gorwitz RJ, Jernigan JA. “Mupirocin resistance.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19673644 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [307]
McDanel JS, Perencevich EN, Diekema DJ et al.. “Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25900170 ↗
L2OTHERCited in: Diagnosis and Workup - [308]
Kadri SS, Lai YL, Warner S et al.. “Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.” The Lancet. Infectious diseases (2020). PMID: 32916100 ↗
L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [309]
den Heijer CD, van Bijnen EM, Paget WJ et al.. “Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study.” The Lancet. Infectious diseases (2013). PMID: 23473661 ↗
L4OTHERCited in: Diagnosis and Workup, Special Hosts and Populations - [310]
García-Álvarez L, Holden MT, Lindsay H et al.. “Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study.” The Lancet. Infectious diseases (2011). PMID: 21641281 ↗
L4OTHERCited in: Diagnosis and Workup - [311]
Humphries RM, Pollett S, Sakoulas G. “A current perspective on daptomycin for the clinical microbiologist.” Clinical microbiology reviews (2013). PMID: 24092854 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [312]
Perry JD. “A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics.” Clinical microbiology reviews (2017). PMID: 28122803 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [313]
Laupland KB, Church DL. “Population-based epidemiology and microbiology of community-onset bloodstream infections.” Clinical microbiology reviews (2014). PMID: 25278570 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [314]
Jain R, Kralovic SM, Evans ME et al.. “Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections.” The New England journal of medicine (2011). PMID: 21488764 ↗
L2OTHERCited in: Diagnosis and Workup, Prevention and Infection Control - [315]
Turner NA, Hamasaki T, Doernberg SB et al.. “Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.” JAMA (2025). PMID: 40802264 ↗
L1OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History - [316]
Kallen AJ, Mu Y, Bulens S et al.. “Health care-associated invasive MRSA infections, 2005-2008.” JAMA (2010). PMID: 20699455 ↗
L2OTHERCited in: Diagnosis and Workup, Prevention and Infection Control, Special Hosts and Populations - [317]
Saravolatz SN, Martin H, Pawlak J et al.. “Ceftaroline-heteroresistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2014). PMID: 24637680 ↗
L5OTHERCited in: Diagnosis and Workup - [318]
Suzuki Y, Kawada-Matsuo M, Thuan VTT et al.. “D-alanine synthesis and exogenous alanine affect the antimicrobial susceptibility of Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40503952 ↗
L5OTHERCited in: Diagnosis and Workup - [319]
Chan LC, Basuino L, Diep B et al.. “Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2015). PMID: 25753637 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [320]
Ma D, Arya R, Knapick BA et al.. “Methicillin-resistant Staphylococcus aureus has phenotypic variation in mecA expression that alters antibiotic sensitivity.” Antimicrobial agents and chemotherapy (2026). PMID: 41677252 ↗
L5OTHERCited in: Diagnosis and Workup - [321]
Karau MJ, Schmidt-Malan SM, Cunningham SA et al.. “Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.” Antimicrobial agents and chemotherapy (2021). PMID: 34723626 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [322]
Truong-Bolduc QC, Wang Y, Reedy JL et al.. “Staphylococcus aureus Efflux Pumps and Tolerance to Ciprofloxacin and Chlorhexidine following Induction by Mupirocin.” Antimicrobial agents and chemotherapy (2021). PMID: 34930023 ↗
L5OTHERCited in: Diagnosis and Workup - [323]
Bortolaia V, Kaas RS, Ruppe E et al.. “ResFinder 4.0 for predictions of phenotypes from genotypes.” The Journal of antimicrobial chemotherapy (2020). PMID: 32780112 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [324]
Lenhard JR, Bulman ZP. “Inoculum effect of β-lactam antibiotics.” The Journal of antimicrobial chemotherapy (2019). PMID: 31170287 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [325]
Rudilla H, Pérez-Guillén I, Rabanal F et al.. “Novel synthetic polymyxins kill Gram-positive bacteria.” The Journal of antimicrobial chemotherapy (2018). PMID: 30215733 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [326]
Turner NA, Xu A, Zaharoff S et al.. “Determination of plasma protein binding of dalbavancin.” The Journal of antimicrobial chemotherapy (2022). PMID: 35488862 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [327]
Holland M, Bjanes E, Nizet V et al.. “Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa.” The Journal of antimicrobial chemotherapy (2022). PMID: 34893834 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [328]
Kaul G, Akhir A, Shukla M et al.. “Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo.” The Journal of antimicrobial chemotherapy (2022). PMID: 35748613 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [329]
Hawkey PM. “Pre-clinical experience with daptomycin.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829726 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [330]
Jin Y, Zhou W, Chen W et al.. “Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections.” The Journal of antimicrobial chemotherapy (2025). PMID: 40601387 ↗
L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [331]
Hu J, Chen L, Li G et al.. “Prevalence and genetic characteristics of fosB-positive Staphylococcus aureus in duck farms in Guangdong, China in 2020.” The Journal of antimicrobial chemotherapy (2023). PMID: 36691844 ↗
L5OTHERCited in: Diagnosis and Workup - [332]
Cañas MA, García-de-la-Mària C, García-González J et al.. “Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains.” The Journal of antimicrobial chemotherapy (2025). PMID: 40424179 ↗
L5OTHERCited in: Diagnosis and Workup - [333]
Miller MM, Van Schooneveld TC, Stohs EJ et al.. “Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation.” Open forum infectious diseases (2023). PMID: 37564742 ↗
L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [334]
Honkanen M, Jämsen E, Karppelin M et al.. “Periprosthetic Joint Infections as a Consequence of Bacteremia.” Open forum infectious diseases (2019). PMID: 31214625 ↗
L2OTHERCited in: Diagnosis and Workup - [335]
Shaw R, Zander A, Ronnie T et al.. “Assessing the Predictive Value of Methicillin-Resistant Staphylococcus aureus Nares Colonization Among Transplant Recipients and Patients With Neutropenia.” Open forum infectious diseases (2024). PMID: 39050229 ↗
L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [336]
Maurer M, McCulloch M, Willey AM et al.. “Detection of Bacteriuria by Canine Olfaction.” Open forum infectious diseases (2016). PMID: 27186578 ↗
L2OTHERCited in: Diagnosis and Workup - [337]
Musher DM, Jesudasen SS, Barwatt JW et al.. “Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia.” Open forum infectious diseases (2020). PMID: 32968689 ↗
L2OTHERCited in: Diagnosis and Workup - [338]
Comba IY, Go JR, Vaillant J et al.. “Sequential Time to Positivity as a Prognostic Indicator in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2024). PMID: 38617074 ↗
L2OTHERCited in: Diagnosis and Workup, Complications - [339]
Phillip KI, Webster AS, Ray SM et al.. “Estimating the Burden of Clinically Significant Staphylococcus aureus Infections and Predictors for Hospitalization for Skin and Soft Tissue Infections, Fulton County, Georgia, 2017.” Open forum infectious diseases (2023). PMID: 38107016 ↗
L2OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [340]
Seidelman J, Ritter AS, Poehlein E et al.. “Multisite Study of the Management of Musculoskeletal Infection After Trauma: The MMUSKIT Study.” Open forum infectious diseases (2024). PMID: 38854390 ↗
L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [341]
Schneider-Lindner V, Delaney JA, Dial S et al.. “Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom.” Emerging infectious diseases (2007). PMID: 18214170 ↗
L3OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [342]
Francois P, Harbarth S, Huyghe A et al.. “Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005.” Emerging infectious diseases (2008). PMID: 18258126 ↗
L4OTHERCited in: Diagnosis and Workup, Special Hosts and Populations - [343]
Lo WT, Lin WJ, Tseng MH et al.. “Methicillin-resistant Staphylococcus aureus in children, Taiwan.” Emerging infectious diseases (2006). PMID: 16965712 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [344]
Alesana-Slater J, Ritchie SR, Heffernan H et al.. “Methicillin-resistant Staphylococcus aureus, Samoa, 2007-2008.” Emerging infectious diseases (2011). PMID: 21749763 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [345]
Johnson JK, Khoie T, Shurland S et al.. “Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone.” Emerging infectious diseases (2007). PMID: 17953091 ↗
L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [346]
Wulf M, van Nes A, Eikelenboom-Boskamp A et al.. “Methicillin-resistant Staphylococcus aureus in veterinary doctors and students, the Netherlands.” Emerging infectious diseases (2006). PMID: 17326948 ↗
L4OTHERCited in: Diagnosis and Workup - [347]
Tucker NJ, Chow L, Linde P et al.. “Germanium-embedded bioactive fabric reduces bacterial bioburden and modulates fibroblast and macrophage behavior in vitro.” Frontiers in bioengineering and biotechnology (2026). PMID: 42416535 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [348]
Getnet F, Marami D, Mohammed S et al.. “Bacterial pathogens and antimicrobial resistance patterns in infections associated with stillbirths and under-five deaths in Ethiopia: a post-mortem surveillance study.” BMC infectious diseases (2026). PMID: 42410519 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [349]
Guo HZ, Xing ZC, Ao T et al.. “Development and validation of a risk prediction model for hospital mortality in adult patients with Staphylococcus aureus bacteremia.” Frontiers in cellular and infection microbiology (2026). PMID: 42394821 ↗
L3OTHERCited in: Diagnosis and Workup - [350]
Ulziijargal J, Faermark E, Khenchbish U et al.. “Bacterial profile and antimicrobial resistance in patients with pulmonary infection: a retrospective tertiary hospital-based study.” BMC infectious diseases (2026). PMID: 42387436 ↗
L4OTHERCited in: Diagnosis and Workup - [351]
Ammoura J, Alshamaa N, Elamin A et al.. “Antimicrobial resistance and microbiological gap analysis for central nervous system-assocaited bacterial pathogens in Nigeria.” Frontiers in microbiology (2026). PMID: 42382344 ↗
L4OTHERCited in: Diagnosis and Workup - [352]
Salam T, Tufael, Siddique MAB et al.. “Multidrug-resistant bacterial infections in a tertiary hospitals: culture positivity, pathogen spectrum, and antibiotic susceptibility.” BMC microbiology (2026). PMID: 42381050 ↗
L4OTHERCited in: Diagnosis and Workup - [353]
Sanderford V, Tabliago NRA, Alnami S et al.. “Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia.” Microbiology spectrum (2026). PMID: 42379823 ↗
L3OTHERCited in: Diagnosis and Workup - [354]
Ding T, Liu X, Liao F et al.. “Bacterial pathogen spectrum and antimicrobial resistance in positive pus cultures from hospitalized patients at a maternal and child healthcare specialty hospital in Shenzhen, China, 2021-2025.” Frontiers in cellular and infection microbiology (2026). PMID: 42376315 ↗
L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [355]
Peng X, Zhou H, Liu W et al.. “In vitro interspecies interactions between methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa: effects on bacterial growth, antibiotic susceptibility, and transcriptomic reprogramming.” Frontiers in cellular and infection microbiology (2026). PMID: 42369189 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [356]
Falcone M, Russo A, Venditti M et al.. “Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 24046298 ↗
L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification - [357]
Karanika S, Kinamon T, Grigoras C et al.. “Colonization With Methicillin-resistant Staphylococcus aureus and Risk for Infection Among Asymptomatic Athletes: A Systematic Review and Metaanalysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27090988 ↗
L2SR_OBSCited in: Severity Assessment and Risk Stratification - [358]
López-Cortés LE, Del Toro MD, Gálvez-Acebal J et al.. “Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23929889 ↗
L2SR_OBSCited in: Severity Assessment and Risk Stratification - [359]
Bhavnani SM, Ambrose PG, Hammel JP et al.. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial agents and chemotherapy (2015). PMID: 26711755 ↗
L1RCTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [360]
Bassetti M, Righi E, Fasce R et al.. “Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit.” The Journal of antimicrobial chemotherapy (2007). PMID: 17540673 ↗
L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification - [361]
Malik U, Armstrong D, Ashworth M et al.. “Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review.” The Journal of antimicrobial chemotherapy (2018). PMID: 29149266 ↗
L3SR_OBSCited in: Severity Assessment and Risk Stratification - [362]
Panagides V, Cuervo G, Llopis J et al.. “Infective Endocarditis After Transcatheter Versus Surgical Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37552784 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [363]
Nelson RE, Evans ME, Simbartl L et al.. “Methicillin-resistant Staphylococcus aureus Colonization and Pre- and Post-hospital Discharge Infection Risk.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107401 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [364]
Humphreys H, Fitzpatick F, Harvey BJ. “Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26202769 ↗
L5REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification - [365]
Guimaraes AO, Cao Y, Hong K et al.. “A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30165412 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [366]
García-Granja PE, López J, Vilacosta I et al.. “Impact of Valve Culture in the Prognosis of Active Left-sided Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107544 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [367]
Ebruke BE, Deloria Knoll M, Haddix M et al.. “The Etiology of Pneumonia From Analysis of Lung Aspirate and Pleural Fluid Samples: Findings From the Pneumonia Etiology Research for Child Health (PERCH) Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32710751 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification - [368]
Chong YP, Moon SM, Bang KM et al.. “Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.” Antimicrobial agents and chemotherapy (2012). PMID: 23254436 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [369]
Jin R, Wang M, Ke J et al.. “Correlation between Staphylococcus aureus colonization and disease severity in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 42183252 ↗
L1SR_MA_RCTCited in: Severity Assessment and Risk Stratification - [370]
Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Outcomes and Risk Factors of Septic Shock in Patients With Infective Endocarditis: A Prospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34189153 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [371]
Lim CJ, Cheng AC, Kennon J et al.. “Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study.” The Journal of antimicrobial chemotherapy (2014). PMID: 24710025 ↗
L3CASE_CONTROLCited in: Severity Assessment and Risk Stratification - [372]
van der Meulen LWJ, Bergmans ME, Assil S et al.. “Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trial.” British journal of clinical pharmacology (2026). PMID: 42115134 ↗
L1RCTCited in: Severity Assessment and Risk Stratification - [373]
Sousa-Regueiro D, Alonso-Alvarez A, Balboa-Barreiro V et al.. “Determinants of cure and survival in vascular graft and endograft infections: a 13-year single-centre cohort study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42119888 ↗
L3COHORTCited in: Severity Assessment and Risk Stratification - [374]
Harris AD, Furuno JP, Roghmann MC et al.. “Targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy.” Antimicrobial agents and chemotherapy (2010). PMID: 20479207 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [375]
Moore CL, Lu M, Cheema F et al.. “Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.” Antimicrobial agents and chemotherapy (2011). PMID: 21825294 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [376]
Pericàs JM, Cervera C, Garcia-de-la-Mària C et al.. “Relationship between Vancomycin MIC and Virulence Gene Expression in Clonal Complexes of Methicillin-Susceptible Staphylococcus aureus Strains Isolated from Left-Sided Endocarditis.” Antimicrobial agents and chemotherapy (2020). PMID: 31907181 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification - [377]
Ikeh MAC, Fidel PL, Noverr MC. “Prostaglandin E2 Receptor Antagonist with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2018). PMID: 29263068 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [378]
Van Wart SA, Ambrose PG, Rubino CM et al.. “Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.” Antimicrobial agents and chemotherapy (2013). PMID: 24277021 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [379]
Lefèvre S, Saleh M, Marcellin L et al.. “Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.” Antimicrobial agents and chemotherapy (2012). PMID: 22371888 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [380]
Brown J, Brown K, Forrest A. “Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.” Antimicrobial agents and chemotherapy (2011). PMID: 22123681 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [381]
Meléndez-Carmona MÁ, Mancheño-Losa M, Ruiz-Sorribas A et al.. “Strain-to-strain variability among Staphylococcus aureus causing prosthetic joint infection drives heterogeneity in response to levofloxacin and rifampicin.” The Journal of antimicrobial chemotherapy (2022). PMID: 36124848 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [382]
Lalanne S, Cattoir V, Guerin F et al.. “Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.” The Journal of antimicrobial chemotherapy (2023). PMID: 37248684 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [383]
Kanerva M, Ollgren J, Lyytikäinen O. “Benchmarking antibiotic use in Finnish acute care hospitals using patient case-mix adjustment.” The Journal of antimicrobial chemotherapy (2011). PMID: 21846673 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [384]
López-Cortés LE, Velasco C, Retamar P et al.. “Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?” The Journal of antimicrobial chemotherapy (2015). PMID: 26023210 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [385]
Hong M, Xiang W, Kong L et al.. “Corynebacterium Striatum Infective Endocarditis: A Systematic Review.” Journal of inflammation research (2025). PMID: 41403720 ↗
L4SR_OBSCited in: Severity Assessment and Risk Stratification - [386]
Song J, Liu T, Yu Y et al.. “MHR and CRP/Albumin Ratio Correlate with Wagner Grade in Diabetic Foot Ulcers: A Chinese Retrospective Study with Pathogen Analysis.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42267252 ↗
L4COHORTCited in: Severity Assessment and Risk Stratification - [387]
Kato H, Kitaura T, Noma H et al.. “Risk factors for community-acquired metastatic infections without infective endocarditis in patients with Staphylococcus aureus bacteremia: A retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42162662 ↗
L3COHORTCited in: Severity Assessment and Risk Stratification, Complications - [388]
Smit J, Dalager-Pedersen M, Adelborg K et al.. “Influence of Acetylsalicylic Acid Use on Risk and Outcome of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Study.” Open forum infectious diseases (2019). PMID: 31660413 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [389]
Guimaraes AO, Gutierrez J, Maskarinec SA et al.. “Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 31041341 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification - [390]
Ross JJ, Ard KL. “Septic Arthritis of the Spinal Facet Joint: Review of 117 Cases.” Open forum infectious diseases (2024). PMID: 38449920 ↗
L4REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification, Complications, Prognosis and Natural History - [391]
Barshes NR, Clark NJ, Bidare D et al.. “Polymicrobial Foot Infection Patterns Are Common and Associated With Treatment Failure.” Open forum infectious diseases (2022). PMID: 36267251 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification, History and Evolution of Treatment - [392]
Forsblom E, Frilander H, Ruotsalainen E et al.. “Formal Infectious Diseases Specialist Consultation Improves Long-term Outcome of Methicillin-Sensitive Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 32128337 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [393]
Mendy A, Vieira ER, Albatineh AN et al.. “Staphylococcus aureus Colonization and Long-Term Risk for Death, United States.” Emerging infectious diseases (2016). PMID: 27767920 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [394]
Miller LG, Daum RS, Creech CB et al.. “Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.” The New England journal of medicine (2015). PMID: 25785967 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations - [395]
Baeten D, Baraliakos X, Braun J et al.. “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2013). PMID: 24035250 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications - [396]
Falagas ME, Giannopoulou KP, Ntziora F et al.. “Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.” The Journal of antimicrobial chemotherapy (2007). PMID: 17550889 ↗
L4SR_OBSCited in: Empiric Management, Acute Care and Source Control - [397]
Holland TL, Raad I, Boucher HW et al.. “Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.” JAMA (2018). PMID: 30264119 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [398]
Prokocimer P, De Anda C, Fang E et al.. “Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.” JAMA (2013). PMID: 23403680 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications - [399]
Davey P, Brown E, Fenelon L et al.. “Systematic review of antimicrobial drug prescribing in hospitals.” Emerging infectious diseases (2006). PMID: 16494744 ↗
L2SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [400]
Ulloa ER, Singh KV, Geriak M et al.. “Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31773134 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [401]
Rybak MJ. “The pharmacokinetic and pharmacodynamic properties of vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16323118 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [402]
Paterson DL, Depestel DD. “Doripenem.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19527173 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [403]
Rose W, Fantl M, Geriak M et al.. “Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33993226 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [404]
Jordan H, Kozierowski K, Pickles R et al.. “Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study.” Open forum infectious diseases (2025). PMID: 40657166 ↗
L4TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control - [405]
Katragadda S, Baddour LM, Chesdachai S et al.. “Postoperative Treatment Regimens in Patients With Native Valve Endocarditis due to Staphylococcus aureus Who Undergo Valve Replacement or Repair.” Open forum infectious diseases (2025). PMID: 40207048 ↗
L3TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control, Complications - [406]
Cosimi RA, Beik N, Kubiak DW et al.. “Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.” Open forum infectious diseases (2017). PMID: 28702467 ↗
L5SR_OBSCited in: Empiric Management, Acute Care and Source Control - [407]
Scheper H, Gerritsen LM, Pijls BG et al.. “Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.” Open forum infectious diseases (2021). PMID: 34258321 ↗
L1SR_OBSCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [408]
Lek A, Wong B, Keeler A et al.. “Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.” The New England journal of medicine (2023). PMID: 37754285 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control - [409]
Zasowski EJ, Trinh TD, Claeys KC et al.. “Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.” Open forum infectious diseases (2021). PMID: 35146040 ↗
L3COHORTCited in: Empiric Management, Acute Care and Source Control - [410]
Partridge SR, Kwong SM, Firth N et al.. “Mobile Genetic Elements Associated with Antimicrobial Resistance.” Clinical microbiology reviews (2018). PMID: 30068738 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [411]
Williamson DA, Carter GP, Howden BP. “Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.” Clinical microbiology reviews (2017). PMID: 28592405 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [412]
Septimus EJ, Schweizer ML. “Decolonization in Prevention of Health Care-Associated Infections.” Clinical microbiology reviews (2016). PMID: 26817630 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [413]
Forrest GN, Tamura K. “Rifampin combination therapy for nonmycobacterial infections.” Clinical microbiology reviews (2010). PMID: 20065324 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [414]
Grundmann H, Aires-de-Sousa M, Boyce J et al.. “Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.” Lancet (London, England) (2006). PMID: 16950365 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [415]
Alomair SM, Al Sulaiman K, Alharbi A et al.. “Effectiveness of cefazolin versus anti-staphylococcal β-lactam for treating methicillin-susceptible Staphylococcus aureus pneumonia in critically ill patients admitted to intensive care units: a multicenter cohort study.” Annals of clinical microbiology and antimicrobials (2026). PMID: 42421008 ↗
L3COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [416]
Sánchez García M, De la Torre MA, Morales G et al.. “Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.” JAMA (2010). PMID: 20530779 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [417]
Kleinhenz M, Beesetty P, Yang C et al.. “Antibiotic Treatment of Staphylococcus aureus Infection Inhibits the Development of Protective Immunity.” Antimicrobial agents and chemotherapy (2022). PMID: 35266822 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [418]
Lepelletier D, Maillard JY, Pozzetto B et al.. “Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization.” Antimicrobial agents and chemotherapy (2020). PMID: 32571829 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [419]
Zelmer AR, Yang D, Gunn NJ et al.. “Osteomyelitis-relevant antibiotics at clinical concentrations show limited effectivity against acute and chronic intracellular S. aureus infections in osteocytes.” Antimicrobial agents and chemotherapy (2024). PMID: 39194210 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [420]
Molina KC, Morrisette T, Miller MA et al.. “The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32312776 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [421]
Truong-Bolduc QC, Wang Y, Ferrer-Espada R et al.. “Staphylococcus aureus AbcA transporter enhances persister formation under β-lactam exposure.” Antimicrobial agents and chemotherapy (2024). PMID: 38364015 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [422]
Frapwell CJ, Skipp PJ, Howlin RP et al.. “Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms.” Antimicrobial agents and chemotherapy (2020). PMID: 32122902 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [423]
Cooper EC, Curtis N, Cranswick N et al.. “Pristinamycin: old drug, new tricks?” The Journal of antimicrobial chemotherapy (2014). PMID: 24891428 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [424]
Simon S, Frank BJH, Hartmann S et al.. “Dalbavancin in Gram-positive periprosthetic joint infections.” The Journal of antimicrobial chemotherapy (2022). PMID: 35678452 ↗
L3OTHERCited in: Empiric Management, Acute Care and Source Control, Complications - [425]
Laudano JB. “Ceftaroline fosamil: a new broad-spectrum cephalosporin.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482565 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [426]
Hawkey PM. “The growing burden of antimicrobial resistance.” The Journal of antimicrobial chemotherapy (2008). PMID: 18684701 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [427]
Nicholson OA, Levi E. “Outcomes of single-stage excision in infected preauricular sinus: a retrospective cohort study.” International journal of pediatric otorhinolaryngology (2026). PMID: 42391915 ↗
L2COHORTCited in: Empiric Management, Acute Care and Source Control - [428]
Rappo U, Puttagunta S, Shevchenko V et al.. “Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.” Open forum infectious diseases (2018). PMID: 30648126 ↗
L1OTHERCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications - [429]
Gobao VC, Alfishawy M, Smith C et al.. “Risk Factors, Screening, and Treatment Challenges in Staphylococcus aureus Native Septic Arthritis.” Open forum infectious diseases (2020). PMID: 33511230 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [430]
Yang WT, Meisner JA, Maguire C et al.. “Multidisciplinary Guidance to Care for Persons With Xylazine-Associated Wounds.” Open forum infectious diseases (2025). PMID: 40453883 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [431]
Bowen AC, Carapetis JR, Currie BJ et al.. “Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.” Open forum infectious diseases (2017). PMID: 29255730 ↗
L2REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [432]
Dagher M, Fowler VG, Wright PW et al.. “A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?” Open forum infectious diseases (2020). PMID: 32523971 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [433]
Moenster RP, Wallace-Lacey A, Western H et al.. “Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.” Open forum infectious diseases (2023). PMID: 37937043 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [434]
Randad PR, Larsen J, Kaya H et al.. “Transmission of Antimicrobial-Resistant Staphylococcus aureus Clonal Complex 9 between Pigs and Humans, United States.” Emerging infectious diseases (2021). PMID: 33622471 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [435]
Faires MC, Traverse M, Tater KC et al.. “Methicillin-resistant and -susceptible Staphylococcus aureus infections in dogs.” Emerging infectious diseases (2010). PMID: 20031045 ↗
L3OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [436]
David MZ, Crawford SE, Boyle-Vavra S et al.. “Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates.” Emerging infectious diseases (2006). PMID: 16704812 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [437]
Carrel M, Perencevich EN, David MZ. “USA300 Methicillin-Resistant Staphylococcus aureus, United States, 2000-2013.” Emerging infectious diseases (2015). PMID: 26484389 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [438]
Zhang QJ, Li YX, Yan YX et al.. “Design, synthesis, anti-MRSA activity evaluation, and mechanism of action study of 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivatives.” European journal of medicinal chemistry (2026). PMID: 42430954 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [439]
Liu F, Chen H, Huang Y et al.. “Phage-guided rapid enrichment of copper-protocatechuic acid nanoparticles for targeted antibacterial therapy.” Journal of nanobiotechnology (2026). PMID: 42426746 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [440]
Zhou F, Luan J, Wei L et al.. “Synergistic Magneto-Electro-Thermal Biochemical Cascade Modulation Enables Rapid Healing and Functional Restoration of Infected Wounds.” Acta biomaterialia (2026). PMID: 42425219 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [441]
Zhang JQ, Wang Y, Ou JG et al.. “Inflammation-responsive liposomes co-delivering tobramycin and nitric oxide for overcoming mucus barriers against MRSA pneumonia.” Colloids and surfaces. B, Biointerfaces (2026). PMID: 42424783 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [442]
Lai X, Wang S, Ding C et al.. “Enhanced Antibacterial Properties of Lyotropic Liquid Crystalline Nanoparticles via Curvature Modulation.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 42423613 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [443]
Khairnar SV, Sommers A, Muldiiarova E et al.. “Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42422740 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [444]
Boadi AO, Akenten CW, Thye T et al.. “Characterization of secondary bacterial infections in Buruli ulcer disease in Ghana: a focus on antimicrobial resistant Staphylococcus aureus.” BMC infectious diseases (2026). PMID: 42420877 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [445]
Fonfara M, Stölzl D, Hartmann J et al.. “Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry.” The Journal of investigative dermatology (2026). PMID: 42413573 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [446]
Luan T, Zhang Y, Zhu W et al.. “Crosslinker-free PVA hydrogel incorporating a water-soluble Ir(III) photosensitizer for antibacterial photodynamic applications in wound healing.” Journal of materials chemistry. B (2026). PMID: 42412212 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [447]
Ayhan YE, Sarı Küçük R, Özkan AN et al.. “Guideline-informed vancomycin therapeutic drug monitoring indications in an adult intensive care unit: a retrospective descriptive study.” BMC anesthesiology (2026). PMID: 42410537 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [448]
Moghaddam AM, Ahmadishoar S, Aval SF. “Synthesis of zinc oxide nanoparticles and their effect on biofilm of methicillin-resistant Staphylococcus aureus isolates.” BMC microbiology (2026). PMID: 42410350 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [449]
Daneman N, Sarwar S, Fowler RA et al.. “Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2013). PMID: 23352693 ↗
L1SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [450]
Ong SWX, Pinto R, Mahar RK et al.. “Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial.” The Lancet. Infectious diseases (2025). PMID: 41237792 ↗
L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [451]
Freling S, Wald-Dickler N, Banerjee J et al.. “Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36881940 ↗
L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History - [452]
Talan DA, Mower WR, Krishnadasan A et al.. “Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess.” The New England journal of medicine (2016). PMID: 26962903 ↗
L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [453]
Paul M, Kariv G, Goldberg E et al.. “Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2010). PMID: 20947620 ↗
L3SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [454]
Ji X-w, Mak WY, Xue F et al.. “Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD.” Antimicrobial agents and chemotherapy (2025). PMID: 39878492 ↗
L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [455]
Schwameis R, Syré S, Marhofer D et al.. “Pharmacokinetics of Cefuroxime in Synovial Fluid.” Antimicrobial agents and chemotherapy (2017). PMID: 28784675 ↗
L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [456]
Butler-Laporte G, Cheng MP, Thirion DJG et al.. “Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis.” Open forum infectious diseases (2020). PMID: 33209948 ↗
L2TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [457]
Bitterman R, Awwad A, Darawsha B et al.. “Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 39871614 ↗
L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [458]
Taher AQM, Aqel R, Alnajjar M et al.. “Posttraumatic Pseudomonas aeruginosa Osteomyelitis in Mosul and Gaza: A Retrospective Cohort Study, 2018-2022.” Open forum infectious diseases (2024). PMID: 39411226 ↗
L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [459]
Sati H, Carrara E, Savoldi A et al.. “The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.” The Lancet. Infectious diseases (2025). PMID: 40245910 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [460]
Tacconelli E, Carrara E, Savoldi A et al.. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.” The Lancet. Infectious diseases (2017). PMID: 29276051 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [461]
Simor AE. “Staphylococcal decolonisation: an effective strategy for prevention of infection?” The Lancet. Infectious diseases (2011). PMID: 22115070 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [462]
Oehler RL, Velez AP, Mizrachi M et al.. “Bite-related and septic syndromes caused by cats and dogs.” The Lancet. Infectious diseases (2009). PMID: 19555903 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [463]
Magnan C, Plumet L, Morsli M et al.. “A narrative review of coagulase-negative staphylococci in diabetic foot infections.” Clinical microbiology reviews (2025). PMID: 41186420 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [464]
Haddad Kashani H, Schmelcher M, Sabzalipoor H et al.. “Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.” Clinical microbiology reviews (2017). PMID: 29187396 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [465]
Beenken KE, Campbell MJ, Reyes-Pardo H et al.. “Mechanistic insights into the pathogenesis and therapeutic recalcitrance of Staphylococcus aureus osteomyelitis.” Clinical microbiology reviews (2026). PMID: 41989162 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [466]
Howden BP, Davies JK, Johnson PD et al.. “Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.” Clinical microbiology reviews (2010). PMID: 20065327 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [467]
Álvarez R, López Cortés LE, Molina J et al.. “Optimizing the Clinical Use of Vancomycin.” Antimicrobial agents and chemotherapy (2016). PMID: 26856841 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [468]
Haynes AS, Wei Z, Anderson P et al.. “Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.” Antimicrobial agents and chemotherapy (2024). PMID: 38597672 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [469]
Gonzalez D, Delmore P, Bloom BT et al.. “Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrobial agents and chemotherapy (2016). PMID: 26926644 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [470]
McNeil JC, Sommer LM, Boyle M et al.. “Cefazolin Inoculum Effect and Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2020). PMID: 32660989 ↗
L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History, Special Hosts and Populations - [471]
Canouï E, Kerneis S, Morand P et al.. “Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections.” The Journal of antimicrobial chemotherapy (2022). PMID: 35178577 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [472]
Rampacci E, Felicetti T, Pietrella D et al.. “Drug efflux transporters in Staphylococcus pseudintermedius: in silico prediction and characterization of resistance.” The Journal of antimicrobial chemotherapy (2022). PMID: 36173389 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [473]
Taupin D, Karchmer AW, Davis RB et al.. “Uncomplicated Staphylococcus aureus Bacteremia Treatment Duration and Outcomes at an Academic Medical Center.” Open forum infectious diseases (2020). PMID: 33134421 ↗
L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [474]
Walker B, Heidel E, Shorman M. “Clinical Characteristics and Outcome of Staphylococcus aureus Prostate Abscess, Ten-Year Experience at a Tertiary Care Center.” Open forum infectious diseases (2019). PMID: 31430373 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [475]
Okada N, Niimura T, Saisyo A et al.. “Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System.” Open forum infectious diseases (2023). PMID: 37601729 ↗
L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [476]
Sawada K, Inose R, Goto R et al.. “Effectiveness of Noncertified Pharmacist-Led Antimicrobial Stewardship Programs in a Medium-Sized Hospital Without an Infectious Disease Specialist: A Retrospective Pre-Post Study.” Open forum infectious diseases (2023). PMID: 36949877 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [477]
Fabre V, Cosgrove SE, Lessa FC et al.. “Antibiotic Use in Medical-Surgical Intensive Care Units and General Wards in Latin American Hospitals.” Open forum infectious diseases (2024). PMID: 39494448 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [478]
Novak AR, Krsak M, Kiser TH et al.. “Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients.” Open forum infectious diseases (2021). PMID: 35111872 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [479]
Greenfield A, Marsh K, Siegfried J et al.. “Impact of Streptococcus pneumoniae Urinary Antigen Testing in Patients With Community-Acquired Pneumonia Admitted Within a Large Academic Health System.” Open forum infectious diseases (2021). PMID: 34993258 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [480]
Nichols CN, Wardlow LC, Coe KE et al.. “Clinical Outcomes With Definitive Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia With Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy With Vancomycin, Daptomycin, or Ceftaroline.” Open forum infectious diseases (2021). PMID: 34337094 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [481]
Abbara S, Guillemot D, Smith DRM et al.. “Antimicrobial Resistance as Risk Factor for Recurrent Bacteremia after Staphylococcus aureus, Escherichia coli, or Klebsiella spp. Community-Onset Bacteremia.” Emerging infectious diseases (2024). PMID: 38666612 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [482]
McCaig LF, McDonald LC, Mandal S et al.. “Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care.” Emerging infectious diseases (2006). PMID: 17283622 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [483]
Legg A, Boast A, Piera K et al.. “Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.” British journal of clinical pharmacology (2026). PMID: 42414075 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [484]
Barahim EK, Smith EP, Yong ST et al.. “Evaluation of Antimicrobial Peptide-Antibiotic Combination Treatment for Tackling Ocular and Systemic Staphylococcus aureus Infections.” International journal of molecular sciences (2026). PMID: 42353286 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [485]
Lamilla C, Rubilar O, San Martin I et al.. “Biotechnological Potential of Rhizospheric Bacillus Strains from Lonquimay, Chile, as Producers of Antimicrobial Biosurfactants.” International journal of molecular sciences (2026). PMID: 42353120 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [486]
Bușilă M, Tăbăcaru A, Botezatu AV et al.. “Tuning Anticancer Activity and Antimicrobial Response of ZnO Nanoparticles Through Halogenosilane Surface Modification.” International journal of molecular sciences (2026). PMID: 42353108 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [487]
Cottet C, Kikot PA, Nobile ML et al.. “Active Chitosan Films Enriched with Yerba Mate Kombucha Infusion: Formulation and Characterization.” International journal of molecular sciences (2026). PMID: 42353065 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [488]
da Silva MEB, Kamio ABS, da Silva MGR et al.. “Antimicrobial efficacy of hypochlorite-based gels for disinfecting heat-polymerized and 3D printed denture bases.” The Journal of prosthetic dentistry (2026). PMID: 42348746 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [489]
Kayani A, Raza A, Zhou Q et al.. “Orchestrating Diabetic Wound Healing by a Sunlight-Activated AIEgen-Selenide Nanospray: From Infection Control to Tissue Regeneration.” ACS applied materials & interfaces (2026). PMID: 42347974 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [490]
Gupta N, Bhattacharya S, Lela L et al.. “Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistant Staphylococcus aureus.” Frontiers in pharmacology (2026). PMID: 42344795 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [491]
Li K, Wang K, Zhang G et al.. “An Acceptor-Donor-Acceptor Semiconductor Conjugated Polymer-Based Composite Hydrogel for Photothermal/Photodynamic Dual Phototherapy of Infected Wounds.” ACS applied materials & interfaces (2026). PMID: 42333676 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [492]
Zervou FN, Zacharioudakis IM, Ziakas PD et al.. “Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25031291 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations - [493]
Pujol M, Miró JM, Shaw E et al.. “Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32725216 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [494]
Fowler VG, Das AF, Lipka-Diamond J et al.. “Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38297916 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History - [495]
Mitchell BG, Hall L, White N et al.. “An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.” The Lancet. Infectious diseases (2019). PMID: 30858014 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control - [496]
Ibrahim LF, Hopper SM, Orsini F et al.. “Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 30853250 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations - [497]
Johnson DW, Badve SV, Pascoe EM et al.. “Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.” The Lancet. Infectious diseases (2013). PMID: 24119840 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prevention and Infection Control, Special Hosts and Populations - [498]
Huang SS, Septimus E, Hayden MK et al.. “Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial.” The Lancet. Infectious diseases (2015). PMID: 26631833 ↗
L1RCTCited in: History and Evolution of Treatment, Prevention and Infection Control - [499]
Daum RS, Miller LG, Immergluck L et al.. “A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.” The New England journal of medicine (2017). PMID: 28657870 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations - [500]
Perl TM, Cullen JJ, Wenzel RP et al.. “Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.” The New England journal of medicine (2002). PMID: 12063371 ↗
L1RCTCited in: History and Evolution of Treatment - [501]
Yu VL, Goetz A, Wagener M et al.. “Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.” The New England journal of medicine (1986). PMID: 3523240 ↗
L2RCTCited in: History and Evolution of Treatment - [502]
Rodvold KA, McConeghy KW. “Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24343828 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [503]
de Jonge E, Schultz MJ, Spanjaard L et al.. “Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial.” Lancet (London, England) (2003). PMID: 14522530 ↗
L1RCTCited in: History and Evolution of Treatment - [504]
Lipsky BA, Armstrong DG, Citron DM et al.. “Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.” Lancet (London, England) (2005). PMID: 16291062 ↗
L1RCTCited in: History and Evolution of Treatment - [505]
Keighley MR, Arabi Y, Alexander-Williams J et al.. “Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery.” Lancet (London, England) (1979). PMID: 86666 ↗
L1RCTCited in: History and Evolution of Treatment - [506]
Smack DP, Harrington AC, Dunn C et al.. “Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial.” JAMA (1996). PMID: 8805732 ↗
L1RCTCited in: History and Evolution of Treatment - [507]
Pugin J, Auckenthaler R, Lew DP et al.. “Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial.” JAMA (Unknown). PMID: 2023353 ↗
L1RCTCited in: History and Evolution of Treatment - [508]
Fowler VG, Allen KB, Moreira ED et al.. “Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.” JAMA (2013). PMID: 23549582 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prevention and Infection Control - [509]
Harris AD, Pineles L, Belton B et al.. “Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial.” JAMA (2013). PMID: 24097234 ↗
L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prevention and Infection Control - [510]
Segers P, Speekenbrink RG, Ubbink DT et al.. “Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial.” JAMA (2006). PMID: 17119142 ↗
L1RCTCited in: History and Evolution of Treatment - [511]
Moran GJ, Krishnadasan A, Mower WR et al.. “Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.” JAMA (2017). PMID: 28535235 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [512]
Oliveira DC, Tomasz A, de Lencastre H. “Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus.” The Lancet. Infectious diseases (2002). PMID: 11944188 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [513]
Cetinkaya Y, Falk P, Mayhall CG. “Vancomycin-resistant enterococci.” Clinical microbiology reviews (2000). PMID: 11023964 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [514]
Shirtliff ME, Mader JT. “Acute septic arthritis.” Clinical microbiology reviews (2002). PMID: 12364368 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [515]
Skurray RA, Rouch DA, Lyon BR et al.. “Multiresistant Staphylococcus aureus: genetics and evolution of epidemic Australian strains.” The Journal of antimicrobial chemotherapy (1988). PMID: 2838448 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [516]
Griffith RS. “Vancomycin use--an historical review.” The Journal of antimicrobial chemotherapy (1984). PMID: 6394574 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [517]
Donnelly JP. “Bacterial complications of transplantation: diagnosis and treatment.” The Journal of antimicrobial chemotherapy (1995). PMID: 8601544 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [518]
. “Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” The Lancet. Infectious diseases (2024). PMID: 38640940 ↗
L2OTHERCited in: History and Evolution of Treatment, Special Hosts and Populations - [519]
Gamell A, Velasco-Arnaiz E, López-Ramos MG et al.. “Off-label use of dalbavancin in children: a case series.” The Journal of antimicrobial chemotherapy (2024). PMID: 38958260 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations - [520]
Belew H, Tegegne BA, Kindie Y et al.. “Bacterial neonatal sepsis, antimicrobial resistance, and risk factors among neonates in Ethiopia: a systematic review and meta-analysis.” Therapeutic advances in infectious disease (2026). PMID: 42222265 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [521]
Gomes AR, Westh H, de Lencastre H. “Origins and evolution of methicillin-resistant Staphylococcus aureus clonal lineages.” Antimicrobial agents and chemotherapy (2006). PMID: 17005800 ↗
L5OTHERCited in: History and Evolution of Treatment - [522]
Liu X, Wang Y, Chang W et al.. “AgrA directly binds to the promoter of vraSR and downregulates its expression in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2024). PMID: 38259090 ↗
L5OTHERCited in: History and Evolution of Treatment - [523]
Campion JJ, McNamara PJ, Evans ME. “Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.” Antimicrobial agents and chemotherapy (2004). PMID: 15561851 ↗
L5OTHERCited in: History and Evolution of Treatment - [524]
Chen F, Yin Y, Chen H et al.. “Global genetic diversity and Asian clades evolution: a phylogeographic study of Staphylococcus aureus sequence type 5.” Antimicrobial agents and chemotherapy (2024). PMID: 38259089 ↗
L5OTHERCited in: History and Evolution of Treatment - [525]
Rolo J, Worning P, Nielsen JB et al.. “Evolutionary Origin of the Staphylococcal Cassette Chromosome mec (SCCmec).” Antimicrobial agents and chemotherapy (2017). PMID: 28373201 ↗
L5OTHERCited in: History and Evolution of Treatment - [526]
Giulieri SG. “Case Commentary: The hidden side of oxacillin resistance in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2023). PMID: 37655923 ↗
L5OTHERCited in: History and Evolution of Treatment - [527]
Chen Y, Moran JC, Campbell-Lee S et al.. “Transcriptomic Responses and Survival Mechanisms of Staphylococci to the Antimicrobial Skin Lipid Sphingosine.” Antimicrobial agents and chemotherapy (2021). PMID: 34902269 ↗
L5OTHERCited in: History and Evolution of Treatment - [528]
Petersen ME, Khamas AB, Østergaard LJ et al.. “Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40084881 ↗
L5OTHERCited in: History and Evolution of Treatment - [529]
León-Sampedro R, Novais C, Peixe L et al.. “Diversity and Evolution of the Tn5801-tet(M)-Like Integrative and Conjugative Elements among Enterococcus, Streptococcus, and Staphylococcus.” Antimicrobial agents and chemotherapy (2016). PMID: 26729505 ↗
L5OTHERCited in: History and Evolution of Treatment - [530]
Strommenger B, Bartels MD, Kurt K et al.. “Evolution of methicillin-resistant Staphylococcus aureus towards increasing resistance.” The Journal of antimicrobial chemotherapy (2013). PMID: 24150844 ↗
L5OTHERCited in: History and Evolution of Treatment - [531]
Jiang N, Wyres KL, Li J et al.. “Evolution and genomic insight into methicillin-resistant Staphylococcus aureus ST9 in China.” The Journal of antimicrobial chemotherapy (2021). PMID: 33822977 ↗
L5OTHERCited in: History and Evolution of Treatment - [532]
Duval J. “Evolution and epidemiology of MLS resistance.” The Journal of antimicrobial chemotherapy (1985). PMID: 3932300 ↗
L5OTHERCited in: History and Evolution of Treatment - [533]
Liu P, Hao Z, Liu M et al.. “Genetic mutations in adaptive evolution of growth-independent vancomycin-tolerant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2021). PMID: 34302174 ↗
L5OTHERCited in: History and Evolution of Treatment - [534]
Olsen JE, Christensen H, Aarestrup FM. “Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci.” The Journal of antimicrobial chemotherapy (2006). PMID: 16449305 ↗
L5OTHERCited in: History and Evolution of Treatment - [535]
Nuevo JJM, Fortaleza JAG, Cabuhat KSP et al.. “CRISPR-driven strategies to disrupt methicillin-resistant Staphylococcus aureus biofilms: a review.” Frontiers in cellular and infection microbiology (2026). PMID: 42211656 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [536]
Matsuo T, Hayashi K, Uehara Y et al.. “The STAPH Score: A Predictor of Staphylococcus aureus as the Causative Microorganism of Native Vertebral Osteomyelitis.” Open forum infectious diseases (2020). PMID: 33447627 ↗
L3OTHERCited in: History and Evolution of Treatment - [537]
Peterson LR, Samia NI, Skinner AM et al.. “Antimicrobial Stewardship Lessons From Mupirocin Use and Resistance in Methicillin-Resitant Staphylococcus Aureus.” Open forum infectious diseases (2017). PMID: 28702468 ↗
L2OTHERCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [538]
Lee YW, Bae S, Yang E et al.. “Clinical and Microbiological Characteristics of Hospital-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia Caused by a Community-Associated PVL-Negative Strain.” Open forum infectious diseases (2021). PMID: 34676275 ↗
L2OTHERCited in: History and Evolution of Treatment - [539]
Theodore DA, Goodwin RD, Zhang YV et al.. “History of Depression and Increased Risk of Sternal Wound Infection After Cardiothoracic Surgery: A Novel and Potentially Modifiable Risk Factor.” Open forum infectious diseases (2019). PMID: 30949529 ↗
L3OTHERCited in: History and Evolution of Treatment - [540]
Henig O, Pogue JM, Cha R et al.. “Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy.” Open forum infectious diseases (2018). PMID: 30402532 ↗
L2OTHERCited in: History and Evolution of Treatment - [541]
Turabelidze G, Lin M, Wolkoff B et al.. “Personal hygiene and methicillin-resistant Staphylococcus aureus infection.” Emerging infectious diseases (2006). PMID: 16704779 ↗
L3OTHERCited in: History and Evolution of Treatment - [542]
Odutola A, Bottomley C, Zaman SA et al.. “Staphylococcus aureus Bacteremia in Children of Rural Areas of The Gambia, 2008-2015.” Emerging infectious diseases (2019). PMID: 30882307 ↗
L2OTHERCited in: History and Evolution of Treatment - [543]
Buck JM, Como-Sabetti K, Harriman KH et al.. “Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003.” Emerging infectious diseases (2005). PMID: 16318692 ↗
L3OTHERCited in: History and Evolution of Treatment - [544]
Brodíková K, Destanque T, Haenni M et al.. “Clonal Complex 398 Methicillin-Resistant Staphylococcus aureus Producing Panton-Valentine Leukocidin, Czech Republic, 2023.” Emerging infectious diseases (2025). PMID: 39714442 ↗
L4OTHERCited in: History and Evolution of Treatment - [545]
Li M, Wang Y, Zhu Y et al.. “Increased Community-Associated Infections Caused by Panton-Valentine Leukocidin-Negative MRSA, Shanghai, 2005-2014.” Emerging infectious diseases (2016). PMID: 27767912 ↗
L4OTHERCited in: History and Evolution of Treatment - [546]
Peters PJ, Brooks JT, McAllister SK et al.. “Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults.” Emerging infectious diseases (2013). PMID: 23631854 ↗
L2OTHERCited in: History and Evolution of Treatment - [547]
Moran GJ, Amii RN, Abrahamian FM et al.. “Methicillin-resistant Staphylococcus aureus in community-acquired skin infections.” Emerging infectious diseases (2005). PMID: 15963289 ↗
L4OTHERCited in: History and Evolution of Treatment - [548]
Wuerth BA, Bonnewell JP, Wiemken TL et al.. “Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002-2011(1).” Emerging infectious diseases (2016). PMID: 27532154 ↗
L2OTHERCited in: History and Evolution of Treatment, Prognosis and Natural History - [549]
Lewis HC, Mølbak K, Reese C et al.. “Pigs as source of methicillin-resistant Staphylococcus aureus CC398 infections in humans, Denmark.” Emerging infectious diseases (2008). PMID: 18760004 ↗
L3OTHERCited in: History and Evolution of Treatment - [550]
Lee JH, Cho MC. “Impact of bacteriospermia on sperm DNA fragmentation: a narrative review.” Translational andrology and urology (2026). PMID: 42293827 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [551]
Ansari I, Sindgi RP, Srivastava AK et al.. “Advances in Quorum-Sensing Inhibitors as Novel Therapeutic Targets.” Microbial pathogenesis (2026). PMID: 42285423 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [552]
Ilyas MH, Adio A, Gonzalez-Morgado D et al.. “Social Determinants of Health Are Associated With Increased Risk of Preoperative Methicillin-Resistant Staphylococcus aureus Colonization in Patients Undergoing Total Joint Arthroplasty.” Arthroplasty today (2026). PMID: 42434293 ↗
L2OTHERCited in: History and Evolution of Treatment - [553]
Nathan H, Hiironen I, Harrington P et al.. “Distribution of putative SSI risk factors in adults undergoing open reduction and fixation of long bone fracture.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026). PMID: 42406128 ↗
L2OTHERCited in: History and Evolution of Treatment - [554]
Alexander AM, Loo HQ, Askew L et al.. “Intraspecific diversity of Staphylococcus aureus populations isolated from cystic fibrosis respiratory infections.” Microbiology spectrum (2026). PMID: 42405791 ↗
L4OTHERCited in: History and Evolution of Treatment - [555]
Liu W, Guo W, Xiao D et al.. “Phthalazine-based quaternary ammonium salts: synthesis, biological evaluation and membrane-targeting mechanism against Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42404800 ↗
L5OTHERCited in: History and Evolution of Treatment - [556]
Krämer CL, Arndt F, Boschert AL et al.. “Bacterial resistance across habitats: from German schools to the International Space Station.” Frontiers in microbiology (2026). PMID: 42395912 ↗
L5OTHERCited in: History and Evolution of Treatment - [557]
Hermsen ED, Amos J, Townsend A et al.. “Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis.” The Lancet. Infectious diseases (2024). PMID: 39527961 ↗
L2SR_OBSCited in: Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [558]
Stryjewski ME, Corey GR. “Methicillin-resistant Staphylococcus aureus: an evolving pathogen.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24343827 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [559]
Saravolatz LD, Stein GE. “Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30060092 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [560]
Mody L, Bradley SF, Galecki A et al.. “Conceptual model for reducing infections and antimicrobial resistance in skilled nursing facilities: focusing on residents with indwelling devices.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21292670 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [561]
Miyakis S, Pefanis A, Tsakris A. “The challenges of antimicrobial drug resistance in Greece.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21690626 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [562]
Rossi F. “The challenges of antimicrobial resistance in Brazil.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21467020 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [563]
Moghnieh RA, Kanafani ZA, Tabaja HZ et al.. “Epidemiology of common resistant bacterial pathogens in the countries of the Arab League.” The Lancet. Infectious diseases (2018). PMID: 30292478 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [564]
Petit H, de Tymowski C, Dudoignon E et al.. “Epidemiology and Outcomes of Bloodstream Infections in Patients in a Burns Intensive Care Unit: An 8-Year Retrospective Study.” Open forum infectious diseases (2025). PMID: 40182133 ↗
L2COHORTCited in: Antimicrobial Resistance and Stewardship - [565]
Périchon B, Courvalin P. “VanA-type vancomycin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2009). PMID: 19506057 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [566]
File TM, Ramirez JA, Wilde AM. “New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).” Antimicrobial agents and chemotherapy (2025). PMID: 39817764 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [567]
Reynolds R. “Antimicrobial resistance in the UK and Ireland.” The Journal of antimicrobial chemotherapy (2009). PMID: 19675014 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [568]
Livermore DM. “Has the era of untreatable infections arrived?” The Journal of antimicrobial chemotherapy (2009). PMID: 19675016 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [569]
Bisgaard H, Hermansen MN, Buchvald F et al.. “Childhood asthma after bacterial colonization of the airway in neonates.” The New England journal of medicine (2007). PMID: 17928596 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [570]
. “Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” Lancet (London, England) (2022). PMID: 36423648 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [571]
Mohamad M, Hurst MM, Elkrewi E et al.. “Nature of bacitracin resistance in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 41186227 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [572]
Woosley LN, Castanheira M, Jones RN. “CEM-101 activity against Gram-positive organisms.” Antimicrobial agents and chemotherapy (2010). PMID: 20176910 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [573]
Chatterjee SS, Chen L, Gilbert A et al.. “PBP4 Mediates β-Lactam Resistance by Altered Function.” Antimicrobial agents and chemotherapy (2017). PMID: 28807923 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [574]
Cazer CL, Westblade LF, Simon MS et al.. “Analysis of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated Antibiogram.” Antimicrobial agents and chemotherapy (2021). PMID: 33431415 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [575]
Petersiel N, Howden BP, Giulieri S et al.. “An Achilles' heel for methicillin-resistant Staphylococcus aureus? Re-evaluating β-lactam susceptibility of MRSA.” Antimicrobial agents and chemotherapy (2026). PMID: 42405967 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [576]
Virgillio AM, Felton EA, Jackson JK et al.. “Genomic and Phenotypic Characterization of Mupirocin-resistant Staphylococcus aureus Clinical Isolates.” Open forum infectious diseases (2025). PMID: 40698033 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [577]
Tenover FC, Goff DA. “Surveillance and Stewardship: Where Infection Prevention and Antimicrobial Stewardship Intersect.” Open forum infectious diseases (2023). PMID: 37089778 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [578]
Timbrook TT, Olin KE, Spaulding U et al.. “Epidemiology of Antimicrobial Resistance Among Blood and Respiratory Specimens in the United States Using Genotypic Analysis From a Cloud-Based Population Surveillance Network.” Open forum infectious diseases (2022). PMID: 35873295 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [579]
Diekema DJ, Pfaller MA, Shortridge D et al.. “Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program.” Open forum infectious diseases (2019). PMID: 30895214 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [580]
Wozniak TM, Dyda A, Lee X. “The Increased Length of Hospital Stay and Mortality Associated With Community-Associated Infections in Australia.” Open forum infectious diseases (2022). PMID: 35493114 ↗
L3OTHERCited in: Antimicrobial Resistance and Stewardship - [581]
Becker K, van Alen S, Idelevich EA et al.. “Plasmid-Encoded Transferable mecB-Mediated Methicillin Resistance in Staphylococcus aureus.” Emerging infectious diseases (2018). PMID: 29350135 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [582]
Hsu LY, Tan TY, Jureen R et al.. “Antimicrobial drug resistance in Singapore hospitals.” Emerging infectious diseases (2007). PMID: 18258055 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [583]
Gooskens J, Konstantinovski MM, Kraakman MEM et al.. “Panton-Valentine Leukocidin-Positive CC398 MRSA in Urban Clinical Settings, the Netherlands.” Emerging infectious diseases (2023). PMID: 36913919 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [584]
Sharma T, Chandley P. “Host-pathogen interactions during ESKAPE-mediated urinary tract infections and ventilator-associated pneumonia: a review.” Folia microbiologica (2026). PMID: 42423835 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [585]
Kiani M, Mehboodi M, Khanbabaie H et al.. “Lactobacillus strains in the prevention and disruption of antimicrobial-resistance in pathogenic microbial biofilms: a review of mechanisms and clinical perspective.” Folia microbiologica (2026). PMID: 42412160 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [586]
Antoniolli A, Ruge T, Biron A et al.. “Emergence of antimicrobial resistance in New Caledonia: 20-year trends from laboratory-based surveillance (2005-2024).” The Lancet regional health. Western Pacific (2026). PMID: 42434433 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [587]
Piper KR, Buiatte ABG, Souza SSR et al.. “Plasmids of co-circulating Staphylococcus aureus serve as vehicles for antimicrobial resistance sharing across diseased host-species at short timescales.” BMC microbiology (2026). PMID: 42426609 ↗
L3OTHERCited in: Antimicrobial Resistance and Stewardship - [588]
Abrahamian FM, Sakoulas G, Tzanis E et al.. “Omadacycline for Acute Bacterial Skin and Skin Structure Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367742 ↗
L1RCTCited in: Complications - [589]
Corey GR. “Staphylococcus aureus bloodstream infections: definitions and treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374581 ↗
L5CASE_REPORTCited in: Complications - [590]
Boucher HW, Wilcox M, Talbot GH et al.. “Once-weekly dalbavancin versus daily conventional therapy for skin infection.” The New England journal of medicine (2014). PMID: 24897082 ↗
L1RCTCited in: Complications - [591]
Eljaaly K, Alshehri S, Erstad BL. “Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.” Antimicrobial agents and chemotherapy (2018). PMID: 29437617 ↗
L1SR_OBSCited in: Complications - [592]
Karanika S, Paudel S, Grigoras C et al.. “Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs.” Antimicrobial agents and chemotherapy (2016). PMID: 27246783 ↗
L1SR_OBSCited in: Complications - [593]
Kidd JM, Sakon CM, Oleksiuk LM et al.. “Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.” Antimicrobial agents and chemotherapy (2019). PMID: 31685468 ↗
L4TRIAL_NONRANDOMCited in: Complications - [594]
Holland TL, Shorr AF, Overcash JS et al.. “Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.” The Journal of antimicrobial chemotherapy (2025). PMID: 40155066 ↗
L2TRIAL_NONRANDOMCited in: Complications - [595]
Arbona-Lampaya A, Pérez-Ojeda RA, Santos-Marrero M et al.. “Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer.” The Lancet. Infectious diseases (2025). PMID: 41429139 ↗
L4CASE_REPORTCited in: Complications - [596]
Beaumont AL, Mestre F, Decaux S et al.. “Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.” Open forum infectious diseases (2024). PMID: 38737431 ↗
L4TRIAL_NONRANDOMCited in: Complications, Prognosis and Natural History - [597]
Weber MA, Klein NJ, Hartley JC et al.. “Infection and sudden unexpected death in infancy: a systematic retrospective case review.” Lancet (London, England) (2008). PMID: 18514728 ↗
L4REVIEW_NARRATIVECited in: Complications - [598]
Kristiansen JE, Hendricks O, Delvin T et al.. “Reversal of resistance in microorganisms by help of non-antibiotics.” The Journal of antimicrobial chemotherapy (2007). PMID: 17403708 ↗
L5REVIEW_NARRATIVECited in: Complications - [599]
Principi N, Caironi M, Venturini F et al.. “Daptomycin in paediatrics: current knowledge and the need for future research.” The Journal of antimicrobial chemotherapy (2014). PMID: 25406298 ↗
L5REVIEW_NARRATIVECited in: Complications, Special Hosts and Populations - [600]
Parkins MD, Elborn JS. “Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.” The Journal of antimicrobial chemotherapy (2010). PMID: 20605846 ↗
L5REVIEW_NARRATIVECited in: Complications - [601]
Akita S, Okamura T, Tanigawa K. “Clinical Efficacy and Broad-Spectrum Antimicrobial Activity of pH-Controlled Sodium Hypochlorite Solution (HACCP'ER) in Acute and Chronic Wound Management: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42278958 ↗
L4COHORTCited in: Complications - [602]
Kiefer T, Park L, Tribouilloy C et al.. “Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure.” JAMA (2011). PMID: 22110106 ↗
L2OTHERCited in: Complications - [603]
Renzoni A, Von Dach E, Landelle C et al.. “Impact of Exposure of Methicillin-Resistant Staphylococcus aureus to Polyhexanide In Vitro and In Vivo.” Antimicrobial agents and chemotherapy (2017). PMID: 28784678 ↗
L5OTHERCited in: Complications - [604]
Ortines RV, Liu H, Cheng LI et al.. “Neutralizing Alpha-Toxin Accelerates Healing of Staphylococcus aureus-Infected Wounds in Nondiabetic and Diabetic Mice.” Antimicrobial agents and chemotherapy (2018). PMID: 29311091 ↗
L5OTHERCited in: Complications - [605]
Kwon DH, Lu CD. “Polyamine effects on antibiotic susceptibility in bacteria.” Antimicrobial agents and chemotherapy (2007). PMID: 17438056 ↗
L5OTHERCited in: Complications - [606]
Wasielewski AS, Casapao AM, Jankowski CA et al.. “Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.” Antimicrobial agents and chemotherapy (2024). PMID: 39324801 ↗
L2OTHERCited in: Complications - [607]
Couderc C, Thiébaut AC, Lawrence C et al.. “Fluoroquinolone Impact on Nasal Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Colonization Durations in Neurologic Long-Term-Care Facilities.” Antimicrobial agents and chemotherapy (2015). PMID: 26416866 ↗
L2OTHERCited in: Complications - [608]
Barlow GD. “Swine flu and antibiotics.” The Journal of antimicrobial chemotherapy (2009). PMID: 19740909 ↗
L5OTHERCited in: Complications - [609]
Shah S, Clarke LG, Balasubramani GK et al.. “Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40448546 ↗
L2OTHERCited in: Complications - [610]
Das S, Li J, Iaconis J et al.. “Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2019). PMID: 30380060 ↗
L2OTHERCited in: Complications, Special Hosts and Populations - [611]
Eustace MB, Braddick M, Alcorn K et al.. “Central Skull Base Osteomyelitis in Queensland, Australia, 2010-2020.” Open forum infectious diseases (2024). PMID: 39450399 ↗
L4OTHERCited in: Complications, Prognosis and Natural History - [612]
Roberts K, Dewar S, Sutherland RK et al.. “Respiratory Virus Coinfection Is a Risk Factor for Adverse Outcomes During Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2026). PMID: 41859699 ↗
L2OTHERCited in: Complications - [613]
Hiskey L, Saifuddin H, Levy ER et al.. “First-Generation Cephalosporins for Treatment of Acute Hematogenous Osteomyelitis in Children: A Study of Efficacy and Adverse Effects.” Open forum infectious diseases (2023). PMID: 38156049 ↗
L2OTHERCited in: Complications, Special Hosts and Populations - [614]
Richter SE, Miller L, Needleman J et al.. “Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods.” Open forum infectious diseases (2019). PMID: 30863785 ↗
L3OTHERCited in: Complications - [615]
Pettigrew MM, Gent JF, Revai K et al.. “Microbial interactions during upper respiratory tract infections.” Emerging infectious diseases (2008). PMID: 18826823 ↗
L2OTHERCited in: Complications, Prevention and Infection Control, Special Hosts and Populations - [616]
McDanel JS, Perencevich EN, Storm J et al.. “Increased Mortality Rates Associated with Staphylococcus aureus and Influenza Co-infection, Maryland and Iowa, USA(1).” Emerging infectious diseases (2016). PMID: 27315549 ↗
L2OTHERCited in: Complications, Prognosis and Natural History - [617]
Saxena S, Thompson P, Birger R et al.. “Increasing skin infections and Staphylococcus aureus complications in children, England, 1997-2006.” Emerging infectious diseases (2010). PMID: 20202439 ↗
L2OTHERCited in: Complications - [618]
Magill SS, Dumyati G, Ray SM et al.. “Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United States.” Emerging infectious diseases (2015). PMID: 26291035 ↗
L5OTHERCited in: Complications, Prevention and Infection Control - [619]
Kreisel KM, Johnson JK, Stine OC et al.. “Illicit drug use and risk for USA300 methicillin-resistant Staphylococcus aureus infections with bacteremia.” Emerging infectious diseases (2010). PMID: 20735927 ↗
L2OTHERCited in: Complications - [620]
Liang H, Mao ZF, Huang JY et al.. “Case Report: Moxibustion-induced burns leading to disseminated methicillin-resistant Staphylococcus aureus infection in a patient with type 2 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42272806 ↗
L4CASE_REPORTCited in: Complications - [621]
Carey GB, Holleck JL, Ein Alshaeba S et al.. “Estimated mortality with early empirical antibiotic coverage of methicillin-resistant Staphylococcus aureus in hospitalized patients with bacterial infections: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36964648 ↗
L1SR_OBSCited in: Prognosis and Natural History - [622]
Tacconelli E, De Angelis G, Cataldo MA et al.. “Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2007). PMID: 17986491 ↗
L1SR_OBSCited in: Prognosis and Natural History - [623]
Paulsen J, Solligård E, Damås JK et al.. “The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review.” Open forum infectious diseases (2016). PMID: 27047985 ↗
L2SR_OBSCited in: Prognosis and Natural History - [624]
Dancer SJ. “Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.” Clinical microbiology reviews (2014). PMID: 25278571 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Prevention and Infection Control - [625]
Kondo Y, Klompas M, McKenna CS et al.. “Association Between the Sequence of β-Lactam and Vancomycin Administration and Mortality in Patients With Suspected Sepsis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39657016 ↗
L2OTHERCited in: Prognosis and Natural History - [626]
Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗
L2OTHERCited in: Prognosis and Natural History - [627]
Gibert C, Marchetti C, Guery B et al.. “Outcome Predictors of Candida Prosthetic Joint Infections: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2025). PMID: 40463834 ↗
L2SR_OBSCited in: Prognosis and Natural History - [628]
Østergaard L, Voldstedlund M, Bruun NE et al.. “Prevalence and Mortality of Infective Endocarditis in Community-Acquired and Healthcare-Associated Staphylococcus aureus Bacteremia: A Danish Nationwide Registry-Based Cohort Study.” Open forum infectious diseases (2022). PMID: 36540385 ↗
L2COHORTCited in: Prognosis and Natural History - [629]
Plumet L, Costechareyre D, Lavigne J-P et al.. “Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.” Antimicrobial agents and chemotherapy (2024). PMID: 39248472 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [630]
Marro FC, Abad L, Blocker AJ et al.. “In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature.” The Journal of antimicrobial chemotherapy (2021). PMID: 34459881 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [631]
Kuehl R, Morata L, Meylan S et al.. “When antibiotics fail: a clinical and microbiological perspective on antibiotic tolerance and persistence of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2020). PMID: 32016348 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [632]
Seaton RA. “Daptomycin: rationale and role in the management of skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829721 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [633]
Dancer SJ. “The effect of antibiotics on methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2007). PMID: 18057071 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [634]
Ong SWX, Patrikar A, Pinto R et al.. “Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial.” Open forum infectious diseases (2026). PMID: 42338985 ↗
L2TRIAL_NONRANDOMCited in: Prognosis and Natural History - [635]
Lewandowski T, Huang J, Fan F et al.. “Staphylococcus aureus formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity.” Antimicrobial agents and chemotherapy (2013). PMID: 23571548 ↗
L5OTHERCited in: Prognosis and Natural History - [636]
Clarke RS, Ha KP, Edwards AM. “RexAB Promotes the Survival of Staphylococcus aureus Exposed to Multiple Classes of Antibiotics.” Antimicrobial agents and chemotherapy (2021). PMID: 34310219 ↗
L5OTHERCited in: Prognosis and Natural History - [637]
Truong-Bolduc QC, Yonker LM, Wang Y et al.. “NorA efflux pump mediates Staphylococcus aureus response to Pseudomonas aeruginosa pyocyanin toxicity.” Antimicrobial agents and chemotherapy (2024). PMID: 38231535 ↗
L5OTHERCited in: Prognosis and Natural History, Special Hosts and Populations - [638]
Klein E, Smith DL, Laxminarayan R. “Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005.” Emerging infectious diseases (2007). PMID: 18258033 ↗
L2OTHERCited in: Prognosis and Natural History - [639]
Gutierrez K, Halpern MS, Sarnquist C et al.. “Staphylococcal infections in children, California, USA, 1985-2009.” Emerging infectious diseases (2013). PMID: 23260060 ↗
L2OTHERCited in: Prognosis and Natural History - [640]
Pastagia M, Kleinman LC, Lacerda de la Cruz EG et al.. “Predicting risk for death from MRSA bacteremia.” Emerging infectious diseases (2012). PMID: 22709685 ↗
L2OTHERCited in: Prognosis and Natural History - [641]
Aguado JM, San-Juan R, Lalueza A et al.. “High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia.” Emerging infectious diseases (2011). PMID: 21749780 ↗
L2OTHERCited in: Prognosis and Natural History - [642]
Robinson AL, Boyle MG, Hogan PG et al.. “Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households - A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41276461 ↗
L1RCTCited in: Prevention and Infection Control, Special Hosts and Populations - [643]
Anderson DJ, Moehring RW, Weber DJ et al.. “Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection).” The Lancet. Infectious diseases (2018). PMID: 29880301 ↗
L2RCTCited in: Prevention and Infection Control - [644]
Gemmell CG, Edwards DI, Fraise AP et al.. “Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.” The Journal of antimicrobial chemotherapy (2006). PMID: 16507559 ↗
L1GUIDELINECited in: Prevention and Infection Control - [645]
Gould FK, Brindle R, Chadwick PR et al.. “Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.” The Journal of antimicrobial chemotherapy (2009). PMID: 19282331 ↗
L1GUIDELINECited in: Prevention and Infection Control - [646]
Crawford T, Rodvold KA, Solomkin JS. “Vancomycin for surgical prophylaxis?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22328468 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [647]
Daum RS, Spellberg B. “Progress toward a Staphylococcus aureus vaccine.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 22186773 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [648]
Hetem DJ, Bootsma MC, Bonten MJ. “Prevention of Surgical Site Infections: Decontamination With Mupirocin Based on Preoperative Screening for Staphylococcus aureus Carriers or Universal Decontamination?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26658054 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [649]
Santos RP, Mayo TW, Siegel JD. “Healthcare epidemiology: active surveillance cultures and contact precautions for control of multidrug-resistant organisms: ethical considerations.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18491966 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [650]
Price JR, Cole K, Bexley A et al.. “Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing.” The Lancet. Infectious diseases (2016). PMID: 27863959 ↗
L2COHORTCited in: Prevention and Infection Control - [651]
Bojang A, Baines SL, Donovan L et al.. “Genomic investigation of Staphylococcus aureus recovered from Gambian women and newborns following an oral dose of intra-partum azithromycin.” The Journal of antimicrobial chemotherapy (2019). PMID: 31424550 ↗
L4RCTCited in: Prevention and Infection Control - [652]
Dancer SJ. “Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning.” The Lancet. Infectious diseases (2007). PMID: 17974481 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [653]
Okomo U, Fitzgerald F, Feasey N et al.. “Infection prevention and control in low- and middle-income countries: policy, practice, and implementation challenges in sub-Saharan Africa.” Clinical microbiology reviews (2026). PMID: 42132371 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [654]
Soge OO, Thibault CS, Cannon CA et al.. “Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40036749 ↗
L2OTHERCited in: Prevention and Infection Control - [655]
Diekema DJ, Nori P, Stevens MP et al.. “Are Contact Precautions "Essential" for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37738565 ↗
L5OTHERCited in: Prevention and Infection Control - [656]
Zong Z, Wu A, Hu B. “Infection Control in the Era of Antimicrobial Resistance in China: Progress, Challenges, and Opportunities.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 33367579 ↗
L5OTHERCited in: Prevention and Infection Control - [657]
Evans ME, Simbartl LA, McCauley BP et al.. “Active Surveillance and Contact Precautions for Preventing Methicillin-Resistant Staphylococcus aureus Healthcare-Associated Infections During the COVID-19 Pandemic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37390613 ↗
L2OTHERCited in: Prevention and Infection Control - [658]
Cabral SM, Harris AD, Cosgrove SE et al.. “Adherence to Antimicrobial Prophylaxis Guidelines for Elective Surgeries Across 825 US Hospitals, 2019-2020.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36774539 ↗
L2OTHERCited in: Prevention and Infection Control - [659]
Wyllie D, Paul J, Crook D. “Waves of trouble: MRSA strain dynamics and assessment of the impact of infection control.” The Journal of antimicrobial chemotherapy (2011). PMID: 21948966 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [660]
Cattoir V, Leclercq R. “Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?” The Journal of antimicrobial chemotherapy (2012). PMID: 23208830 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [661]
Edgeworth JD. “Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care.” The Journal of antimicrobial chemotherapy (2010). PMID: 20852273 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [662]
Johnson AP, Davies J, Guy R et al.. “Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years.” The Journal of antimicrobial chemotherapy (2012). PMID: 22223229 ↗
L2REVIEW_NARRATIVECited in: Prevention and Infection Control - [663]
Harbarth S, Samore MH. “Interventions to control MRSA: high time for time-series analysis?” The Journal of antimicrobial chemotherapy (2008). PMID: 18556707 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [664]
. “Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” The Lancet. Infectious diseases (2025). PMID: 41412141 ↗
L2OTHERCited in: Prevention and Infection Control, Special Hosts and Populations - [665]
Grayson ML, Stewardson AJ, Russo PL et al.. “Effects of the Australian National Hand Hygiene Initiative after 8 years on infection control practices, health-care worker education, and clinical outcomes: a longitudinal study.” The Lancet. Infectious diseases (2018). PMID: 30274723 ↗
L2OTHERCited in: Prevention and Infection Control - [666]
Handapangoda NP, Ruwansiri LP, Vidanapathirana GU et al.. “Prevalence of Streptococcus pneumoniae and Staphylococcus aureus co-colonization in healthy children under five years: a systematic review.” BMC pediatrics (2026). PMID: 41826897 ↗
L3SR_OBSCited in: Prevention and Infection Control, Special Hosts and Populations - [667]
Ter Steeg L, Domínguez-Andrés J, Netea MG et al.. “Trained Immunity as a Preventive Measure for Surgical Site Infections.” Clinical microbiology reviews (2021). PMID: 34585978 ↗
L5OTHERCited in: Prevention and Infection Control - [668]
Khairy TF, Lupien MA, Nava S et al.. “Infections Associated with Resterilized Pacemakers and Defibrillators.” The New England journal of medicine (2020). PMID: 32374963 ↗
L2OTHERCited in: Prevention and Infection Control - [669]
Yang C, Peng C, Yan J et al.. “Cefazolin Alone versus Vancomycin Plus Cefazolin for Intravenous Prophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.” The Journal of arthroplasty (2026). PMID: 42069021 ↗
L1SR_OBSCited in: Prevention and Infection Control - [670]
Hurley JC. “Arms-Based Meta-Analysis of Microbiological Endpoints of 88 VAP Prevention Studies Using Antimicrobial Versus Non-Antimicrobial Strategies-Towards 'VAP-Zero'?” Antibiotics (Basel, Switzerland) (2026). PMID: 41750518 ↗
L1SR_OBSCited in: Prevention and Infection Control - [671]
Mostofi K, Caragliano G. “Surgical Site Infections in Spine Surgery: A Retrospective Study of 1,578 Procedures with Identification of Tattooed Skin as a Novel Risk Factor Associated with Surgical Site Infection.” The Journal of hospital infection (2026). PMID: 42314879 ↗
L2COHORTCited in: Prevention and Infection Control - [672]
Takahashi H, Taku K, Mizuki K et al.. “Comparison of methicillin-resistant Staphylococcus aureus carriage in a neonatal intensive care unit between pre- and post-COVID-19 pandemic periods, following the introduction of strengthened infection control measures: a retrospective study.” The Journal of hospital infection (2026). PMID: 42162920 ↗
L2COHORTCited in: Prevention and Infection Control - [673]
Nikolić D, Petrović K, Manojlović V et al.. “Increasing Methicillin-Resistant Staphylococcus aureus Burden in 90-Day Groin Surgical Site Infection After Femoral Arterial Exposure: A 15-Year Single-Centre Cohort Study.” International wound journal (2026). PMID: 42117325 ↗
L2COHORTCited in: Prevention and Infection Control - [674]
Molendijk MM, Boekema BKHL, Lattwein KR et al.. “Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model.” Antimicrobial agents and chemotherapy (2024). PMID: 39136463 ↗
L5OTHERCited in: Prevention and Infection Control - [675]
Wei J, Tong K, Wang H et al.. “Dosage, Efficacy, and Safety of Intra-articular Vancomycin for Prophylaxis of Periprosthetic Joint Infection Caused by Methicillin-Resistant Staphylococcus aureus after Total Knee Arthroplasty in a Rat Model.” Antimicrobial agents and chemotherapy (2021). PMID: 34807762 ↗
L5OTHERCited in: Prevention and Infection Control - [676]
Stiefel P, Mauerhofer S, Schneider J et al.. “Enzymes Enhance Biofilm Removal Efficiency of Cleaners.” Antimicrobial agents and chemotherapy (2016). PMID: 27044552 ↗
L5OTHERCited in: Prevention and Infection Control - [677]
Tornero E, García-Ramiro S, Martínez-Pastor JC et al.. “Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.” Antimicrobial agents and chemotherapy (2014). PMID: 25403662 ↗
L2OTHERCited in: Prevention and Infection Control - [678]
Mao Y, Valour F, Nguyen NTQ et al.. “Multimechanistic Monoclonal Antibody Combination Targeting Key Staphylococcus aureus Virulence Determinants in a Rabbit Model of Prosthetic Joint Infection.” Antimicrobial agents and chemotherapy (2021). PMID: 33903108 ↗
L5OTHERCited in: Prevention and Infection Control - [679]
Diep BA, Hilliard JJ, Le VT et al.. “Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.” Antimicrobial agents and chemotherapy (2017). PMID: 28115346 ↗
L5OTHERCited in: Prevention and Infection Control - [680]
Freire MP, Pierrotti LC, Zerati AE et al.. “Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.” Antimicrobial agents and chemotherapy (2018). PMID: 29987150 ↗
L4OTHERCited in: Prevention and Infection Control - [681]
McNeil JC, Kok EY, Vallejo JG et al.. “Clinical and Molecular Features of Decreased Chlorhexidine Susceptibility among Nosocomial Staphylococcus aureus Isolates at Texas Children's Hospital.” Antimicrobial agents and chemotherapy (2015). PMID: 26666947 ↗
L4OTHERCited in: Prevention and Infection Control, Special Hosts and Populations - [682]
Saint-Genis Q, Marchand S, Chauzy A et al.. “Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery.” The Journal of antimicrobial chemotherapy (2026). PMID: 41744034 ↗
L2OTHERCited in: Prevention and Infection Control - [683]
Pitt-Kendall R, Sun S, Hughes S et al.. “Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016-20.” The Journal of antimicrobial chemotherapy (2024). PMID: 38517444 ↗
L2OTHERCited in: Prevention and Infection Control - [684]
Bayston R, Vera L, Mills A et al.. “In vitro antimicrobial activity of silver-processed catheters for neurosurgery.” The Journal of antimicrobial chemotherapy (2009). PMID: 19942617 ↗
L5OTHERCited in: Prevention and Infection Control - [685]
Houston A, Hooker E, Rankin A et al.. “Environmental surface sampling in health and care settings: a scoping review of published guidance.” The Journal of hospital infection (2026). PMID: 42025699 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [686]
Albaloul H, Nemer A, Saini N et al.. “Infectious Diseases: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974008 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control, Special Hosts and Populations - [687]
Pathinathan K, Sial A, Khalil O et al.. “Strategies to prevent post-operative surgical site infection in spinal surgery: a narrative review.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026). PMID: 41936664 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [688]
Bosetti D, Lee A, Catho G et al.. “Beyond Methicillin-resistant Staphylococcus aureus: Prevention Strategies for Health Care-Associated Staphylococcus aureus Infection.” Infectious disease clinics of North America (2026). PMID: 41896065 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [689]
Bryce A, Davison S, Currie BJ et al.. “Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis.” Open forum infectious diseases (2024). PMID: 39130084 ↗
L4OTHERCited in: Prevention and Infection Control - [690]
Creech CB, Frenck RW, Fiquet A et al.. “Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).” Open forum infectious diseases (2019). PMID: 31993453 ↗
L4OTHERCited in: Prevention and Infection Control - [691]
DeSimone DC, Lahr BD, Anavekar NS et al.. “Temporal Trends of Infective Endocarditis in Olmsted County, Minnesota, Between 1970 and 2018: A Population-Based Analysis.” Open forum infectious diseases (2021). PMID: 33728357 ↗
L2OTHERCited in: Prevention and Infection Control - [692]
Aslam S, Lampley E, Wooten D et al.. “Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States.” Open forum infectious diseases (2020). PMID: 33005701 ↗
L4OTHERCited in: Prevention and Infection Control - [693]
Lesens O, Haus-Cheymol R, Dubrous P et al.. “Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, Côte d'Ivoire.” Emerging infectious diseases (2007). PMID: 17552109 ↗
L4OTHERCited in: Prevention and Infection Control - [694]
Zilberberg MD, Shorr AF, Kollef MH. “Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.” Emerging infectious diseases (2008). PMID: 18976563 ↗
L2OTHERCited in: Prevention and Infection Control - [695]
Huson MA, Stolp SM, van der Poll T et al.. “Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 24046307 ↗
L2SR_OBSCited in: Special Hosts and Populations - [696]
Rice S, Carr K, Sobiesuo P et al.. “Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review.” The Lancet. Infectious diseases (2023). PMID: 37001543 ↗
L2SR_OBSCited in: Special Hosts and Populations - [697]
Payne SC, Benninger MS. “Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17968816 ↗
L1SR_OBSCited in: Special Hosts and Populations - [698]
Doernberg SB, Arias CA, Altman DR et al.. “Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37843115 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [699]
Fritz SA, Hogan PG, Camins BC et al.. “Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections.” Antimicrobial agents and chemotherapy (2012). PMID: 23147738 ↗
L2RCTCited in: Special Hosts and Populations - [700]
Campbell AJ, Al Yazidi LS, Phuong LK et al.. “Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34089594 ↗
L2OTHERCited in: Special Hosts and Populations - [701]
Park DE, Baggett HC, Howie SRC et al.. “Colonization Density of the Upper Respiratory Tract as a Predictor of Pneumonia-Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Pneumocystis jirovecii.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28575367 ↗
L3OTHERCited in: Special Hosts and Populations - [702]
Popovich KJ, Weinstein RA, Aroutcheva A et al.. “Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20192731 ↗
L3OTHERCited in: Special Hosts and Populations - [703]
Dicko CH, N'Dri DN, Snoussi M et al.. “Etiology, prevalence, and mortality of sepsis among children under five years in Africa: a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 42035015 ↗
L1SR_OBSCited in: Special Hosts and Populations - [704]
Aleissa MM, Gonzalez-Bocco IH, Zekery-Saad S et al.. “The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study.” Open forum infectious diseases (2022). PMID: 35949404 ↗
L2COHORTCited in: Special Hosts and Populations - [705]
Bodey GP. “The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.” The Journal of antimicrobial chemotherapy (2009). PMID: 19372179 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [706]
Musicha P, Cornick JE, Bar-Zeev N et al.. “Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study.” The Lancet. Infectious diseases (2017). PMID: 28818544 ↗
L2OTHERCited in: Special Hosts and Populations - [707]
Okike IO, Ribeiro S, Ramsay ME et al.. “Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study.” The Lancet. Infectious diseases (2014). PMID: 24508198 ↗
L2OTHERCited in: Special Hosts and Populations - [708]
Liou TG, Adler FR, Cox DR et al.. “Lung transplantation and survival in children with cystic fibrosis.” The New England journal of medicine (2007). PMID: 18032764 ↗
L2OTHERCited in: Special Hosts and Populations - [709]
Mohamud SM, Nor LA, Doğan S et al.. “Antimicrobial resistance patterns of Staphylococcus aureus isolates in tertiary hospital in Somalia: a retrospective study.” BMC infectious diseases (2026). PMID: 42087083 ↗
L4COHORTCited in: Special Hosts and Populations - [710]
Sng ECY, Teo DCH, Wong MJ et al.. “Microbiology and clinical characteristics of brain abscess in adults from 3 tertiary hospitals in Singapore - a 11-year multicenter retrospective study.” BMC infectious diseases (2026). PMID: 42062945 ↗
L4COHORTCited in: Special Hosts and Populations - [711]
Wang C, Wang K, Zhu H et al.. “Analysis of risk factors for concurrent osteomyelitis in children with septic arthritis: A retrospective cohort study.” The American journal of emergency medicine (2026). PMID: 42061203 ↗
L2COHORTCited in: Special Hosts and Populations - [712]
Krymko H, Abelson N, El Mahdi N et al.. “Predictors of definite and possible infective endocarditis in children with bacteremia: a reginal cohort study.” European journal of pediatrics (2026). PMID: 41866405 ↗
L2COHORTCited in: Special Hosts and Populations - [713]
Attaianese F, Benhard J, Cohen JF et al.. “Oral switch therapy for paediatric Staphylococcus aureus bloodstream infections: A retrospective study in a tertiary hospital.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41846044 ↗
L2COHORTCited in: Special Hosts and Populations - [714]
Autmizguine J, Melloni C, Hornik CP et al.. “Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.” Antimicrobial agents and chemotherapy (2017). PMID: 29084742 ↗
L4OTHERCited in: Special Hosts and Populations - [715]
McNeil JC, Hulten KG, Kaplan SL et al.. “Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children.” Antimicrobial agents and chemotherapy (2011). PMID: 21282426 ↗
L4OTHERCited in: Special Hosts and Populations - [716]
Szumowski JD, Cohen DE, Kanaya F et al.. “Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.” Antimicrobial agents and chemotherapy (2006). PMID: 17116664 ↗
L2OTHERCited in: Special Hosts and Populations - [717]
Tabor DE, Yu L, Mok H et al.. “Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.” Antimicrobial agents and chemotherapy (2016). PMID: 27324766 ↗
L4OTHERCited in: Special Hosts and Populations - [718]
Verdejo MÁ, Malano-Barletta D, Pitart C et al.. “Empirical glycopeptide exposure and acute kidney injury during cloxacillin therapy in Staphylococcus aureus bacteremia.” Antimicrobial agents and chemotherapy (2026). PMID: 42080550 ↗
L2OTHERCited in: Special Hosts and Populations - [719]
Kok EY, Vallejo JG, Sommer LM et al.. “Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2018). PMID: 29530845 ↗
L2OTHERCited in: Special Hosts and Populations - [720]
Brahami A, Karlowsky JA, McCracken M et al.. “Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).” The Journal of antimicrobial chemotherapy (2025). PMID: 40873028 ↗
L4OTHERCited in: Special Hosts and Populations - [721]
Nichol KA, Adam HJ, Golding GR et al.. “Characterization of MRSA in Canada from 2007 to 2016.” The Journal of antimicrobial chemotherapy (2019). PMID: 31505646 ↗
L4OTHERCited in: Special Hosts and Populations - [722]
Helbo T, Boel JB, Bartels MD et al.. “Carriage of methicillin-resistant Staphylococcus aureus in children <6 years old: a retrospective follow-up study of the natural course and effectiveness of decolonization treatment.” The Journal of antimicrobial chemotherapy (2024). PMID: 38334373 ↗
L2OTHERCited in: Special Hosts and Populations - [723]
Song JH, Hsueh PR, Chung DR et al.. “Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393157 ↗
L2OTHERCited in: Special Hosts and Populations - [724]
Villar M, Marimón JM, García-Arenzana JM et al.. “Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393177 ↗
L4OTHERCited in: Special Hosts and Populations - [725]
Drewett GP, Jacob M, Culhane B et al.. “Malignant Otitis Externa in Central Australia: A 15-Year Retrospective Review Between 2009 and 2024.” The Medical journal of Australia (2026). PMID: 41837387 ↗
L4REVIEW_NARRATIVECited in: Special Hosts and Populations - [726]
Morelli MK, Veve MP, Shorman MA. “Maternal Bacteremia Caused by Staphylococcus Aureus With a Focus on Infective Endocarditis.” Open forum infectious diseases (2020). PMID: 32766382 ↗
L4OTHERCited in: Special Hosts and Populations - [727]
Sullivan SB, Kamath S, McConville TH et al.. “Staphylococcus epidermidis Protection Against Staphylococcus aureus Colonization in People Living With Human Immunodeficiency Virus in an Inner-City Outpatient Population: A Cross-Sectional Study.” Open forum infectious diseases (2016). PMID: 28018932 ↗
L4OTHERCited in: Special Hosts and Populations - [728]
Crum-Cianflone NF, Wang X, Weintrob A et al.. “Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among Human Immunodeficiency Virus-Infected Persons.” Open forum infectious diseases (2015). PMID: 26380335 ↗
L2OTHERCited in: Special Hosts and Populations - [729]
Stavropoulou E, Ledergerber B, Fourré N et al.. “Infective Endocarditis and Antimicrobial Timing: A Case for Delay?” Open forum infectious diseases (2025). PMID: 41141452 ↗
L2OTHERCited in: Special Hosts and Populations - [730]
Popovich KJ, Zawitz C, Weinstein RA et al.. “The Intersecting Epidemics of Human Immunodeficiency Virus, Community-Associated Methicillin-Resistant Staphylococcus aureus, and Incarceration.” Open forum infectious diseases (2015). PMID: 26543878 ↗
L2OTHERCited in: Special Hosts and Populations - [731]
Koeck M, Como-Sabetti K, Boxrud D et al.. “Burdens of Invasive Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Disease, Minnesota, USA.” Emerging infectious diseases (2019). PMID: 30561319 ↗
L4OTHERCited in: Special Hosts and Populations - [732]
Franzini M, Chirumbolo S, Ricevuti G et al.. “SIOOT® Adjunct Oxygen-Ozone Therapy Against Multidrug-Resistant Bacteria: A Pilot Study of 257 Cases.” Antibiotics (Basel, Switzerland) (2026). PMID: 42650693 ↗
L4Cited in: Definition, Classification and Causative Organisms - [733]
El-Sehrawy AAMA, Jasim SA, Jasim HF et al.. “Comprehensive in silico genomics analysis of global trends and host-specific emergence of aminoglycoside resistance in Staphylococcus aureus: a One-Health perspective.” BMC microbiology (2026). PMID: 42661162 ↗
L2aCited in: Definition, Classification and Causative Organisms - [734]
Gatermann SG, Becker K, Ewig S et al.. “Antibiotic Treatment of Severe Infections with Multiresistant Bacteria.” Deutsches Arzteblatt international (2026). PMID: 42661422 ↗
L1cCited in: Definition, Classification and Causative Organisms - [735]
Ghaffarı AN, Ergon MC, Çelik M. “Impact of a standardized management protocol and antimicrobial stewardship intervention on mortality and quality of care in Staphylococcus aureus bacteremia: a before-after study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42640390 ↗
L2bCited in: Definition, Classification and Causative Organisms - [736]
Fukuda Y, Oda N, Honda T et al.. “Guideline-concordant therapy for community-onset pneumonia considering risk factors for drug-resistant pathogens: a propensity score-matched study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42640391 ↗
L3bCited in: Definition, Classification and Causative Organisms - [737]
Hahn N, Jäger M, Wegner A et al.. “Decoding resistance: a comprehensive study on pathogens and antibiotic efficacy in periprosthetic joint infections.” Journal of orthopaedic surgery and research (2026). PMID: 42632884 ↗
L3bCited in: Definition, Classification and Causative Organisms - [738]
Shinohara K, Tochitani K, Katada Y et al.. “Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody.” Infection (2026). PMID: 42611161 ↗
L3bCited in: Definition, Classification and Causative Organisms - [739]
Baratta P, Cresti A, De Sensi F et al.. “Avoidable delays in the care of infective endocarditis patients: a priority issue.” Frontiers in cardiovascular medicine (2026). PMID: 42609283 ↗
L3bCited in: Definition, Classification and Causative Organisms - [740]
Lo DK, Jahnke N, Smith S et al.. “Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.” The Cochrane database of systematic reviews (2026). PMID: 42658648 ↗
L1aCited in: Definition, Classification and Causative Organisms - [741]
Heck RS, Lins RS, Speransa DR et al.. “A Systematic Review and Meta-Analysis Comparing the Diagnostic Accuracy of Swab Cultures and Tissue Biopsy for Diagnosing Diabetic Foot Infections.” International journal of endocrinology (2026). PMID: 42630424 ↗
L2aCited in: Definition, Classification and Causative Organisms - [742]
Liu FC, Lu A, Yang PR et al.. “Temporal Trends in Pathogens and Clinical Outcomes of Adult Deep Neck Infections: An 18-Year Multicenter Cohort Study of 12,063 Cases.” Microorganisms (2026). PMID: 42655170 ↗
L3bCited in: Definition, Classification and Causative Organisms - [743]
Wójcik-Bojek U, Rywaniak J, Sadowska B. “Will It Be Possible in the Future to Target Innate Immunity Against Staphylococcus aureus Using Resident Microbiota and Plant Extracts?” Journal of immunology research (2026). PMID: 42667544 ↗
L5Cited in: Definition, Classification and Causative Organisms - [744]
Bogaerts B, Kowalewicz C, De Keersmaecker SCJ et al.. “Genomic characterization of non-CC398 methicillin-resistant Staphylococcus aureus from Belgian livestock reveals high similarity to human-associated lineages.” Frontiers in public health (2026). PMID: 42661682 ↗
L5Cited in: Definition, Classification and Causative Organisms - [745]
Zheng X, Ma L, Li Y et al.. “Isolation and characterization of a novel Staphylococcus phage SPD: genomic insights and its anti-biofilm efficacy against methicillin-resistant Staphylococcus aureus.” Frontiers in cellular and infection microbiology (2026). PMID: 42656269 ↗
L5Cited in: Definition, Classification and Causative Organisms - [746]
Dai Y, Xia L, Yang Y et al.. “Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics.” Viruses (2026). PMID: 42655688 ↗
L5Cited in: Definition, Classification and Causative Organisms - [747]
Jiao Y, Zhang Z, Gao J et al.. “Subzero Control of Human Norovirus and Indicator Microorganisms on Frozen Foods Using an Antifreeze-Peracetic Acid Formulation.” Viruses (2026). PMID: 42655664 ↗
L5Cited in: Definition, Classification and Causative Organisms - [748]
Loreni F, Fortuni F, Affronti A et al.. “Infective Endocarditis on Aortic Valve: From Diagnosis to Cardiac Surgical Intervention-Narrative Review.” Journal of clinical medicine (2026). PMID: 42652867 ↗
L5Cited in: Definition, Classification and Causative Organisms - [749]
Shittu AO, Perovic O, Layer-Nicolaou F et al.. “Molecular characterization of mupirocin-resistant MRSA from Germany and South Africa.” Frontiers in cellular and infection microbiology (2026). PMID: 42643317 ↗
L5Cited in: Definition, Classification and Causative Organisms - [750]
Clegg J, Cova G, Carignano A et al.. “Single-Cell Profiling Identifies Skin-Resident Memory CD4+ T Cells as a Potential Correlate of Immunity During Staphylococcus aureus Skin Infection.” European journal of immunology (2026). PMID: 42635357 ↗
L5Cited in: Definition, Classification and Causative Organisms - [751]
Xue ZJ, Huang MY, Wang JF et al.. “Cryptotanshinone inhibits Staphylococcus aureus NdhC via uncompetitive inhibition: Collateral sensitivity in respiratory-deficient SCVs.” Virulence (2026). PMID: 42635182 ↗
L5Cited in: Definition, Classification and Causative Organisms - [752]
Fan Y, Wang S, Zhu X et al.. “The evolving landscape of Staphylococcus aureus immune evasion: a data-driven atlas over two decades.” Frontiers in immunology (2026). PMID: 42534757 ↗
L2aCited in: Microbiology and Pathogenesis - [753]
Maj M, Czupryniak L. “Five-Year Evolution of the Microbiological Landscape of Diabetic Foot Infections (2021-2025): Rising Polymicrobial Gram-Negative Predominance and Emergence of Resistant Enterobacterales at a Single Large-Volume Outpatient Centre.” Antibiotics (Basel, Switzerland) (2026). PMID: 42650648 ↗
L3bCited in: Microbiology and Pathogenesis - [754]
Carnovale BJ, Wakelin SH, Don N et al.. “Surgical Site Infection, Microbiology, and Antibiotic Utilization After Posterior Cervical Spinal Decompression and Fusion: A 10-Year Experience.” Global spine journal (2026). PMID: 42610634 ↗
L3bCited in: Microbiology and Pathogenesis - [755]
Terracciano R, Cerchione R, Cimbalo C et al.. “The role of ETI therapy in managing sinusitis in cystic fibrosis pediatric population: A study on clinical outcomes.” Respiratory medicine (2026). PMID: 42521036 ↗
L4Cited in: Microbiology and Pathogenesis - [756]
Phuetphaichit S, Samanloh S, Kamolvit W et al.. “Impact of hemo-alert program on appropriate antimicrobial therapy in hospitalized patients with bacteremia: a quasi-experimental study.” Antimicrobial stewardship & healthcare epidemiology : ASHE (2026). PMID: 42534226 ↗
L2bCited in: Microbiology and Pathogenesis - [757]
Agbanrin MD, Adegbite BR, Gouleu CS et al.. “Bacterial spectrum and proportion of multidrug-resistant bacteria in clinical samples from a regional hospital in Lambaréné, Gabon (2017-2023): Implications for antimicrobial resistance surveillance and public health.” PLOS global public health (2026). PMID: 42640916 ↗
L3bCited in: Microbiology and Pathogenesis - [758]
Omer H, Darweesh O, Karim G et al.. “Antimicrobial Resistance Across Four Iraqi Governorates: A Multicenter Cross-Sectional Surveillance Analysis With Implications for Antimicrobial Stewardship Policy and WHO AWaRe-Aligned Public Health Strategies.” JMIR public health and surveillance (2026). PMID: 42622566 ↗
L3bCited in: Microbiology and Pathogenesis - [759]
Analuisa KQ, Bittar-Carlini G, Elbenawi HR et al.. “Cardiovascular Implantable Electronic Device Infections Requiring Extraction: A National Analysis of Contemporary Trends, Clinical Predictors, and Economic Burden, 2016-2022.” Heart rhythm (2026). PMID: 42612892 ↗
L3bCited in: Microbiology and Pathogenesis - [760]
Conlon P, Skally M, de Barra E et al.. “Declining rates of bloodstream infections among haemodialysis patients and the temporal association with changes in infection, prevention and control bundles of care between 2009 and 2023.” Journal of nephrology (2026). PMID: 42599172 ↗
L3bCited in: Microbiology and Pathogenesis - [761]
Meller N, Amit S, Amitai Komem D et al.. “Microbiological profile and clinical correlates of post-cesarean surgical site infections.” Journal of perinatal medicine (2026). PMID: 42592644 ↗
L3bCited in: Microbiology and Pathogenesis - [762]
Liu FC, Yang PR, Tsai YT et al.. “Long-Term Trends in Microbiology and Outcomes of Pediatric Deep Neck Infections: An 18-Year Study.” International journal of medical sciences (2026). PMID: 42524637 ↗
L3bCited in: Microbiology and Pathogenesis - [763]
de Freitas GV, Oliveira ÍS, Ribeiro TC et al.. “Postoperative spinal infection after spinal arthrodesis: incidence, microbiology, risk factors, and outcomes in a tertiary-care hospital cohort.” Journal of global antimicrobial resistance (2026). PMID: 42521081 ↗
L3bCited in: Microbiology and Pathogenesis - [764]
Pineda Etcheber IH, Mutel Gonzalez C, Bascuñan Maiz JA et al.. “Infective Endocarditis, a Current Perspective: Clinical and Epidemiological Profile in a High-Volume Chilean Tertiary Centre Between 2021-2023.” Pathogens (Basel, Switzerland) (2026). PMID: 42515054 ↗
L3bCited in: Microbiology and Pathogenesis - [765]
Martens A, Schauer M, Motevalli M et al.. “Microbial Contamination of Gym Equipment: Diversity Patterns, Temporal Dynamics, Staphylococcus Hotspots, and Device-Level Risk Indices.” Pathogens (Basel, Switzerland) (2026). PMID: 42515034 ↗
L3bCited in: Microbiology and Pathogenesis - [766]
Prastiyanto ME, Khairunnisa A, Sah SK. “Prevalence, Antimicrobial Resistance Profile, and Multidrug Resistance of Methicillin-Resistant Staphylococcus aureus (MDR-MRSA) in Clinical Isolates From Indonesian Healthcare Facility: A Cross-Sectional Study.” Health science reports (2026). PMID: 42597439 ↗
L3bCited in: Microbiology and Pathogenesis - [767]
Rodriguez P, Schilliger M, Khan A et al.. “How Should Bacteriological Sampling Be Stratified in Paediatric Septic Arthritis? A Narrative Review with a Proposed Risk-Stratified Framework.” Antibiotics (Basel, Switzerland) (2026). PMID: 42650644 ↗
L5Cited in: Microbiology and Pathogenesis - [768]
Alzahrani AJ. “Microbiome-mediated regulation of pathogen virulence: Molecular mechanisms and clinical implications.” Virulence (2026). PMID: 42642836 ↗
L5Cited in: Microbiology and Pathogenesis - [769]
Kumaran P, Wier J, Telang SS et al.. “Microbiologic Patterns Found in Periprosthetic Joint Infections Following Total Joint Arthroplasty Differ Across Race and Sex.” Arthroplasty today (2026). PMID: 42631002 ↗
L5Cited in: Microbiology and Pathogenesis - [770]
Kozhakhmetova SS, Zholdybayeva EV, Basharova DA et al.. “Whole-genome analysis and phenotypic antimicrobial resistance of Staphylococcus aureus isolated from foods in Northern Kazakhstan.” Frontiers in microbiology (2026). PMID: 42630150 ↗
L5Cited in: Microbiology and Pathogenesis - [771]
Miao L, Hou X, Wang Y et al.. “Vancomycin-associated acute kidney injury in patients with moderate CKD: a multicentre retrospective cohort study.” JAC-antimicrobial resistance (2026). PMID: 42666502 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [772]
Naidu M, Chandra Y. “The Hidden Epidemic: Epidemiology of Acute Infections in People Who Inject Drugs in Fiji.” Drug and alcohol review (2026). PMID: 42618048 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [773]
Yan L, Zhang H, Fu H et al.. “Targeted next-generation sequencing for pediatric community-acquired pneumonia pathogen detection: a single-center study.” Frontiers in cellular and infection microbiology (2026). PMID: 42591296 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [774]
Yang J, Song X, Wang Y et al.. “Differences and trends in pathogens between ventilator-associated pneumonia and non-ventilator-associated pneumonia: data from 61 hospitals in Suzhou, China, 2020-2024.” BMJ open (2026). PMID: 42551999 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [775]
Pham TM, Zhang Y, Nevers M et al.. “Antimicrobial selection and multidrug resistance in four major pathogens in the US Veterans Affairs health-care system: a multicentre, retrospective, cohort study.” The Lancet. Microbe (2026). PMID: 42537681 ↗
L4Cited in: Epidemiology, Transmission and Risk Factors - [776]
Li Z, Lin M, Li H et al.. “A retrospective analysis of pathogen distribution and antimicrobial resistance trends of bacteria in a tertiary hospital in China, 2021-2025.” Frontiers in cellular and infection microbiology (2026). PMID: 42528518 ↗
L4Cited in: Epidemiology, Transmission and Risk Factors - [777]
Cheng S, Tong D, Zhao Q et al.. “Association between MDROs colonization and subsequent infections in ICU patients: a retrospective cohort study.” Frontiers in public health (2026). PMID: 42524283 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [778]
Areti AS, Hafeez H, Sangineni PV et al.. “Elevated risk of wound and systemic complications in MRSA-colonized patients undergoing lower extremity orthopedic trauma surgery.” European journal of trauma and emergency surgery : official publication of the European Trauma Society (2026). PMID: 42507131 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [779]
Pangseeta T, Pussadu T, Putthanachote N et al.. “Changes in the Epidemiology of Multidrug-Resistant Organisms During the COVID-19 Pandemic: A Six-Year Retrospective Study at a Tertiary Care Hospital in Northeastern Thailand.” Medical sciences (Basel, Switzerland) (2026). PMID: 42506335 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [780]
Han Q, Deng X, Jin R et al.. “Pathogenic spectrum, antibiotic resistance, and risk factors for 28-day mortality in pediatric bloodstream infection-associated sepsis: a 10-year retrospective cohort study.” Microbiology spectrum (2026). PMID: 42474196 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [781]
Kopparapu PK, Deshmukh M, Subhash S et al.. “Complement receptor 2 downregulation is associated with mortality in Staphylococcus aureus sepsis in both mice and humans.” Frontiers in immunology (2026). PMID: 42495651 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [782]
B'sop FG, Mbouombouo M, Tchatchouang S et al.. “Investigation of bacterial agents in yaws-like ulcers in children and their environment in Cameroon: An experience from the Akonolinga Health District.” PLoS neglected tropical diseases (2026). PMID: 42507723 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [783]
Wang B, Wei X, Ma W et al.. “Pathogenic characteristics and factors associated with multidrug-resistant bacterial infections after perianal abscess surgery.” Frontiers in surgery (2026). PMID: 42614441 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [784]
Kim T, Kim SK, Kim JW et al.. “Bedside external ventricular drainage in the NICU: procedural efficiency and infection trends in a 15-year single-center cohort.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2026). PMID: 42593702 ↗
L3bCited in: Epidemiology, Transmission and Risk Factors - [785]
Ismail NF, Citartan M, Mahbud NA et al.. “Aptamer-based biosensors for the diagnostics of infectious disease-causing bacteria using spiked and clinical samples: a systematic review.” Journal of applied microbiology (2026). PMID: 42518210 ↗
L2aCited in: Clinical Presentation - [786]
Le TVT, Pham EC, Do TTH et al.. “Pediatric necrotizing pneumonia: Clinical features, microbiology, management, and outcomes in the tertiary center.” The American journal of emergency medicine (2026). PMID: 42456543 ↗
L4Cited in: Clinical Presentation - [787]
Jones TPW, Davis P, O'Sullivan O et al.. “Outcomes of Surgical Site Infection Following Cranial Surgery From a UK Tertiary Center.” Open forum infectious diseases (2026). PMID: 42440732 ↗
L3bCited in: Clinical Presentation - [788]
Dunbar D, Jain S, Berle L et al.. “Diagnosing necrotizing fasciitis: is there a difference between type I and type II with respect to computer tomography scan features?” Infectious diseases (London, England) (2026). PMID: 42434860 ↗
L3bCited in: Clinical Presentation - [789]
Jomaa O, Sarraj R, Ardhaoui M et al.. “Pubic symphysis osteomyelitis presenting as groin pain in a patient with rheumatoid arthritis: a case report.” BMC infectious diseases (2026). PMID: 42477559 ↗
L3bCited in: Clinical Presentation - [790]
Okay ZÜ, Okay B, Çelebi E et al.. “Evaluation of 1,094 children diagnosed with scabies in Turkey: a 5-year retrospective observational study.” Parasite (Paris, France) (2026). PMID: 42546217 ↗
L3bCited in: Clinical Presentation - [791]
Prangenberg C, Zellner AA, Roos J et al.. “Hand Phlegmons: Clinical Burden, Microbiological Spectrum, and Predictors of Surgical Complexity.” Diagnostics (Basel, Switzerland) (2026). PMID: 42510048 ↗
L4Cited in: Clinical Presentation - [792]
Bradley S, Ashy C, Baird H et al.. “Rising Incidence of Group A Streptococcal Musculoskeletal Infections in Pediatric Patients.” Orthopedics (2026). PMID: 42412077 ↗
L4Cited in: Clinical Presentation - [793]
Funderburk E, Ding H, Mang N et al.. “Impact of Xpert® MRSA/SA blood culture PCR test on antimicrobial utilization at a large teaching hospital.” Diagnostic microbiology and infectious disease (2026). PMID: 42378733 ↗
L3bCited in: Clinical Presentation - [794]
Zhu N, Skeggs J, Bennett I et al.. “Surgical resection of a ruptured left frontal mycotic aneurysm localized with ICG angiography: a case report.” International journal of surgery case reports (2026). PMID: 42578156 ↗
L1bCited in: Clinical Presentation - [795]
Ding H, Lei C, Liu D et al.. “Right forearm wound and soft tissue abscess complicated with sepsis due to Streptococcus suis: a case report.” Frontiers in medicine (2026). PMID: 42500537 ↗
L4Cited in: Clinical Presentation - [796]
Yamaguchi T, Uno K, Nagata K et al.. “Septic shock due to a ruptured ovarian abscess caused by hematogenous Staphylococcus aureus infection in a sexually inactive woman with atopic dermatitis: a case report.” BMC women's health (2026). PMID: 42469754 ↗
L4Cited in: Clinical Presentation - [797]
Rice MC, Imun M, Jung SW et al.. “MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide.” eLife (2026). PMID: 42611943 ↗
L5Cited in: Clinical Presentation - [798]
Dupieux C, Martins Simoes P, Youenou B et al.. “A fluorogenic biotracer for reliable detection of staphylococcal beta-lactamase: towards improved precision therapy in severe MSSA infections.” The Journal of antimicrobial chemotherapy (2026). PMID: 42599769 ↗
L5Cited in: Clinical Presentation - [799]
Kumar R, Sumana G, Yadav S et al.. “Label-Free Liquid Crystal-Based Dielectric Genosensor for Infectious Bacterial Detection.” ACS infectious diseases (2026). PMID: 42503677 ↗
L5Cited in: Clinical Presentation - [800]
Werneburg F, Beschauner J, Werneburg LI et al.. “Cefazolin Versus Flucloxacillin for Methicillin-Susceptible Staphylococcus aureus Bone and Joint Infections: A Retrospective Single-Center Comparative Study of Effectiveness and Renal Safety of Intravenous Monotherapy.” Antibiotics (Basel, Switzerland) (2026). PMID: 42650723 ↗
L2bCited in: Diagnosis and Workup - [801]
Pinto E, Ubhaus B, Taha B et al.. “Methicillin-resistant Staphylococcus aureus Nares Utility in Non-pneumonia Related Infections.” Clinical therapeutics (2026). PMID: 42629225 ↗
L3bCited in: Diagnosis and Workup - [802]
Tarabichi S, Paul BR, Verhey JT et al.. “Impact of Organism Profile on Ideal Timing of Reimplantation in Patients Undergoing Two-Stage Exchange Arthroplasty.” The Journal of arthroplasty (2026). PMID: 42617924 ↗
L3bCited in: Diagnosis and Workup - [803]
Magdy Abd El Razeek Haridi M, El Sayed Zaki M, Abd El-Hamid H et al.. “Methicillin-Resistant Staphylococcus aureus in Adult Conjunctivitis: Antimicrobial Resistance Patterns, Molecular Characteristics, and Association of Prior Antibiotic Exposure With Clinical Outcome.” Cornea (2026). PMID: 42634938 ↗
L3bCited in: Diagnosis and Workup - [804]
Vishwakarma S, Nishad JH, Anjali et al.. “A metabolomics approach to target the effect of histone protein methyltransferase-specific probe UNC1999 on cryptic metabolites in an endophytic fungus Xylaria papulis Lloyd.” Frontiers in microbiology (2026). PMID: 42666487 ↗
L5Cited in: Diagnosis and Workup - [805]
Dittmer M, Liegenfeld SC, Krueger N et al.. “Interkingdom Biofilms in Chronic Wounds: The Collaboration of Candida albicans and Staphylococcus aureus Against Conventional Wound Antiseptics in a Wound-like Leucocyte-Rich Human Plasma Biofilm Model (lhBIOM).” Antibiotics (Basel, Switzerland) (2026). PMID: 42650664 ↗
L5Cited in: Diagnosis and Workup - [806]
Monreal A, Ballestero D, Yus C et al.. “Towards Antimicrobial Formulations of Repurposed Drugs and Cationic Surfactants: Efficacy, Cytotoxicity on Human Cell Lines, and Ecotoxicity in Aquatic Models.” Antibiotics (Basel, Switzerland) (2026). PMID: 42650646 ↗
L5Cited in: Diagnosis and Workup - [807]
Cheon S, Yoo J, Oh Y et al.. “Application-focused validation of a viability-selective PMA-qPCR assay for selected skin-associated and cosmetic-relevant bacteria.” Frontiers in microbiology (2026). PMID: 42643727 ↗
L5Cited in: Diagnosis and Workup - [808]
Jiang S, Liu J, Schaffer K et al.. “Trends in Pathogens Causing Late-Onset Sepsis in Very Preterm Infants: 2010-2023.” Pediatrics (2026). PMID: 42637238 ↗
L5Cited in: Diagnosis and Workup - [809]
Peng X, Li S, Shi H et al.. “Complete versus partial mesh removal for mesh infection after tension-free inguinal hernioplasty: A retrospective study.” Surgery (2026). PMID: 42632277 ↗
L5Cited in: Diagnosis and Workup - [810]
Calderón-Parra J, Diego-Yagüe I, Muñoz P et al.. “Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant staphylococci left-sided infective endocarditis: results from a nationwide prospective, multicentre cohort.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42097302 ↗
L2bCited in: Severity Assessment and Risk Stratification - [811]
Feng Q, Ha X, Song Y. “Risk stratification and source classification in Staphylococcus aureus bloodstream infections: high mortality linked to mrsa, biomarkers, and treatment efficacy.” Frontiers in immunology (2026). PMID: 42327752 ↗
L3bCited in: Severity Assessment and Risk Stratification - [812]
Verdejo MÁ, Malano-Barletta D, Boán J et al.. “Platelet dynamics in methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: Distinct patterns and prognostic implications.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42264067 ↗
L3bCited in: Severity Assessment and Risk Stratification - [813]
Deng JT, Kong WJ, Lu PH et al.. “Association of Staphylococcus aureus bloodstream infection with 7-day incident delirium in critically Ill adults: a propensity-weighted competing risk analysis.” BMC infectious diseases (2026). PMID: 42251249 ↗
L3bCited in: Severity Assessment and Risk Stratification - [814]
de Miguel-Álava M, López J, Vilacosta I et al.. “Pre-admission and in-hospital embolisms have a different prognostic significance in infective endocarditis.” European journal of internal medicine (2026). PMID: 42242954 ↗
L4Cited in: Severity Assessment and Risk Stratification - [815]
Cosson G, Allaham W, Rousseau MA et al.. “Isolated Staphylococcus aureus spinal epidural abscesses: severe initial neurological deficits do not predict worse outcomes compared with spondylodiscitis-associated cases.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026). PMID: 42043529 ↗
L3bCited in: Severity Assessment and Risk Stratification - [816]
Jackson H, Hernandez Padilla AC, Vintcent LEM et al.. “Perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe.” Critical care (London, England) (2026). PMID: 41821089 ↗
L4Cited in: Severity Assessment and Risk Stratification - [817]
Chen H, Fan Y, Hu R et al.. “Longitudinal SOFA score trajectories and risk stratification in ICU patients with Staphylococcus aureus bloodstream infection: insights from group-based trajectory modeling.” Frontiers in cellular and infection microbiology (2026). PMID: 41736791 ↗
L3bCited in: Severity Assessment and Risk Stratification - [818]
Zhang N, Zhang X, Guo Y et al.. “Microbial characteristics and risk factors in PICU with freshwater drowning-associated pneumonia.” European journal of pediatrics (2026). PMID: 41665687 ↗
L3bCited in: Severity Assessment and Risk Stratification - [819]
Zuluaga Monroy JD, Perez Ardila MA, Millan Prada HA et al.. “Mortality and prognostic factors in infective endocarditis: A Colombian multicenter cohort.” IJID regions (2026). PMID: 42253699 ↗
L2bCited in: Severity Assessment and Risk Stratification - [820]
Behairy OGA, El-Gaffar AOA, Ali BG et al.. “Trefoil factor 3 as a marker of gastrointestinal cell injury during sepsis.” European journal of pediatrics (2026). PMID: 42154329 ↗
L3bCited in: Severity Assessment and Risk Stratification - [821]
Cabanillas I, Escudero-Sanchez R, Cobo J et al.. “Partial prosthetic exchange in the management of chronic prosthetic hip joint infection: a systematic review.” Orthopaedics & traumatology, surgery & research : OTSR (2026). PMID: 42686094 ↗
L2aCited in: Empiric Management, Acute Care and Source Control - [822]
Allison L, Kirby EF, Goldenberg M et al.. “Comparison of Empiric Antibiotics With and Without MRSA Coverage in Staphylococcal Scalded Skin Syndrome.” Hospital pediatrics (2026). PMID: 42702367 ↗
L4Cited in: Empiric Management, Acute Care and Source Control - [823]
Yingxing L, Lina G, Fangyuan L et al.. “Long-term epidemiology of bacterial pathogens and antimicrobial resistance in a secondary hospital in China: a 12-year retrospective study.” BMC microbiology (2026). PMID: 42693415 ↗
L3bCited in: Empiric Management, Acute Care and Source Control - [824]
Feng Q, Song Y, Ha X. “Risk factors for prolonged hospitalization and disease course in osteomyelitis: a single-centre cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 42688153 ↗
L3bCited in: Empiric Management, Acute Care and Source Control - [825]
Iacobelli R, Ragni L, Samperi S et al.. “Infective endocarditis in the pediatric population: A single-center retrospective study of outcomes and predictors.” European journal of pediatrics (2026). PMID: 42684500 ↗
L3bCited in: Empiric Management, Acute Care and Source Control - [826]
Sinkeler FS, Kouijzer IJE, Jager NGL et al.. “Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment.” The Journal of antimicrobial chemotherapy (2026). PMID: 42683513 ↗
L3bCited in: Empiric Management, Acute Care and Source Control - [827]
Endo A, Hanai Y, Mikawa T et al.. “Pharmacist-coordinated IDST treatment bundle achievement and impact on mortality in MRSA bacteraemia: a single-centre retrospective cohort study.” Infection prevention in practice (2026). PMID: 42701368 ↗
L4Cited in: Empiric Management, Acute Care and Source Control - [828]
Guo Z, Qi H, Zhang Q et al.. “Severe co-infection with influenza A virus H3N2 and community-acquired methicillin-susceptible Staphylococcus aureus in a child presenting with septic shock, acute respiratory distress syndrome, and necrotizing pneumonia: a rare case report.” Frontiers in cellular and infection microbiology (2026). PMID: 42688005 ↗
L4Cited in: Empiric Management, Acute Care and Source Control - [829]
Hashemi SA, Haghbin A, Motlagh AV et al.. “Detection of livestock-associated MRSA ST398/t011 and hospital-associated MRSA ST239/t037 in a referral hospital in northeastern Iran: A six-month cross-sectional surveillance study (July-December 2025).” New microbes and new infections (2026). PMID: 42701398 ↗
L4Cited in: Empiric Management, Acute Care and Source Control - [830]
Chiotos K, Jaggi P, Facer EE et al.. “Reducing Empiric Vancomycin Use in the Pediatric Intensive Care Unit: a Multicenter Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42700377 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [831]
Kamo A, Ye S, Liang X et al.. “Multifunctional CuSbS2 Nanocrystals as an Integrated Flexocatalytic-Photocatalytic-Nanozymatic Platform for Antibacterial Therapy.” ACS applied materials & interfaces (2026). PMID: 42700123 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [832]
Lorente-Torres B, Castañera P, Llano-Verdeja J et al.. “Fighting the invader: strategies against intracellular bacteria.” Frontiers in pharmacology (2026). PMID: 42694373 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [833]
Idrees A, Abbas IS, Li J et al.. “Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus.” Frontiers in pharmacology (2026). PMID: 42688403 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [834]
Li Z, Lei M, Chen C et al.. “Sprayable NIR/pH-responsive NSC/PF127 hydrogel loaded with MoO₂, ciprofloxacin, and FGF-2 for enhanced antibacterial and pro-regenerative infected wound healing.” Drug delivery (2026). PMID: 42687712 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [835]
Le J, Sayles T, Nguyen DK et al.. “Methicillin resistant staphylococcus aureus treatment and control in neonates: lessons learned - a Vietnam perspective.” Expert review of anti-infective therapy (2026). PMID: 42687663 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [836]
Miyazaki K, Kanda Y, Yurube T et al.. “A Novel Gelatin Hydrogel-Based Drug-Delivery System Promotes Antimicrobial Efficacy in a Pyogenic Spondylodiscitis Rat Model.” JOR spine (2026). PMID: 42683161 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [837]
Xu C, Hu Z, Liu Y et al.. “P1D6 inhibits FnBP-induced extracellular proteome remodeling: proteomic evidence for a novel intervention strategy in atopic dermatitis.” Molecular medicine (Cambridge, Mass.) (2026). PMID: 42681617 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [838]
Abeydeera-Keshmiri NA, Miller LG. “Staphylococcus aureus Skin and Soft Tissue Infections.” Infectious disease clinics of North America (2026). PMID: 42680671 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [839]
Bravo AR, Cuevas MF, Rubilar-Huenchuman M et al.. “Antimicrobial photodynamic therapy across ESKAPE pathogens: Efficacy, limitations, and a pathogen-adapted framework toward clinical translation.” Pharmacology & therapeutics (2026). PMID: 42680073 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [840]
Han Y, Yin Z, Liao D et al.. “Reversed unidirectional transport in a Janus polyurethane/alginate dressing for directional postbiotic delivery to infected wounds.” Journal of materials chemistry. B (2026). PMID: 42676180 ↗
L5Cited in: Empiric Management, Acute Care and Source Control - [841]
Yang W, Wang L, Yan L et al.. “Pulmonary pharmacokinetics, epithelial lining fluid exposure and PK/PD characterization of the novel pleuromutilin derivative APTM against methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae in mice.” The Journal of antimicrobial chemotherapy (2026). PMID: 42669629 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [842]
Bundgaard H, Pries-Heje M, Hjulmand J et al.. “Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis.” The New England journal of medicine (2026). PMID: 42663314 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [843]
Ruga S, Matarese E, Castagna F et al.. “Plant-Derived Compounds as Antibiotic Adjuvants Against Drug-Resistant ESKAPE Pathogens: Mechanisms of Action, Synergistic Strategies, and Translational Challenges.” Antibiotics (Basel, Switzerland) (2026). PMID: 42650686 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [844]
Lin H, Huang J, Xie X et al.. “A pH-responsive nanozyme-integrated fibrous biointerface for chemodynamic antibacterial therapy and infected wound healing.” Colloids and surfaces. B, Biointerfaces (2026). PMID: 42632255 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [845]
Campione E, Cosio T, Artosi F. “Rapidly progressive methicillin-susceptible Staphylococcus aureus abscess of the lower lip: A case report.” IDCases (2026). PMID: 42699332 ↗
L3bCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [846]
Russo A, Celletti C, Trecarichi EM. “Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) carriage among rehabilitation facilities for patients at admission: a systematic review and meta-analysis.” The Journal of hospital infection (2026). PMID: 42567321 ↗
L2aCited in: History and Evolution of Treatment - [847]
Özgözen AL, Altunay E. “Changes in Antibiotic Resistance Patterns in Diabetic Foot Infections Requiring Toe Amputation: A Long-Term Single-Center Retrospective Study.” Antibiotics (Basel, Switzerland) (2026). PMID: 42505644 ↗
L3bCited in: History and Evolution of Treatment - [848]
Wang S, Xie F, Sang S. “Global burden of bacterial antimicrobial resistance among children under five years 1990-2021: a systematic analysis with forecasts to 2050.” International journal of antimicrobial agents (2026). PMID: 42674241 ↗
L3bCited in: History and Evolution of Treatment - [849]
Turgimbayeva A, Yakupov B, Abeldenov S. “Base excision repair in Staphylococcus aureus: a defense against oxidative DNA damage and a potential target for novel antibiotics.” Frontiers in microbiology (2026). PMID: 42676798 ↗
L5Cited in: History and Evolution of Treatment - [850]
Schapp S, Seibold P, Reisser Y et al.. “Experimental evolution of phage K enhances antibacterial activity against USA300 MRSA in lung infection models.” Emerging microbes & infections (2026). PMID: 42640217 ↗
L5Cited in: History and Evolution of Treatment - [851]
Plumet L, Magnan C, Morsli M et al.. “Training a phage to expand its host range: directed evolution against Staphylococcus aureus from diabetic foot infections.” Antimicrobial agents and chemotherapy (2026). PMID: 42635480 ↗
L5Cited in: History and Evolution of Treatment - [852]
Myburgh DA, da Silva NA, Flux AL et al.. “Genomic insights into pre-antibiotic osteomyelitis pathogens and their link to current resistant hospital strains.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42632420 ↗
L5Cited in: History and Evolution of Treatment - [853]
Keerthi V, Ravindran P, Kaliyur S et al.. “A comprehensive review of emerging therapeutic strategies against methicillin-resistant Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42614264 ↗
L5Cited in: History and Evolution of Treatment - [854]
Hsiao CH, Kang EY, Liu YT et al.. “Longitudinal Changes in Clonal Distribution and Fluoroquinolone Resistance of Ocular MRSA.” Biomedical journal (2026). PMID: 42595088 ↗
L5Cited in: History and Evolution of Treatment - [855]
Papanikolaou NG, Giapros V, Papaioannou E et al.. “Evolution of Antimicrobial Resistance in Neonatal Sepsis: A Narrative Review.” Antibiotics (Basel, Switzerland) (2026). PMID: 42505645 ↗
L5Cited in: History and Evolution of Treatment - [856]
Lee H, Hyun DG, Lim CM et al.. “Factors Associated with Methicillin-Resistant Staphylococcus aureus Infection Among Patients with Sepsis Presenting to Emergency Departments: A Nationwide Multicenter Cohort Study.” Antibiotics (Basel, Switzerland) (2026). PMID: 42792064 ↗
L2bCited in: Definition, Classification and Causative Organisms - [857]
Köller J, Zellner AA, Roos J et al.. “Hand Osteomyelitis: Exploratory Associations of Admission C-Reactive Protein and MRI with Surgical Burden and Hospital Length of Stay.” Journal of clinical medicine (2026). PMID: 42739735 ↗
L4Cited in: Definition, Classification and Causative Organisms - [858]
Nishiyama Y, Matsumura M, Yasui Y et al.. “Successful hemodialysis withdrawal with glucocorticoid treatment after achieving infection control in a case of crescentic IgA-dominant staphylococcus-associated glomerulonephritis.” CEN case reports (2026). PMID: 42752782 ↗
L1bCited in: Definition, Classification and Causative Organisms - [859]
Wiratama BS, Maziyya AA, Wafi AH et al.. “Dominance of Bacillus cereus and Staphylococcus aureus in Foodborne Outbreaks: A 19-Year Systematic Review of Surveillance Data in Yogyakarta, Indonesia.” Pathogens (Basel, Switzerland) (2026). PMID: 42796703 ↗
L2aCited in: Definition, Classification and Causative Organisms - [860]
Gessen S, Morel J, Ezingeard E et al.. “Impact of Nasal Staphylococcus aureus Carriage on Ventilator-Associated Pneumonia after Acute Brain Injury.” Anaesthesia, critical care & pain medicine (2026). PMID: 42826762 ↗
L4Cited in: Definition, Classification and Causative Organisms - [861]
Kundakci B, Dalgic Y, Dalkir KA et al.. “Clinical, etiological, and microbiological differences between foot and non-foot osteomyelitis.” Archives of orthopaedic and trauma surgery (2026). PMID: 42802270 ↗
L3bCited in: Definition, Classification and Causative Organisms - [862]
Jogenfors A, Mernelius S, Löfgren S et al.. “Combatting a Tobramycin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit: the impact of hygiene intervention and antibiotic substitution.” BMC infectious diseases (2026). PMID: 42768321 ↗
L3bCited in: Definition, Classification and Causative Organisms - [863]
Zhao Y, Chen W, Chen P et al.. “Gut microbiota and fecal metabolomic alterations in hospitalized patients with Staphylococcus aureus infection: an exploratory multi-omics study.” Frontiers in cellular and infection microbiology (2026). PMID: 42755805 ↗
L4Cited in: Definition, Classification and Causative Organisms - [864]
Chen TY, Crowe TP, Fakhimi M et al.. “Selective Expansion of TCR Vβ2+ Tregs and Impaired Lymphocyte TSST-1 Responsiveness in Bullous Pemphigoid Patients Colonised by Staphylococcus aureus.” Experimental dermatology (2026). PMID: 42765457 ↗
L3bCited in: Definition, Classification and Causative Organisms - [865]
Malik M, Chithambaram NS, Kaur J et al.. “Empirical Antibiotic Therapy for the Management of Empyema Thoracis in Children: A Systematic Review.” Indian pediatrics (2026). PMID: 42758457 ↗
L2aCited in: Definition, Classification and Causative Organisms - [866]
Li H, Chen J, Li D et al.. “Squamous Cell Carcinoma Arising from Chronic Osteomyelitis: A Single-Center Case Series of Six Patients.” Infection and drug resistance (2026). PMID: 42774979 ↗
L4Cited in: Definition, Classification and Causative Organisms - [867]
Rossi M, Benboubker M, Belchkar S et al.. “Phenotypic characterization of inducible and constitutive clindamycin resistance in clinical Staphylococcus aureus isolates.” Revista do Instituto de Medicina Tropical de Sao Paulo (2026). PMID: 42788598 ↗
L3bCited in: Definition, Classification and Causative Organisms - [868]
Redding LE, Hu W, Daniel S et al.. “Antimicrobial-resistant organism carriage and metagenomic characterization of the microbiome and resistome in veterinary workers.” Veterinary research communications (2026). PMID: 42747640 ↗
L4Cited in: Definition, Classification and Causative Organisms - [869]
Shafique S, Donia R, Srigley JA et al.. “Challenge of antimicrobial-resistant organisms in neonatal intensive care units: a comprehensive review.” BMJ paediatrics open (2026). PMID: 42829214 ↗
L5Cited in: Definition, Classification and Causative Organisms - [870]
Léguillier V, Gloux K, Khalife M et al.. “Biotope-dependent resistance to reactive oxygen species, antibiotic tolerance, and virulence of Staphylococcus aureus.” Communications biology (2026). PMID: 42823449 ↗
L5Cited in: Definition, Classification and Causative Organisms - [871]
Yengo CK, Liu X, Langley RJ et al.. “HIV-1 interactions with sialic acid-binding bacterial lectins promote virus infectivity in vitro and mucosal transmission in humanized mice.” Frontiers in cellular and infection microbiology (2026). PMID: 42819061 ↗
L5Cited in: Definition, Classification and Causative Organisms - [872]
Kanazawa N, Martens CP, Makino S et al.. “Hyperosmotic niche adaptation and tissue polyamines underlie MRSA persistence in the kidney.” Science translational medicine (2026). PMID: 42814799 ↗
L5Cited in: Definition, Classification and Causative Organisms - [873]
Shandilya UK, Liang Y, Atalla H et al.. “Loss of IL10RA rewires epithelial immune responses to intracellular Staphylococcus aureus small colony variants in bovine mammary epithelial cells.” Frontiers in cellular and infection microbiology (2026). PMID: 42807853 ↗
L5Cited in: Definition, Classification and Causative Organisms - [874]
Ene RL, Popescu R, Cobec AE et al.. “Urinary Tract Infections: Molecular Determinants of Uropathogenicity and Their Translation into Contemporary Clinical Practice.” International journal of molecular sciences (2026). PMID: 42794538 ↗
L5Cited in: Definition, Classification and Causative Organisms - [875]
Golosova NN, Khlusevich YA, Kravchuk BI et al.. “Endolysin LysSte134_1 Reduces Staphylococcus Bacterial Load in Infected Wounds In Vivo.” International journal of molecular sciences (2026). PMID: 42794421 ↗
L5Cited in: Definition, Classification and Causative Organisms - [876]
Morawiec N, Adamczyk B, Adamczyk-Sowa M. “The role of viral infections and other microbial factors in the pathogenesis of multiple sclerosis: a systematic review.” Multiple sclerosis and related disorders (2026). PMID: 42727550 ↗
L2aCited in: Microbiology and Pathogenesis - [877]
Galal B, Barouk N, Kejah A et al.. “A systematic review of antimicrobial resistance among World Health Organization Bacterial Priority Pathogens in Syria (2015-2025).” IJID regions (2026). PMID: 42780020 ↗
L2aCited in: Microbiology and Pathogenesis - [878]
Attaianese F, Venturini E, Tiezzi AC et al.. “Acute Pelvic Osteomyelitis in Children: A 10-year Retrospective Study From a Tertiary Care Hospital.” The Pediatric infectious disease journal (2026). PMID: 42723097 ↗
L4Cited in: Microbiology and Pathogenesis - [879]
Mohammed AY, Dibbasey M, Ceesay B et al.. “Epidemiology and antimicrobial resistance trends of invasive bacterial pathogens in the Gambia: a retrospective analysis, 2019-2024.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42767553 ↗
L3bCited in: Microbiology and Pathogenesis - [880]
Kurzeja A, Mulder I, Zofkie A et al.. “Microbiology Trends among Postcesarean Surgical Site Infections at a Large Public Hospital.” American journal of perinatology (2026). PMID: 42748973 ↗
L3bCited in: Microbiology and Pathogenesis - [881]
Huang X, Ye J, Wu L. “The role and management of dietary and environmental factors in pediatric atopic dermatitis.” Frontiers in pediatrics (2026). PMID: 42769107 ↗
L3bCited in: Microbiology and Pathogenesis - [882]
Serwat A, Aghmiuni SK, Hussain M et al.. “The transcriptional regulator ArcR represses virulence and γ-hemolysin expression in Staphylococcus aureus USA300 LAC.” International journal of medical microbiology : IJMM (2026). PMID: 42828977 ↗
L5Cited in: Microbiology and Pathogenesis - [883]
Novais FO, Scott P. “Beyond the parasite: skin-intrinsic cytolytic circuits drive disease in cutaneous leishmaniasis and reveal targets for host-directed therapy.” Microbiology and molecular biology reviews : MMBR (2026). PMID: 42803567 ↗
L5Cited in: Microbiology and Pathogenesis - [884]
Rühling M, Schmelz F, Ulbrich K et al.. “A novel rapid host cell entry pathway determines the intracellular fate of Staphylococcus aureus.” eLife (2026). PMID: 42775422 ↗
L5Cited in: Microbiology and Pathogenesis - [885]
Jia G, Chen K, Lin H et al.. “From colonisation to immune evasion: a synthesis of the interaction strategies that drive Staphylococcus aureus infection.” FEMS microbiology reviews (2026). PMID: 42758141 ↗
L5Cited in: Microbiology and Pathogenesis - [886]
Maury V, Sridi-Cheniti S, Jonveaux M et al.. “Imaging REASSESSment of embolic events before antibiotic discontinuation in infective endocarditis: REASSESS-IE study.” European heart journal. Cardiovascular Imaging (2026). PMID: 42712271 ↗
L2bCited in: Clinical Presentation - [887]
Kelly EC, Calderon R, Weng P et al.. “Organism-Specific Clinical Features and Outcomes of Culture-Positive Endogenous Endophthalmitis: A Multicenter Cohort Study Over 12 Years.” American journal of ophthalmology (2026). PMID: 42800654 ↗
L3bCited in: Clinical Presentation - [888]
Maurille C, Gravey F, Giard J-C et al.. “In-host adaptation of Staphylococcus aureus during recurrent prosthetic joint infections: a retrospective longitudinal study.” Microbiology spectrum (2026). PMID: 42747164 ↗
L4Cited in: Clinical Presentation - [889]
Idarrha F, Demnati B, Boumediane EM et al.. “Predictive factors for outcomes in pyogenic flexor tenosynovitis: a 10-year analysis of 341 patients.” Injury (2026). PMID: 42721565 ↗
L3bCited in: Clinical Presentation - [890]
Agarwal A, Iqbal MZ, Khurana S et al.. “Radiologic Sequelae of Pediatric Septic Arthritis of the Shoulder: A Retrospective Series and Proposed Classification.” Journal of pediatric orthopedics (2026). PMID: 42802627 ↗
L3bCited in: Clinical Presentation - [891]
Nguyen VH, Nguyen NQ. “Clinical burden and treatment pathways of early deep surgical site infection after lumbar spine surgery: a Vietnamese single-center descriptive study.” Journal of spine surgery (Hong Kong) (2026). PMID: 42718861 ↗
L4Cited in: Clinical Presentation - [892]
Briones-Claudett KH, Solís JB, Mendoza MFP et al.. “Structured clinical adjudication of Streptomyces spp. recovered from bronchoalveolar lavage in severe COVID-19 ARDS complicated by polymicrobial lower respiratory tract infection during invasive mechanical ventilation: a case report.” Frontiers in medicine (2026). PMID: 42723980 ↗
L4Cited in: Clinical Presentation - [893]
Bombo AM, Sadiq AM, Mwingwa AG et al.. “Prevalence of MRSA Bacteremia and Predictors of In-Hospital Mortality Among Critically Ill Adults in a Tanzanian Intensive Care Unit: A Retrospective Cross-Sectional Study.” Health science reports (2026). PMID: 42807237 ↗
L3bCited in: Clinical Presentation - [894]
Ayele L, Asrat D, Seman A et al.. “Diagnostic Performance of Complementary Serum and Cerebrospinal Fluid Multiplex PCR for Acute Bacterial Meningitis.” Diagnostics (Basel, Switzerland) (2026). PMID: 42739230 ↗
L3bCited in: Clinical Presentation - [895]
Reichert F, Perry M, Sandfort M et al.. “Surveillance of antibiotic-resistant bacteria integrating whole genome sequencing and epidemiological information - a global, systematic review, 2012-2023.” Antimicrobial resistance and infection control (2026). PMID: 42791588 ↗
L2aCited in: Diagnosis and Workup - [896]
Lee JH, Shin BS, Kim TS et al.. “Diagnostic contribution of anaerobic bottles in pediatric blood cultures: experience at a tertiary children's hospital.” Journal of clinical microbiology (2026). PMID: 42813824 ↗
L3bCited in: Diagnosis and Workup - [897]
Bujor CG, Dinuti M, Sfrijan F. “Blood Culture Positivity, Microbiological Spectrum, and Inflammatory Correlates in Patients Hospitalized with SARS-CoV-2 Infection During the Omicron BA.5 Wave: A Retrospective Cohort Study.” Microorganisms (2026). PMID: 42795523 ↗
L3bCited in: Diagnosis and Workup - [898]
Adams C, Biggs HM, Jackson KA et al.. “Trends in Mortality and the Effects of the Coronavirus Disease 2019 Pandemic on Mortality Among Adult Patients With Staphylococcus aureus Bacteremia, 20 US Counties, 2005-2022.” Open forum infectious diseases (2026). PMID: 42812850 ↗
L5Cited in: Diagnosis and Workup - [899]
Leszczyński P, Wojnicz D, Tichaczek-Goska D et al.. “Determinants of Antibacterial Activity in Humulus lupulus Hop Extracts: Phytochemical Profiling of Prenylated Acylphloroglucinols and Efficacy Against Methicillin-Resistant Staphylococcus aureus and Multidrug-Resistant Uropathogenic Escherichia coli.” International journal of molecular sciences (2026). PMID: 42794791 ↗
L5Cited in: Diagnosis and Workup - [900]
Di Lodovico S, Fontana A, Di Fermo P et al.. “Graphene Oxide and Methylglyoxal: a combined strategy against chronic wound pathogens.” Applied microbiology and biotechnology (2026). PMID: 42789108 ↗
L5Cited in: Diagnosis and Workup - [901]
Ladines-Lim JB, Van B, Cressman L et al.. “Changes in observed bloodstream infection epidemiology during a single-set blood culture restriction: an interrupted time series analysis.” Journal of clinical microbiology (2026). PMID: 42788904 ↗
L5Cited in: Diagnosis and Workup - [902]
Pawar P, Bakshi S. “Common Pathogens Associated with Diabetic Charcot Neuroarthropathy in the Indian Population: A Retrospective Observational Study.” Annals of African medicine (2026). PMID: 42826376 ↗
L3bCited in: Diagnosis and Workup - [903]
Mammen DE, Rajashekhar RP. “Clinical Profile and Microbiological Spectrum of Tracheostomized Patients in a Tertiary Care Center: A Prospective Observational Study.” Annals of African medicine (2026). PMID: 42798147 ↗
L3bCited in: Diagnosis and Workup - [904]
Nagpal V, Dandekar P, Sharma S et al.. “Recalcitrant Infectious Keratitis in DOCK8 Immunodeficiency Syndrome.” Journal of pediatric ophthalmology and strabismus (2026). PMID: 42765610 ↗
L4Cited in: Diagnosis and Workup - [905]
Lian C, Feng B, Su J. “Post-Traumatic Primary Cutaneous Cryptococcosis Presenting as a Chronic Refractory Forearm Ulcer with Polymicrobial Coinfection: An mNGS-Assisted Case Report and Literature Review.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42763741 ↗
L4Cited in: Diagnosis and Workup - [906]
Huynh TXT, Tran NAT, Huynh VB. “Beyond Staphylococcus aureus: emerging Gram-negative isolates in pediatric impetigo in Southern Vietnam.” Dermatology reports (2026). PMID: 42820482 ↗
L3bCited in: Diagnosis and Workup - [907]
Patawaran AJ, Pagsisihan D. “Risk Factors Associated With Multidrug Resistant Organism (MDRO) Isolates in Infected Diabetic Foot Ulcers (DFU): An Analytical Cross-sectional Study.” Journal of the ASEAN Federation of Endocrine Societies (2026). PMID: 42802778 ↗
L3bCited in: Diagnosis and Workup - [908]
Ayele F, Urgesa K, Mekonnen S et al.. “Mobile phone bacterial contamination among students and staff at Haramaya University, Eastern Ethiopia: A cross-sectional study.” Medicine (2026). PMID: 42798132 ↗
L3bCited in: Diagnosis and Workup - [909]
Kim M, Del Duca E, Correa Da Rosa J et al.. “Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis.” Allergy (2026). PMID: 42543003 ↗
L1bCited in: Severity Assessment and Risk Stratification - [910]
van der Meulen LWJ, Bergmans ME, Assil S et al.. “S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double-blind randomized clinical trial in patients with mild to moderate atopic dermatitis.” British journal of clinical pharmacology (2026). PMID: 42272236 ↗
L1bCited in: Severity Assessment and Risk Stratification - [911]
Jaber F, El Rawas S, Faraj S et al.. “Value of the Pitt bacteremia score in predicting the outcome of nonbacteremic patients with infections caused by multidrug-resistant organisms.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42413686 ↗
L3bCited in: Severity Assessment and Risk Stratification - [912]
Miller LG, Fowler VG, Miro JM et al.. “A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics †.” Open forum infectious diseases (2026). PMID: 42846794 ↗
L1bCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [913]
Stevens RW, DeSimone DC, Hess KA et al.. “Retrospective Evaluation of the Association of Hypoalbuminemia With Acute Treatment Outcomes in Methicillin-Susceptible Staphylococcus Aureus Bacteremia.” The Annals of pharmacotherapy (2026). PMID: 42860811 ↗
L3bCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [914]
Gieling EM, Bevers LAH, Smit WL et al.. “Rapid onset and offset of the interaction between rifampicin and long-acting cabotegravir/rilpivirine: A pharmacokinetic case report.” British journal of clinical pharmacology (2026). PMID: 42802558 ↗
L4Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [915]
Radocchia G, De Angelis M, Martina MG et al.. “Co-infection models of Staphylococcus aureus and respiratory viruses reveal synergistic interactions counteracted by a bithiazole derivative.” Frontiers in cellular and infection microbiology (2026). PMID: 42851573 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [916]
Méndez-Sotelo BJ, Delaye-Martínez MA, Gómez-Quiroz A et al.. “Antimicrobial susceptibility patterns in Jalisco, Mexico: a snapshot of regional resistance (2021-2023).” Frontiers in cellular and infection microbiology (2026). PMID: 42840071 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [917]
Selim MT, Mahmoud NN. “Green extraction routes for conversion of Nerium oleander L. biomass into bioactive agents: phytochemical insights and antimicrobial promise.” BMC complementary medicine and therapies (2026). PMID: 42839274 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [918]
Poloni S, Gagnon A, Valot B et al.. “Genomic determinants of penicillin G susceptibility and cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus bloodstream isolates.” The Journal of antimicrobial chemotherapy (2026). PMID: 42836776 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [919]
Werneburg F, Beschauner J, Werneburg LI et al.. “Cefazolin Versus Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bone and Joint Infections: A Narrative Review.” Antibiotics (Basel, Switzerland) (2026). PMID: 42792080 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [920]
Szemraj M, Sienkiewicz M. “Bacteriocins as Alternative Antimicrobial Agents for Wound-Associated Infections: Mechanisms, Activity Against Biofilms and Translational Potential.” Antibiotics (Basel, Switzerland) (2026). PMID: 42792034 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [921]
Laurent F, Yombi JC. “Rifampicin in Osteoarticular Infections: A Comprehensive Review of Current Evidence.” Antibiotics (Basel, Switzerland) (2026). PMID: 42792022 ↗
L5Cited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [922]
Kerala NO, Kebede HB, Mosa BD et al.. “Prevalence of MRSA and associated factors among wound patients at Werabe Comprehensive Specialized Hospital, Ethiopia.” Journal of infection in developing countries (2026). PMID: 42858344 ↗
L3bCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation